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Human insulinoma and renal cell carcinoma DNAs were analysed by a sib-selection 
tumorigenesis assay to detect the presence of dominant acting oncogenes. Although no 
novel oncogenes were detected in the five tumor DNAs tested, the increased sensitivity of 
the tumorigenesis assay allowed detection of overexpressed ras proto-oncogenes activated 
during transfection. Tumorigenic overexpression of ras proteins occured by two different 
mechanisms: gene amplification, and increased translation efficiency of a fusion protein. 
Thirty to fifty fold amplification of a human N-ras gene was detected in primary and 
secondary mouse tumors. All tumors containing amplified copies of N-ras overexpressed 
p21 and the cloned gene had no coding sequence mutations. Since DNA from the original 
human tumor and several metastases did not show N-ras gene amplification, it was 
concluded that amplification had occured during the primary tumorigenesis assay. 
In another series of tumors co-integration of the mouse c-H -ras gene during the 
secondary transfection resulted in tumorigenic overexpression of ras protein without 
elevation of mRNA levels. Three c-H-ras cDNA clones from secondary tumor RNA contained 
no coding sequence mutations, but were divergent at the 3'end. Polymerase chain reaction 
amplification of RNA showed novel alternative splicing at intron E of mouse c-H-ras mRNA in 
both tumors and untransfected cells . 
An upstream ATG was identified that potentially initiates translation of an open reading 
frame (ORF) overlapping the H-ras p21 translation initiation site . A single base deletion 
within exon -1 of the cDNA clones placed this upstream ATG in frame with the ras coding 
sequence, creating a potential fusion protein. Translation of this mRNA in rabbit 
reticulocyte extracts and Xenopus oocytes showed exclusive production of a p23 ras fusion 
protein. When the upstream ATG was deleted, only p21 ras was translated in both systems. 
Based on these results it is proposed that in vivo recognition of the upstream ATG and 
translation of the ORF overlapping the p21 start site might serve to modulate the translation 
of p21. The single base deletion and resultant ras fusion protein may constitute a novel 
mechanism of ras overexpression by circumventing this translational regulation . 
ACKNOWLEDGMENTS 
A special note of thanks to Dr. Alvaro Puga (National Institute of Child Health and 
Development) , who taught me the fundamentals of molecular biology and has been a source 
of support, encouragement and editorial suggestions. I would like to thank Dr. Michael 
Lerman (National Cancer Institute) for his suggestion of including the sib-selection step and 
for all of the extra trips he made from Frederick to Bethesda. I would also like to thank Dr. 
Frank Hetrick of the University of Maryland, for his patience and perserverance over the 
years , and Dr. Abner Notkins (National Institute of Dental Research) in whose laboratory this 
work was done, for his continued support of my work . 
ii 
TABLE OF CONTENTS 
Section 
List of Figures 
List of Tables 
INTRODUCTION 
Chapter I. ONCOGENES: HISTORY AND PERSPECTIVE 
A. RNA Tumor Viruses 
B. Transfection 
C. Newer Methods to Detect Transforming Genes 
D. The Mammalian ras Oncogenes 
1. Biochemical Characterization 
2. Gene Structure and Expression 
Chapter II . MATERIALS AND METHODS 
A. Purification of DNA 
1. Isolation of DNA from Tumors 
2. Isolation of DNA from Tissue Culture Cells 
3. Purification of Plasmid DNA 
4. Purification of Lambda phage DNA 
B. Transfection of NIH 3T3 Cells 
1. Maintenance of NIH 3T3 Cells 
2. Calcium Phosphate Mediated DNA Transfection 
3. Focus Assay 
4. Tumorigenesis Assay 
C. Detection of Transfected DNA 
1. Screening for Repeated Sequences 
2. Screening for ras Genes 



























1. Isolation of Total RNA from Tumor Tissue 35 
2. Isolation of Cytoplasmic RNA from Cells 36 
3. Poly(A) + RNA Purification 36 
4. Northern Blot Analysis 37 
E. Cloning and Sequencing the Transforming Genes 38 
1. Genomic Library Construction and Screening (N-ras) 38 
2. cDNA Library Construction and Screening (H-ras) 41 
3. Sequence Analysis (N-ras, H-ras) 44 
F. Analysis of mouse c-H-ras expression 47 
1. PCR Amplification of RNA and DNA 47 
2 . Construction of Chimeric cDNA Clones 49 
3. In Vitro Transcription and RNAase Protection Mapping 50 
4. Synthesis of Large Amounts of RNA for Translation 52 
G. Protein Detection 53 
1. Western Blot Analysis 53 
2. In Vitro Translation 55 
3. lmmunoprecipitation 56 
4. Translation in Xenopus Oocytes 57 
Chapter Ill. RESULTS 59 
A. Tumorigenesis Assay Rationale and Early Experiments 59 
B. Renal Cell Carcinoma 63 
1. Detection of Human N-ras in Mouse Tumors 63 
2. Cloning and Sequencing the N-ras Gene 65 
3. Activation of N-ras by Gene Amplification 67 
iv 
C. lnsulinoma 
1. Screening Human lnsulinoma DNAs for Activated Oncogenes 
2. Analysis of the 1-9 Series Nude Mouse Tumors 
3. Alternative Splicing in Mouse c-H-ras mRNA 
4 . In Vitro Translation 
5. Upstream ATG Effects 
Chapter IV. DISCUSSION 
A. Tumorigenesis 
8 . Overexpression by N-ras Gene Amplification 
C. Alternative Splicing of c-H-ras 
D. Translation Initiating at an Upstream ATG 
Appendix A. Buffers for DNA Analysis 
Appendix 8. Media and Buffers for Library Analysis 
Appendix C. Buffers for RNA Analysis 
Appendix D. Sequencing Preparations 
Appendix E. Buffers for Protein Analysis 





















LIST OF FIGURES 
Number 
1. Schematic diagram of the tumorigenesis assay. 60 
2. Southern blot of primary and secondary tumors with BLUR8 probe . 62 
3. Southern blot analysis of primary tumor DNAs for human N-ras. 64 
4. Human N-ras genomic structure and sequencing scheme. 66 
5. Western blot analysis N-ras induced nude mouse tumors. 70 
6. Southern blot of K-series tumors and human tumor DNAs for N-ras. 71 
7. Southern blot of I series tumor DNAs for mouse c-H-ras and Alu . 76 
8. Northern blot of I series tumor RNA for c-H-ras and ~ tubulin . 78 
9. Western blot analysis of tumor proteins for ras p21 expression. 79 
10. Comparison of 3 ' untranslated regions of c-H-ras cDNAs. 82 
11 . PCR of mouse c-H-ras intron E. 84 
12. PCR of mouse c-H-ras intron D. 86 
13. lmmunoprecipitation of!!! vitro translation products 88 
14. Diagram of the structure of c-H-ras chimeras and their translation products. 90 
15. In vivo and In vitro translation of chimeric c-H-ras mRNAs. 91 
16. Comparison of c-H-ras 5' untranslated regions. 93 
17. Predicted translation of normal c-H-ras mRNA. 94 






LIST OF TABLES 
Tumorigenesis Analysis of N-ras Phage Clones. 
Tumorigenesis Analysis of lnsulinoma DNAs. 






Tumorigenesis is a multistep process involving several genetic changes and 
presumably the activation of more than one oncogene. Activated oncogenes have been 
isolated from many tumors and tumor cell lines by induction of focus formation in NIH 3T3 
cells (reviewed in Cooper 1983, Bishop 1987) . The first human oncogene isolated by focus 
formation in NIH 3T3 cells, c-H-ras1, was found to be the cellular homolog of the retroviral v-
H-ras transforming gene of Ha-MSV (Der et al 1982, Santos et al 1982, Parada et al 1982, 
Goldfarb et al 1982) , activated by a single point mutation at codon 12 (Pulciani et al 1982b 
' 
Shih et al 1982, Tabin et al 1982, Taparowsky et al 1982, Capon et al 1983). The oncogenes 
most often detected by the classic focus formation assay (Shih et al 1979) are members of 
the ras family of GTP binding proteins with activating point mutations. Since ras genes may 
be activated in up to 40 % of human tumors, the three members of this gene family, H-, K-, 
and N-ras, have been extensively studied (reviewed in Barbacid 1987) . Ras genes can 
become tumorigenic either by point mutations in two regions involved with GTP binding and 
hydrolysis, or by overexpression of the normal gene product (reviewed in Sistonen and 
Alita lo 1986). Even though the ras literature is vast, the function (s) of the mammalian ras 
genes remain largely speculative, and studies of the regulation of ras gene expression are 
incomplete. The ras genes have unusual promoters high in G + C content like in some of the 
housekeeping genes (Ishii et al 1985) . Recently, Cohen et al (1989) have reported a 
mechanism of alternative splicing in human c-H-ras that post-transcriptionally down-
regulates gene expression by defective splicing. 
Tumorigenesis assays have been developed to detect oncogenes that produce less 
profound morphological changes than those required for focus formation in transfected NIH 
3T3 cells (Blair et al 1982, Keath et al 1984, Fasano et al 1984b, Bos et al 1985, Hirai et al 
1987) . These assays, however, were designed to detect the activation of only the most 
dominant acting oncogene in the donor tumor preparation . Again , mutant ras oncogenes 
produce tumors at a much faster rate than myc oncogenes or overexpressed ras proto-
oncogenes (Keath et al 1984, Fasano et al 1984b). Therefore , their presence would obscure 
the activity of any other oncogene also present in the donor DNA. The tumorigenesis assay 
was modified to increase the chance of detecting both strongly and weakly transforming 
oncogenes from the original tumor DNA. Cells co-transfected with a selectable marker were 
sib-selected by separating colonies of transfectants into pools that potentially represent 
different parts of the donor cell genome for tumorigenesis testing . Using this method, two 
human tumor types, pancreatic insulinoma and renal cell carcinoma, were screened for the 
presence of detectable transforming genes. The nude mouse tumor DNAs were analyzed 
for activated oncogenes, and the mechanisms by which ras proteins can become 
overexpressed in nude mouse tumors were investigated. 
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Chapter I 
ONCOGENES: HISTORY AND PRESPECTIVE 
A. RNA Tumor Viruses 
Although RNA tumor viruses were first detected over eighty years ago, it wasn 't until early 
in this decade that many of the connections between viral oncogenes and cellular proto-
oncogenes were discovered. Ellerman and Bang (1908) first showed that chicken leukemia 
was transmissible through cell free extracts. This finding was generally disregarded at the 
time since leukemia was not yet classified as a form of cancer. In 191 O, Peyton Rous set the 
cornerstone of the field of cancer virology by demonstrating the transmission of chicken 
sarcoma through cell free extracts of tumor tissue (Rous 1910) . In the era from 191 o 
through the 1930 's avian sarcoma virus (ASV) was discovered and shown to fulfill Koch 's 
postulates. In rapid succession, many other viruses were isolated from tumors of different 
species including: rabbit papillomas (Shope 1933), mouse mammary tumors (Bittner 1936) , 
and frog kidney carcinoma (Lucke' 1938) . Studies on the papilloma virus of wild rabbits and 
mouse mammary tumor virus (MMTV) revealed several limitations to the application of 
Koch's postulates in evaluating the etiology of tumors . During the experimental 
transmission of papilloma virus to domestic rabbits , Shope demonstrated that after 
inoculation the virus entered into an eclipse phase and was no longer detectable as an 
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infectious agent in the tumor that it caused (Shope 1933). This effect was host dependent 
since the virus did not eclipse in wild rabbit tumors . Bittner 's studies on the etiology of 
MMTV induced mammary tumors revealed that there was a long latency period between 
infection with the virus through the mother 's milk and the appearance of mammary tumors in 
adulthood (Bittner 1936). He also found that tumor formation depended on both host 
genetic susceptibility factors and the interaction of hormones with the 'milk 
influence ', MMTV, since only females developed tumors (Bittner 1952) . 
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As different strains of inbred mice were developed and studied, it was noted that some 
strains showed a high incidence of developing certain cancers while other strains remained 
essentially cancer resistant. Bittner had demonstrated that the high incidence of mammary 
tumors in the C3H inbred mouse strain was due to virus infection. Gross was the first to 
show that the high incidence of leukemia in the AK mouse strain was also due to a virus. 
After many years of unsuccessful attempts by himself and others to "infect" weanling or 
older mice with leukemia, Gross inoculated newborn mice with a supernatant extract of 
leukemic tissue and succeeded at inducing leukemia in a mouse strain otherwise resistant 
to the disease (Gross 1950). In further studies, he showed that murine leukemia virus (Mul V) 
was vertically passaged from one generation to the next (Gross 1951) , a relatively new 
concept at the time for the spread of infectious agents. Due to the crude methods used for 
virus isolation from animal tissues, many laboratories could not reproduce Gross' results 
until he developed a high titer virus stock, passage " A" (Gross 1957). 
The increased use of tissue culture in the 1950 's and the development of new 
techniques for the cultivation of viruses in vitro aided the propagation and detection of RNA 
tumor viruses. In 1952 Dulbecco adapted the bacteriophage plaque assay to quantitate 
animal viruses in cell culture (Dulbecco 1952) . Manaker and Groupe ' (1956) demonstrated 
that infection of chicken embryo cell cultures with ASV induced the formation of foci of 
transformed cells. In 1958, Temin improved the assay by using a sparse instead of crowded 
monolayer for infection (Temin and Rubin 1958). This quantitative focus formation assay 
became a model for the development of assays for other RNA and DNA tumor viruses. 
Even though the in vitro focus formation assay provided a quick screening method for 
the presence of transformation competent viruses, no conditional lethal mutants of RSV 
were isolated until 1969. Toyoshima reasoned that the restrictive temperature for an avian 
virus should be high since the normal body temperature of chickens is 42 °C. He was the first 
to isolate temperature sensitive and transformation defective RSV mutants (Toyoshima and 
Vogt 1969). The availability of these mutants led to the localization of the src gene within the 
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RSV genome (Duesberg and Vogt 1970, Martin 1970). The first evidence that a viral 
oncogene was derived from the host cell genome was obtained by hybridization of the src 
gene of RSV with avian genomic DNA (Stehelin et al 1976). The src gene product was 
identified as a 60 kd phosphoprotein not essential for viral function (Brugge and Erikson 
1977) . RSV is the only known acutely transforming retrovirus that contains all essential 
genes for replication along with a transduced oncogene. All other transforming retroviruses 
are replication defective since the oncogene they carry has replaced part of the essential 
replication genes, as discussed below. 
Most of the rapidly transforming murine sarcoma viruses (MSVs) have been 
discovered during the passage of MuLV in animals. The first acutely transforming MSV was 
isolated by Harvey in 1964. She serially passaged Moloney murine leukemia virus (Mo-
MuL V) in rats and then inoculated filtered plasma from leukemic rats into newborn BALB/c 
mice. Surprisingly, the mice rapidly developed sarcomas at the site of infection, instead of 
the expected leukemia (Harvey 1964) . Moloney also isolated a sarcoma virus after passage 
of his MuLV strain in newborn BALB/c mice, Moloney-MSV (1966) . Kirsten and Mayer 
isolated another murine sarcoma virus from their strain of Mul V which normally induced 
erythroblastosis in rats (Kirsten and Mayer 1967) . BALB-MSV was isolated from an old 
mouse that developed a 'spontaneous' chloroleukemia during a study to determine the 
incidence of tumorigenesis in BALB/c mice (Peters 1974). Another MSV, Ra-MSV, was 
isolated more recently from a c-type retrovirus producing rat embryo cell line that 
spontaneously transformed after a long period of culture in vitro (Rasheed et al 1978). 
Soon after the isolation of Moloney MSV, an in vitro focus formation assay, similar to 
the assay for ASV, was developed using BALB/c mouse embryo cells (Hartley and Rowe 
1966) . Another cell line, NIH 3T3, was established in the late 1960 's to assay MSV focus 
formation (Jainchill et al 1969) . It was originally thought that focus formation by the 
replication defective MSVs required help by replication competent MuLV. In 1970, it was 
demonstrated that the defective MSV's could induce focus formation alone in BALB/c 
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established mouse cell lines (Aaronson et al 1970) . The helper MuLV was only needed for 
MSV replication and in concert they produced more rapid focus formation by infection of 
neighboring cells . 
In the 1960's, two hypotheses to explain the origin of cancer and cancer causing 
viruses were proposed . Temin proposed the protovirus hypothesis, that oncogenic RNA 
viruses arose spontaneously during DNA to RNA to DNA information transfer (Temin 1964) . 
This idea never became widely accepted until the discovery of the retroviral enzyme that 
could transcribe RNA into DNA, reverse transcriptase, provided a possible mechanism for 
the process (Te min and Mizutani 1970, Baltimore 1970) . Huebner and Todaro proposed the 
" oncogene hypothesis" that carcinogens, radiation or host genetic factors can cause 
tumors by inducing experssion of retroviral genes resident in the genome of most, if not all 
animals (Huebner and Todaro 1969, Todaro and Huebner 1972) . It was subsequently 
shown that the oncogenes that become activated are host genes not endogenous viral 
genes (src : Spector et al 1975, Stehelin et al 1976, ras: Scolnick and Parks 1974, mos: 
Scolnick et al 1975, Oskarsson et.al 1980). Retroviral replication includes reverse 
transcription of the viral RNA genome into DNA and integration into the host genome 
(reviewed in Hughes 1982) . Rare recombination events occur in which host genes are 
fortuitously picked up by the retrovirus , usually at the expense of one of the viral genes 
necessary for replication . Therefore during the passage of murine leukemia viruses in 
rodents, as described above, several acutely transforming MSVs were generated by the 
acquisition of activated oncogenes from the host during illegitimate recombination events. 
Both Ki-MSV and Ha-MSV were shown to contain acquired rat sequences (Scolnick et al. 
1973, Scolnick and Parks 197 4), and a normal cellular protein could be detected with anti-
viral antibodies in uninfected cell extracts (Langbeheim et al 1980) . The proto-oncogene 
and oncogenic forms of these genes were later identified as members of a gene family (Ellis 
et al 1981) termed ras from its original isolation from a rat sarcoma. These two MSVs also 
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contain sequences from rat (30S) endogenous retroviruses and therefore must have 
originated from complex recombinational events (Chien et al 1979). 
Retroviral oncogenes, termed 'v-onc' genes, are transduced, intron-less, usually 
mutant copies of cellular oncogenes, termed 'c-onc ' genes (Bister and Jansen 1986) . With 
the exception of Mo-MSV, which contains the v-mos gene, the replication defective MSVs 
were generated by transduction of host derived ras genes (see Lacal and Tronick 1988 for 
review) . BALB-MSV contains acquired mouse sequences, originally termed v-bas and later 
renamed v-H-ras , homologous to the rat sequence in Ha-MSV (Andersen et al 1981). Unlike 
the other ras containing MSVs which express p21 v-ras, a 21,000 dalton protein, the rat v-H-
ras gene acquired by Ra-MSV during its genesis was integrated such that it is expressed as 
a viral ~-ras fusion protein, p29 (Gonda et al 1982). 
The basic definition of an oncogene has evolved from comparisons of the properties 
of genes which have been implicated in carcinogenesis. An oncogene has four properties 1-
it is a eucaryotic gene, 2- it codes for a protein, 3- it has been conserved through evolution 
and presumably fulfills an essential physiological function in normal growth and 
development and 4- it has the potential to become a dominant oncogenic determinant 
(Bister and Jansen 1986) . The normal cellular alleles of oncogenes have been designated 
as proto-oncogenes and the mutant alleles as active oncogenes (Bishop 1981, Weinberg 
1982, Duesberg 1983) . Comparisons between the cellular proto-oncogenes and the 
transduced viral oncogenes, have revealed several types of genetic mutations including 
truncation, point mutations, frame shift mutations and substitutions (reviewed in Bishop 
1987). 
Retroviral activation of a proto-oncogene can occur by several mechanisms including 
transcriptional effects and mutational effects . Insertion of a viral enhancer or promoter next 
to a proto-oncogene during proviral integration can cause increased proto-oncogene 
expression and tumorigenesis by inappropriate expression of a growth regulatory gene . The 
retrovirus can also cause mutations in proto-oncogenes during the process of integration or 
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replication (see Duesberg 1983 for review). Proto-oncogene activation by promoter 
insertion has been documented in the induction of avian B cell lymphomas by ALV. When 
this virus integrates adjacent to the c-myc proto-oncogene, transcription from the viral 
promoter through the c-myc gene causes enhanced expression of the c-myc gene product 
and neoplastic transformation (Hayward et al 1981). One of the many examples of 
activating mutations found in retrovirally transduced oncogenes is the Avian erythroblastosis 
virus acquired v-onc gene, v-erb B, which is a truncated form of the epidermal growth factor 
(EGF) receptor. The virally transduced receptor is missing a 30 amino acid external domain 
and is no longer responsive to EGF, thus causing transmission of an uncontrolled growth 
signal in the infected cell (Downward et al 1984). 
Two conceptual models of oncogene activation , qualitative and quantitative, were 
described by Bishop in 1981 in an attempt to generalize the known mechanisms of all forms 
of oncogene activation, viral , chemical and spontaneous. The quantitative model invoked a 
"dosage hypothesis" in which disturbances of normal transcriptional or translational control 
can result in overproduction or inappropriate expression of an unaltered gene product which 
then results in uncontrolled cell growth . The above example of viral promoter insertion 
causing the over-expression of the normal c-myc protein provided support for this 
hypothesis in virus induced tumorigenesis . Chromosomal translocations between the c-myc 
proto-oncogene and the immunoglobulin loci in human Burkitts ' lymphoma that result in 
deregulation of c-myc expression also provide support for this hypothesis (Leder et al 1983) . 
Further evidence favoring this model comes from transfection studies in which 
overexpression of proto-oncogenes including mos (Blair er al 1981) , ras (Chang et al 1982) 
and the EGF receptor (Di Fiore et al 1987) under the control of retroviral promoters induces 
transformation . The qualitative model of oncogenesis states that activation of an oncogene 
is due to mutational change(s) in the coding domain of a proto-oncogene resulting in normal 
levels of expression of a functionally altered protein as in the previous example of v-erb-B. 
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The prevalence of specific point mutations activating ras proto-oncogenes in human tumors, 
as discussed below, provides an ample base of support for the qualitative model. 
B. Transfection 
DNA mediated transfection techniques were first established to induce the in vitro 
incorporation and expression of viral genes in eucaryotic cells , thus bypassing the necessity 
for viral infection . Using a DEAE dextran technique, Hill and Hillova (1971) first reported 
recovery of infectious virus by transfection with genomic DNA from cells infected with RSV. 
Graham and Van der Eb (1973) described an improved transfection technique based on 
calcium-phosphate-DNA co-precipitation . In 1978, a modification of the calcium phosphate 
transfection technique was shown to be sensitive enough to transfer single copy eucaryotic 
genes to recipient cells (Wigler etal 1978). Then, in 1979 Shih passaged the phenotype of a 
chemically transformed tumor to recipient NIH 3T3 cells by transfection with tumor DNA 
(Shih et al 1979). Soon several other laboratories reported similar results (Cooper et al 
1980, Krontiris and Cooper 1981, Shih et al 1981 , Pulciani et al 1982a) . The transfection of 
tumor cell DNA, containing certain activated oncogenes, into NIH 3T3 recipient cells results 
in the morphological transformation of these normally contact inhibited cells Into tumor 
cells . Activated oncogenes have been isolated from many tumors of non-viral origin using 
this method (Murray et al 1981 , Perucho et al 1981, Pulciani et al 1982b, Padua et al 1984, 
Shimizu et al 1983, Cooper et al 1984, Eva and Aaronson 1985, Martin-Zanca et al 1986) . 
Many of the tumor associated oncogenes isolated by transfection have turned out to be 
homologs of the retroviral oncogenes, particularly the members of the ras family (see 
Weinberg 1982, and Bishop 1987 for reviews) . Some novel , oncogenes not related to those 
transduced by retroviruses have also been detected. The novel oncogene, trk, isolated from 
a human colon carcinoma, was shown to have been activated by a chromosomal 
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translocation that resulted in the fusion of a non-muscle tropomyosin gene with the 
transmembrane and tyrosine kinase domains of a receptor gene (Martin-Zanca et al 1986) . 
The first oncogene that was isolated by transfection of human tumor cell DNA was a 
homolog of the retroviral v-H-ras transforming gene of Ha-MSV (Der et al 1982, Santos et al 
1982, Parada et al 1982, Goldfarb et al 1982) . This T24 ras (c-Ha-ras-1) oncogene is 
activated by a point mutation in codon 12 of the coding sequence (Pulciani et al 1982b, Shih 
et al 1982, Tabin et al 1982, Taparowsky et al 1982, Capon et al 1983). Several strategies 
were employed by different investigators to isolate this oncogene. They all, however, used 
the NIH 3T3 cell transfection and focus formation assay (Shih et al 1979, Shih et al 1981) to 
detect the presence of a functional transforming gene in the donor DNA. The recipient NIH 
3T3 mouse fibroblast cell line (Jainchill et al 1969) has an enhanced ability to take up and 
express exogenous DNA. When transformed, these normally flat , contact inhibited cells 
become rounded and retractile and show disorganized growth patterns resulting in the 
appearance of foci on top of the monolayer. The assay consists of immobilizing the tumor 
DNA in a calcium phosphate co-precipitate, pipetting the precipitate onto a sparse 
monolayer and observing the cells for the appearance of transformed foci over a period of 3 
to 4 weeks. Since up to 1 o4 kb of the donor cell DNA can be incorporated into a transfected 
cell (Wigler et al 1979, Perucho et al 1980), far more human DNA than that which is 
associated with the oncogene is usually found in the primary transformants . Secondary and 
even tertiary transfections may be required to randomly separate the transforming gene 
from irrelevant donor genes for subsequent cloning. Two types of genetic markers have 
been used to detect the presence of the donor oncogene in the recipient transfected cells : 
either repetitive sequences endogenous to the donor DNA, or a retrievable bacterial marker 
gene ligated to the donor DNA. 
Several families of highly repeated DNA sequences are found interspersed 
throughout the human genome. One of the most abundant repeated sequence families is 
named "Alu" due to the presence of an Alu I restriction site found in most of its members. 
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This 300bp long repeat family is present at 300,000 to 900,000 copies in the human 
genome, with a random interspersion frequency averaging a few kilobases (Rinehart 1981 
Kornberg and Rykowski 1988) . Members of the Alu family were cloned Into pBR322 and 
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named the BLUR @am _!::inked .!:!_biquitous ~epeat) plasmid series (Jelinek, et al 1980). 
Weinberg 's group at the Massachusetts Institute of Technology was first to take advantage 
of this naturally occuring human sequence marker. They screened for the presence of 
human oncogenes in transfected mouse cell DNA by hybridizing Southern blots with the 
cloned BLUR 8 probe which does not cross hybridize with mouse repeated sequences (Shih 
et al 1981) . As mentioned above, the primary transformants contained many co-integrated 
fragments of human DNA, whereas the secondary and tertiary transformants contained less 
human DNA, usually only that associated with the oncogene sequences. To clone the 
oncogene, they screened bacteriophage libraries of genomic DNA from NIH 3T3 cell 
secondary transformants for the presence of human repeated sequences using the same 
radioactively labelled BLUR 8 probe (Shih and Weinberg 1982). This method, and a slight 
variation using radioactively labelled total human genomic DNA, has since been used many 
times to isolate oncogenes from human tumor DNAs that induce focus formation in NIH 3T3 
cells (Murray et al 1981, Pulciani et al 1982, Padua et al 1984, Eva and Aaronson 1985, 
Martin-Zanca et al 1986) . 
Michael Wigler's group at the Cold Spring Harbor Laboratory took a different, more 
generally applicable approach to finding a foreign gene in a genomic library of secondary 
transformants (Goldfarb et al 1982). They digested the human tumor DNA with a restriction 
enzyme which did not destroy its tumorigenicity, and ligated a bacterial marker gene, sup F, 
to each fragment before the primary transfection . This marker gene was then rescued from 
a crippled bacteriophage genomic library of secondary transformants as a tag for the 
presence of the donor DNA from the primary transfection . Theoretically, the bacteriophage 
vector cannot grow due to amber nonsense mutations in two essential genes. Since the 
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marker gene codes for an amber suppressor tRNA which will allow the phage to grow, only 
bacteriophage containing the marker gene should produce plaques when proper growth 
conditions and bacterial host are used. The few phage that grow under the restrictive 
conditions can then be screened for the presence of the oncogene by transfection assays 
on NIH 3T3 cells . In practice, however, the background reversion rate has been much 
higher than expected and tedious genetic analyses of many plaques was required to isolate 
the oncogene (M . Wigler, personal communication) . 
Once the transforming gene was cloned, it was used as a probe to isolate the 
homologous proto-oncogene from a human palcental library and the restriction maps of the 
two genes were compared. No qualitative or quantitative differences could be found 
between the activated T24 ras oncogene and the c-H-ras proto-oncogene. The activating 
mutation was localized by construction of reciprocal hybrid genes between the normal proto-
oncogene and the activated oncogene, and assaying for transforming activity by 
transfection of NIH 3T3 cells (Tabin et al 1982, Reddy et al 1982, Taparowsky et al 1982) . 
The activating lesion was then determined by sequencing the smallest fragment that 
conferred transforming properties to the proto-oncogene. Sequence comparisons between 
the normal and mutant alleles revealed that a point mutation at codon 12 caused the 
substitution of a valine for a glycine in the T24 ras oncogene. This general series of 
experiments has become the standard method for determining the mechanism of activation 
of newly isolated ras oncogenes. Since two "hot spots" for activating point mutations have 
been identified in the ras genes, some newer methods of screening for these mutations only 
have been developed based on polymerase chain reaction amplification of exons one and 
two (Forrester et al 1987, Bos et al 1987). This form of genetic screening is fast and 
sensitive for the presence of mutations, however, the only mutations detected are those 
already known . 
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C. Newer Methods to Detect Transforming Genes 
Since the majority of activated oncogenes detected by the focus formation assay on 
NIH 3T3 cells are members of the ras gene family that are activated by structural point 
mutations, several investigators have attempted to modify the assay and to look for 
alternative assays that are potentially more sensitive in the detection of other oncogenes. In 
an attempt to overcome the apparent bias of the focus formation assay to detect mutant ras 
genes, Blair et al (1982) described a bioassay based on transfection of NIH 3T3 cells 
followed by tumor formation in nude mice. However, the background spontaneous 
transformation rate of NIH 3T3 cells to the tumorigenic phenotype made the analysis of 
many tumors necessary. The increased sensitivity of the tumorigenicity assay for detecting 
oncogenes other than ras was shown by Keath et al (1984) . They demonstrated that NIH 
3T3 cells transfected with the myc oncogene became tumorigenic in nude mice without 
inducing significant morphological transformation. To overcome the high rate of 
spontaneous tumors generated by the tumorigenisity assay, Fasano et al (1984b) co-
transfected limiting amounts of a dominant selectable marker plasmid with an excess of 
genomic tumor DNA. By pre-selecting the cells for the presence of the transfected marker 
gene before tumorigenesis testing, the background of spontaneous tumor formation was 
greatly reduced and the sensitivity of the assay was increased. This assay was sensitive 
enough to detect amplified normal ras genes according to Fasano (1984b) , but in two other 
reports using similar techniques, the authors claimed that normal ras genes did not induce 
tumorigenesis (Bos et al 1985, Hirai et al 1987). Using a tumorigenesis assay, Wigler 's 
group found a new oncogene they called mas, that had been activated by rearrangement in 
the non-coding sequences during transfection (Young et al 1986). Another gene created by 
rearrangements occuring during transfection , rel , was previously reported by Cooper 's 







Spontaneous and chemically induced tumorigenesis is known to be a multi-step 
process (reviewed in Land et al 1983b). Transformation of normal cells in culture into tumor 
cells also requires the cooperation of more than one activated oncogene (Land et al 1983a, 
Newbold et al 1983, Ruley et al 1983) . Oncogenes were placed in two complementation 
classes, the ras- or the myc- class, based upon cooperation in transforming primary cells, 
usually rat embryo fibroblasts . NIH 3T3 cells are pre-neoplastic and only require the action 
of a single activated oncogene to become tumorigenic (reviewed in Cooper 1982). In 
several instances more than one activated oncogene have fortuitously been detected in the 
same tumor using NIH 3T3 cell transfection assays (Murray et al 1983, Fasano et al 1984b) . 
D. The Mammalian ras Oncogenes 
Following the discovery that the human oncogene isolated from T24 cells was 
homologous with a viral ras oncogene (Parada et al 1982), research into the characterization 
of Ras proteins and ras induced transformation has exploded. The impetus to study ras has 
been boosted further with the realization that up to 40% of human tumors contain activated 
ras genes (reviewed in Barbacid 1987) . Using the polymerase chain reaction to detect 
activated ras genes instead of one of the bioassays, two groups showed that a high 
proportion (40%) of colon carcinomas have ras point mutations, usually K-ras (Forrester et al 
1987, Bos et al 1987) . Even though the ras literature is vast , the function (s) of the 
mammalian ras genes remain largely speculative . Of the three mammalian ras genes, H-
ras , K-ras and N-ras, the latter is the only one without a viral homolog. N-ras was first 
discovered by transfection of DNAs from human neuroblastoma, leukemia and sarcoma cell 
lines (Shimizu 1983, Hall 1983). All three genes have similar intron-exon boundaries and the 
p21 proteins are highly homologous in several regions suggesting divergence from a 
common ancestral gene. A series of monoclonal antibodies generated against viral Ras 
proteins show varying cross-reactivities between the three proteins (Furth et al 1982) and 
14 
several of these antibodies have been used extensively for p21 detection and biochemical 
characterization. 
1. Biochemical Characterization 
The p21 Ras proteins bind guanine nucleotides (Shih et al 1980) and are strucutrally 
similar to the signal transducing G proteins. The possibility that they participate in signal 
transduction was reinforced by their localization at the inner surface of the cytoplasmic 
membrane (Willingham et al 1980). The Ras proteins have a low GTPase activity that is 
decreased in oncogenic mutants (Gibbs et al 1984) . All three ras oncogenes have been 
activated by point mutations at codons 12, 13, and 61 by either viruses, chemical 
carcinogens or in human tumors (reviewed in Barbacid 1987). Several other potential 
activating mutations have been identified by in vitro mutagenesis studies (Fasano et al 
1984a, Sig al et al 1986a) . All mutations that activate the oncogenic potential of Ras proteins 
effect the binding or GTPase activity of Ras such that the GTP bound form is favored, 
therefore it is assumed that the GTP bound form is the active form of the Ras protein. The 
retroviral v-H-ras also has a mutation that substitutes a threonine for an alanine at position 
59 which becomes auto-phosphorylated (Shih et al 1980); the normal p21 Ras is not 
phosphorylated. 
Two tools have greatly facilitated the characterization of Ras proteins: production of 
large quantities of functionally active Ras p21 in E.coli (Lautenberger et al 1983, Poe et al 
1985), and of monoclonal antibodies that bind to specific epitopes of the p21 s. Micro-
injection of physiological amounts of purified v-H-ras p21 into NIH 3T3 cells caused 
morphological transformation and thymidine incorporation; micro-injection of a larger 
quantity of the normal protein was required for transformation (Stacey and Kung 1984). Of 
the monoclonal antibodies that were made to viral Ras proteins, Y13-259 has been used 
most extensively to detect and characterize Ras p21 's since it cross-reacts with all three 
mammalian Ras proteins (Furth et al 1982, Srivastava et al 1985). Monoclonal antibody 
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Y13-259 binds to 6 amino acids within a conserved epitope, aa 63-73 (Sigal et al 1986b) . 
Antibody binding to p21 interferes with GTP binding, probably by stearic hinderance. 
Microinjection of this monoclona l anti-p21 inhibits serum stimulation of cell growth and 
blocks NIH 3T3 cells in GO supporting the idea that the ras proto-oncogene is involved in 
growth control (Mulcahey et al 1985) . Micro-injection of ras transformed cells with a 
monoclonal antibody specific for the codon 12 mutation caused reversion of the transformed 
phenotype (Feramisco 1985), thus proving that ras activation is required to sustain 
transformation. In an attempt to address the potential signal transduction mechanism of 
Ras proteins, monoclonal Y13-259 was injected into cells transformed with oncogenes 
known to be active in different parts of the cell. Antibody injection blocked the entry into S 
phase of cells transformed by growth factor receptor oncogenes such as fms or oncogenes 
that associate with the cell membrane such as src and fes, but had no effect on the 
cytoplasmic oncogenes mos and raf (Smith et al 1986). These resu lts support the 
hypothesis that p21 Ras is involved in signal transduction of at least some stimuli for growth. 
Micro-injection experiments with ras proteins and antibodies were recently reviewed by Bar-
Segi (1989) . 
Using EM immunocytochemistry, Willingl1am et al (1980) localized Ras proteins to the 
inner surface of the cytoplasmic membrane. Early on it was realized that Ras was 
synthesized as a precursor and was processed in some way that allowed membrane 
association (Shih et al 1982) . The cysteine at position 186 was shown to be required for ras 
mediated transformation and for localization to the plasma membrane (Willumsen et al 
1984). It was first thought that palmitoylation of the amino terminal cysteine was the 
modification required for membrane association (Chen et al 1985), but only a small portion 
of Ras is acylated. More recent experiments have shown that the primary translation 
product, pro-Ras, goes through several post-translational modifications, including addition 
of a farnesyl isoprenoid moiety to Cys 186 (Casey et al 1989), carboxy-termina l trimming of 
the last three amino acids and methylation of the new carboxy terminus, Cys186 (Gutierrez 
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et al 1989) . These irreversible changes are followed by palmitoylation of cysteines within the 
variable region adjacent to Cys186. Since only a small portion of the Ras proteins are 
palmitoylated it has been speculated that this final modification may have a role in directing 
the protein to a specific region of the membrane for signal transduction (Hancock et al 
1989). 
The Ras proteins have two GTP binding domains, aa 106-120 and 152-165 (reviewed 
in Barbacid 1987) , and an effector domain, aa 35-40 (Si gal et al 1986b). At least one protein 
is now known to bind to the effector domain- the §TPase ~ctivator _!:rotein, GAP (Adari et 
al 1988). The GAP protein is responsible for activating the GTPase activity associated with 
normal p21, but it has no effect on the codon 12, 59 or 61 ras mutants associated with 
transformation (Trahey and McCormick 1987). Therefore GAP is thought to have two 
activities in relation to Ras, 1) it specifically binds to Ras p21 and may act as the 
downstream signal transducer when Ras is in the GTP bound state, and 2) GAP activates 
the GTPase activity of Ras inducing dephosphorylation of the bound GTP, thus turning off its 
own activation signal. All ras mutants that do not bind GAP are non-functional and the 12, 
13, and 61 mutants that bind GAP are not susceptible to the GTPase activating activity of 
GAP and therefore are always in the active configuration (reviewed in McCormick 1989). 
2. Gene Structure and Expression 
The three members of the ras family share a basic genomic structure of 4 coding 
exons with identical intron-exon boundaries suggesting that they may have emerged from a 
common ancestral gene (Taparowski et al 1983). A large portion of the 5' non-coding region 
of all three genes is located on a separate -1 exon, and many ras genes have upstream ATG 
initiation codons. The significance of this deviation from the usual case of initiation at the 
ATG closest to the mRNA CAP is not yet understood (Kozak 1989). The promoter regions of 
the ras genes are also unusual. Instead of the usual TATA and CAAT sequences, the ras 
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GC boxes were originally found associated with housekeeping genes, but since these same 
motifs are also associated with the promoter of the EGF receptor it is speculated that this 
type of promoter may be associated with certain genes involved in growth regulation (Ishii et 
al 1985). 
The promoter of the human c-K-ras 2 gene has 4 repeats of G + C rich motifs and no 
TATA or CAAT box. It is the largest member of the ras family due to very large intrans and 
alternative 3 'ends (McGrath et al 1984, McCoy et al 1984). An alternative fourth exon 
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termed 4b, codes for a functional p21 that has no cysteines in the variable region resulting in 
the only form of p21 that is not palmitoylated (Casey et al 1989). The functional significance 
of the two forms of K-ras p21 is not yet clear. This gene is frequently activated by point 
mutations in human colon and lung carcinomas (McCoy et al 1983, reviewed in Kahn et al 
1987). Due to its large size, approximately 45 kb, it has been very dificult to isolate activated 
~ oncogenes from tumor DNAs. Several investigators have used the polymerase chain 
reaction (PCR) to detect mutant K-ras genes in tumor DNAs. This technique is more 
sensitive than transfection and not dependent on the intactness of the DNA sample, but is 
limited by its ability to detect only known mutations. Using PCR, the frequency of K-ras 
mutations was found to be very high in human colorectal tumors (Forrester et al 1987, Bos et 
al 1987). Using a combination of PCR amplification and A Nase A mismatch cleavage, 
Almoguera et al (1988) showed that codon 12 of c-K-ras was mutant in 21 of 22 pancreatic 
carcinomas tested. 
The N-ras gene has been most often associated with tumors of myeloid origin even 
though it was first cloned from a neuroblastoma cell line (Taparowsky et al 1983). Using a 
nude mouse tumorigenesis assay, point mutations in codon 13 were detected in acute 
myeloid leukemias (Bos et al 1985, Hirai et al 1987) . Although codon 13 mutations had been 
shown to activate the oncogenic potential of p21 Ras by site directed mutagenesis, this was 
the first isolation of a codon 13 mutation in a natural tumor type. The translated portions of 







end of the gene was found to be unique (Hall and Brown 1985) . In addition to the 4 coding 
exons and the -1 non-coding exon, N-ras has a very small 3' non-coding exon, exon 5, 
followed by a second non-coding exon, exon 6, which contains two alternative 
polyadenylation sites. The first polyadenylation site is not efficiently recognized , resulting in 
the transcription of two mRNAs of 2 and 4.3 kb, the longer being a read through product of 
the shorter. Like the other ras genes, the promoter region of N-ras consists of regions high 
in G + C nucleotides with 4 repeats of the GGGCGG consensus for binding of the 
transcription factor Sp1 (Dynan and Tjian 1983), called GC boxes . Human N-ras mRNA has 
two upstream ATGs; the second ATG, which is conserved with guinea pig N-ras (Doniger 
1987) , is in a good context for initiation of translation of a short open reading frame that 
terminates 18 nucleotides 5' of the p21 initiation site (Hall and Brown 1985). 
c-H-ras is the smallest of the three ras genes, the active human gene being 
approximately 4.5 kb (Barbacid 1987). Like K-ras and N-ras, this gene has 4 coding exons, 
and a -1 exon representing most of the 5 ' untranslated region (UTR) . It has recently been 
noted that the 3 'UTR of the human gene may be alternatively spliced since some cDNA 
clones contain a deletion 3' of the translation termination site (Cohen et al 1989) . H-ras 
activation by specific point mutations has consistently been found in several animal models 
of carcinogen induced tumorigenesis (reviewed in Barbacid 1987) , including induction of 
mammary tumors in rats (Zarbl et al 1985) and in multistage mouse skin carcinogenesis 
models (Bizub et al 1986). H-ras activation may be an early event in the skin carcinogenesis 
model since mutations have been detected in pre-cancerous lesions (Bal main et al 1984) . 
H-ras was also the first human oncogene identified by transfection of human tumor DNA into -
NIH 3T3 cells and therefore has been the most studied of the three members of this gene 
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family. Even so, studies on the control of ras gene expression have lagged far behind those 
on its biochemical characterization . 
The promoter regions of the human (Ishii et al 1985, Honkawa et al 1986), rat 





sequenced . The H-ras promoter contains 5 GC boxes and was shown to bind the Sp1 
transcription factor at these sites by DNase I footprint analysis of the human gene (Ishii et al 
1986). The published mRNA start sites of t11 e l1uman gene are conflicting (Ishii et al 1985, 
Honkawa et al 1986) but the rat and mouse have 3 similar start sites (Brown et al 1988) . 
Portions of the mouse 5'UTR and putative promoter induced CAT production when placed 
5 ' of a CAT gene. By comparing the relative CAT activity of 3 deletion constructs the authors 
concluded that an enhancer is located in t11 e first intron between exon -1 and 1 of the mouse 
H-ras gene (Brown et al 1988) . Using CAT assays, promoter and enhancer like activity has 
also been demonstrated in a 0.8 kb Sstl genomic fragment that includes the -1 exon of the 
human H-ras gene (Spandidos and Riggio 1986) . 
Recently , a group at Genentech l1 as ident ified a point mutation in the 5 ' splice 
junction of an alternative exon , IDX, witl1in int rnn D (between exons 3 and 4) of the human 
T24 ras , c-H-ras-1 oncogene. This mutation causes increased transforming potential of the 
oncogene (Cohen and Levinson 1988, Col1en et al 1989). Translation of the alternatively 
spliced mRNA putatively results in a trunca ted lorm of H-ras. Whether this truncated protein 
has a function or is actually made has not ye t been proven. Placement of the IDX sequence 
within an intron caused reduced expression of ras and of an unrelated reporter gene (Cohen 
et al 1989). Since the normal 5' spli ce site of I DX is not consensus, a mechanism of 
defective processing of the altern ative ly spliced mRNA was proposed for the observed 
negative effect on expression . Previous stu dies of requirements for 5' splice junctions have 
shown that deviation from consensus can inter fere with the second step of splicing and 
result in defective intermediates that are lost during processing (reviewed in Aebi and 
Weissmann 1987) . Cohen et al (1 989) demonstrated that the splice junction mutation in T24 
ras abolished alternative splic ing of the IDX sequence by rendering its poor 5 ' splice site 
unrecognizable . Point mutation of t11e T24-rns IDX splice junction back to normal reduced 
the focus forming activity of T24 ras 1 O fold wit11out significant accumulation of the 
alternatively spliced mR NA, supporting the notion that the alternatively spliced transcripts 
20 
are defectively processed. Further point mutations to crea te a 5' splice site that matched 
consensus abolished the transforming activity of T24 ras, and resulted in accumulation of 
the alternatively spliced mRNA, possibly by con·ecti on of th e defective splicing. As 
demonstrated by these experiments , defective process in g o f transcripts containing the IDX 
sequence may decrease gene expression by reducing the percentage of transcribed RNAs 
that can be translated . Since the H-ras protein is relative ly stable with a half-life of 20 hours 
(Ulsh and Shih 1984), defective processing may be a mechanism used by the cell to prevent 
overexpression of this potentially oncogenic protein. The l1urnan T24 ras(c-H-ras 1) 
oncogene has both a dominant mutation at codon 12. and a mutation in the 5' splice 
junction of the IDX that increases the transforming pot ential of the gene in transfection 
experiments (Cohen and Levinson 1988) . Earlier studies into the mechanism of activation of 
T24 ras, however, demonstrated that the mutant p21 pr otein was not significantly (less than 
3 fold) overexpressed in the T24 tumor· cells from wl1i c l1 it was derived (Tabin et al 1982, Der 
et al 1982). Other mechanisms must also be invo lved in modulating the expression of p21 in 
the cell . 
The ras proto-oncogene is expressed at low leve ls in all cells (Furth et al 1987) , and at 
all stages of development (Muller et al 1982). Elevated leve ls of p21 have been detected in 
some non-proliferating tissues such as brain , hear-t an cf some terminally differentiated 
endocrine cells (Furth et al 1987) . In addition to its fun cti on as a signal transducer in 
response to growth stimuli , p21 may also function in signal transduction of differentiation 
stimuli in certain cell types . In agreement with thi s hypothes is micro-injection of the codon 
12 substituted ras p21 (Bar-Sagi and Feramisco 1985) . or· th e normal p21 pre-incubated 
with the GTPase resistant GTPyS (Satoh et al 1987) induced terminal differentiation of PC12 
pheochromocytoma cells. Infection of l1uman medull ary th yro d carcinoma cells with Ha-
MSV also induced differentiation into more normal C type tl1 yroid cells (Nakagawa et al 
1987) . Therefore the ras proteins may have a dual fun cti on as a signal transducer for 
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normal cellular proliferation and in certain cells Ras may be involved in the activation of a 
pathway that induces terminal differentiation. 
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A. Purification of DNA 
CHAPTER II 
MATERIALS AND METHODS 
1. Isolation of DNA from tumors 
lnsulinoma tumor tissue was obtained either as fresh tissue on ice from the surgical unit 
at the NIH clinical center or as tissue frozen on dry ice and stored at -70° C from M. Linehan 
(NCI) . Tumor tissue was obtained from nude mice, frozen on dry ice and stored at -70°C 
until use. Tumor tissue was weighed , washed and minced into small pieces . Genomic DNA 
was extracted by a modification of the method of Wigler et al (1979) . The minced tissue was 
homogenized in a dounce homogenizer in TNE buffer (refer to Appendix A tor solutions), and 
SOS was added to a final concentration of 0.5% to lyse the cells . Lysates were treated with 
proteinase K (200 µg/ml , Boehringer Mannheim, Indianapolis , IN) at 56°C overnight. The 
crude DNA was gently extracted with phenol : chloroform (1 part redistilled nucleic acid 
grade phenol, BAL, Gaithersburg , MD, to 1 part reagent grade chloroform , J.T. Baker 
Chemical Co ., Phillipsburg, NJ, containing 1124th volume isoamyl alcohol , hereafter 
referred to as Phe:CHCl3) . After a final extraction with chloroform: isoamyl alcohol (24 parts 
reagent grade chloroform , J .T. Baker, to 1 part reagent grade isoamyl alcohol , J.T. Baker, 
hereafter referred to as CHCl3:IAA), the DNAs were precipitated with 0.2 M NaCl and two 
volumes of 95% ethanol and spooled out of solution on sterile glass rods . The spooled 
DNAs were washed with 70% ethanol, air dried, and dissolved in TE buffer slowly with 
refrigeration . DNAs were then incubated with RNase (60 U RNase A, 60 ug/ml RNase T1, 
see appendix A tor preparation of stock solution) at 37°C tor 30 minutes , followed by 
treatment with proteinase Kat 200 µg/ml for 30 minutes at 56°C. The DNAs were again 
extracted and spooled out of ethanol. The purified DNAs were dissolved in TE buffer and 
the approximate concentrations were determined by absorbance at 260 nm using an 
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extinction coefficient of 20 OD260 = 1 mg dsDNA. The absorbance ratio of 260/280 was 
also determined and was routinely between 1.7 to 1.9. 
2. Isolation of DNA from Tissue Culture Cells 
DNA was extracted from pellets of tissue culture cells in essentially the same manner. 
Cells were trypsinized from two- 150cm2 tissue culture flasks by washing each of the 
monolayers with 5 ml of 0.25 % trypsin, 5 mM EDTA in saline (NIH Media Unit), followed by 
incubation with 1 ml per flask of fresh trypsin solution until the cells released from the 
monolayer. The cells were diluted with growth medium (see transfection of NIH 3T3 cells) 
and the single cell suspension was centrifuged at 1000 g for 5 minutes. The cell pellet was 
washed twice with cold DPBS (Dulbeccos PBS, without calcium and magnesium, Whittaker 
Bioproducts, Walkersville, MD) by gentle resuspension and centrifugation. The final cell 
pellets were resuspended in 1 O ml TNE buffer and processed as for tumor DNA. The final 
yield of DNA was approximately 2 mg/g tissue and 300 µg/107 tissue culture cells. 
3. Purification of Plasmid DNA 
The procaryotic-eucaryotic marker plasmid, pSV2-neo, was obtained from a glycerol 
stock in E.coli HB101. An isolated ampicillin resistant colony was inoculated into 3 ml Luria-
Bertani broth (LB, Digene, Silver Spring, MD) containing 100 µg/ml ampicillin (LB +AMP) 
and the culture was grown overnight at 37°C with shaking. One ml of the overnight culture 
was added to 25 ml LB +AMP and shaken at 37°C until the OD6oO was approximately 0.6. 
This log phase culture was added to 500ml pre-warmed LB+ AMP and shaken at 37 °C for 
2.5 hours. Chloramphenicol was added (2.5 ml of a 34 mg/ml solution in ethanol) and the 
culture was shaken overnight to amplify the plasmid (Clewell, 1972). The cells were 
harvested by centrifugation in a Sorvall RC5 with an HS4 rotor at 4,000 g for 20 minutes. 
The plasmid DNA was isolated by a large scale modification of the Holmes and Quigley 
(1981) boiling procedure. The pellet was resuspended in 25 ml STET (see appendix A) , 
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transferred to an Oakridge tube (Beckman , Paolo Alto , CA) and frozen on dry ice. The cells 
were lysed by rapid thawing and addition of 1 ml freshly prepared lysozyme (10 mg/ml in 20 
mM Tris , pH 8.0) . The suspension was boiled in a water bath for 1 minute and cooled on ice. 
The denatured protein and chromosomal DNA were pelleted in a Beckman LS75 
ultracentrifuge with a Ti60 rotor at 25,000 rpm for 45 minutes at 4 °C. The supernatant was 
carefully removed to a 50 ml polypropylene centrifuge tube (Falcon , Becton Dickinson, 
Lincoln Park N.J.), proteinase K was added to a final concentration of 200 µg/ml, and 
incubated at 56°C for 30 minutes. The plasmid preparation was extracted once with 
Phe:CHCl3 and once with CHCl3:IAA being careful not to disturb the white interface. The 
phases were separated in both extractions by centrifugation at 4000 g for 20 minutes in a 
Sorvall RC-3 at 4 °C. One volume of propanol was added to the aqueous phase from the last 
extraction and incubated at -20 °C overnight to precipitate the plasmid. The precipitate was 
pelleted in a Sorvall RC-3 centrifuge at 4 °C for 30 minutes. The pellet was washed with 5 ml 
of 80% ethanol and dried under vacuum. The plasmid DNA was resuspended in 5 ml TE 
buffer and incubated with 50µ1 RNase stock solution (see appendix A) at 37°C for 30 
minutes . Proteinase K was added to a final concentration of 200 µg/ml and the incubation 
was continued for 30 minutes longer. The aqueous phase was again extracted with 
Phe :CHCl3, and CHCl3:IAA, as mentioned above. Plasmid DNA was precipitated with 0.5 
volume of 7.5 M ammonium acetate and 2 volumes of 95% ethanol at -20°C for at least 2 
hours. The precipitate was pelleted , washed and dried as above, and resuspended in 
approximately 500µ1 TE buffer. 
The plasmid DNA was separated from degraded low molecular weight RNA by column 
chromatography. A 30 cm column of Sephacryl S-1000 (Pharmacia, Piscattaway, NJ) was 
equilibrated with 20 mM Tris , pH 7.2, 1 M NaCl, 1 mM EDTA. The plasmid was layered over 
the column bed and the eluate was monitored for absorbance at OD260. Fractions were 
collected and checked for the presence of the plasmid by electrophoresis in a 1 % agarose 
gel (see appendix 1 for buffer). All positive fractions were pooled and precipitated with 2 
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volumes of 95% ethanol at 4 °C overnight. The pellets were washed and dried as above and 
resuspended in 200 µI TE buffer. The DNA concentration was determined by OD260, as 
with genomic DNA. 
A new method of plasmid purification was used for sequencing the subclones of the 
Phage inserts, preparing chimeric plasmids, and in vitro transcription. The method is based 
on a modification of the alkaline lysis method of Birnboim and Dolby (1979), followed by 
adsorption of plasmid DNA to a Qiagen TM column (Qiagen, Studio City, CA). The degraded 
ANA and protein contaminants were washed through the column and the pure plasmid DNA 
was eluted in 1.2 M NaCl, 50 mM 3-[N-morpholino]propanesulfonic acid (MOPS), 15 % 
ethanol. The Qiagen columns were purchased as complete kits, including buffers, and were 
used according to the instructions of the manufacturer. The eluted plasmid DNA was 
precipitated with o. 7 volumes propanol at room temperature. After washing the precipitate 
with 70 % ethanol, the DNA was resuspended in TE buffer and re-precipitated with 0.5 
volumes of 7.5 M ammonium acetate and 2 volumes of ethanol at -20°C for 2 hours. The 
precipitate was pelleted, washed and dried as above. The pure plasmid DNA was 
resuspended in TE buffer and the concentration was determined by OD2eo as above. The 
purity of these plasmid DNA preparations was equivalent to cesium chloride ethidium 
bromide gradient purified plasmids with a preparation time of hours instead of days. 
4. Purification of Lambda Phage DNA 
Phage clones were grown in the respective E.coli host as mentioned under the library 
construction sections. Minipreparations of phage DNA were prepared from plate lysates by 
adsorption with lambdasorb TM (Promega Corp., Madison, WI) . Two- 100 mm petri dishes 
(1025, Falcon) or one- 150 mm plate (3025, Falcon) were overlayed with 6 ml (total) warm LB 
top agarose containing 300 µI freshly prepared host bacteria infected with 105 phage. The 
agar was allowed to solidify at room temperature, then the plates were incubated at 37°C 
until complete lysis occured, usually 8 hours to overnight . The phage were harvested by 
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layering 5 ml phage dilution buffer (TM , see appendix B) over the plate(s) and allowing the 
phage to diffuse into the buffer during a 1 hour incubation in the cold with gentle rocking. 
The buffer was collected and replaced with fresh buffer for one additional hour. The phage 
were pooled and the total volume was adjusted to 1 0 ml with TM buffer. The phage 
suspensions were shaken with a few drops of chloroform and the debris was pelleted by 
centrifugation at 4,000 gin a Sorvall RC3 . The supernatant bacteriophage were adsorbed 
to 100 µI lambdasorb TM for 30 minutes on ice with i1termittant mixing in a polypropylene 
tube (2059, Falcon). The lambdasorb-pl1age precipitate was collected by centrifugation at 
10,000 g for 30 minutes at 5 °C. The pellet was carefully resuspended in 1 ml TM buffer and 
transferred to a 1.5 ml Eppendorf tube. The lambd asorb was re-pelleted in a microfuge for 
1 minute, and washed again in 1 ml TM buffer . The final pellet was resuspended in 0.5 ml 
TE buffer, EDTA was added to 1 O mM and the phage DNA was released by incubation at 
70°C for 5 minutes. The debris was pelleted in a microfuge for 10 minutes and the 
supernatant was extracted once with Phe:CHCl3 and once with CHCl3:IAA. The DNA was 
precipitated with 0.5 volumes 7.5 M ammonium aceiate and 2 volumes ethanol at -20°C for 
2 hours. The DNA precipitate was pelleted in a microfuge, washed with 70 % ethanol , dried 
under vacuum , and gently resuspended in 200 µI TE buffer. Residual RNA contamination 
was removed by digestion with RNase (see appendi< A for stock solution) at 37°C for 15 
minutes. The DNA was then re-e xtracted and precipitated as above. Phage DNAs prepared 
by this method were used for restriction mapping and subcloning . 
Liquid lysates were grown of selected phage clones to make large amounts of purified 
phage DNA for transfection studies. A 1 O ml culture of host bacteria, eg. E.coli LE392 was 
grown overnight and the OD500 was determined. An OD of 1.8 = 1.4 X 1 o9 cells. The 
equivalent of 1O10 cells were pelleted and resuspended in 3 ml SM buffer. The bacteria 
were inoculated with 101 O phage and incubated without shaking at 37°C for 20 minutes for 
phage attachment. The infected cells were inoculated into 500 ml NZCYM broth (see 
appendix B) and shaken in a rotary shaker at 200 revolutions per minute for approximately 5 
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hours at 37°C until the culture lysed. Chloroform (5 ml) was added to help complete the 
lysis and the culture was shaken for 15 minutes . Sodium chloride was added to 0.5 Mand 
the culture was shaken for 15 more minutes. The bacteriophage were purified by a 
modification of the method first described by Yamamoto et al (1970) . The cellular debris 
was pelleted by centrifugation at 7,000 g for 15 minutes at 5 °C and the phage in the 
supernatant were precipitated with 10% polyethylene glycol (PEG 8000, Baker) on ice for 1 
hour. The precipitate was collected by centrifugation at 7,000 g for 15 minutes at 5°c. The 
precipitated phage were gently resuspended in SM buffer using a wide bore pipet and the 
polyethylene glycol was extracted from the bacteriophage suspension by shaking with with 
an equal volume of chloroform . The phases were separated by centrifugation at 3,000 g for 
15 minutes at 5 °C and the aqueous phase containing the phage particles was used for 
further purification. 
The phage were banded on a cesium chloride step gradient. The resuspended phage 
were diluted to 20 ml with SM buffer and half was layered over each of two step gradients 
consisting of 13 ml 1.4 g/ml cesium chloride in TM over 13 ml 1. 6 g/ml cesium chloride in TM 
in polyallomer ultracentrifuge tubes (326823, Beckman). The gradients were run in an 
SW28 rotor at 20,000 rpm, for 18 hours at 20°C. The phage bands were collected, pooled, 
and desalted by column chromatography on pre-packed Sephadex columns (PD10, 
Pharmacia) equilibrated with TM buffer. The desalted phage were digested with crude 
DNase (1 µg/ml, Sigma) , and RNase (6 µg/ml T1 , Sigma) at 37°C for 30 minutes. 
Proteinase K was added to 200 µg/ml , EDTA to 10 mM, SDS to 0.5% , and the lysed phage 
were incubated at 56°C for 30 minutes. Phage DNA was extracted with Phe:CHCl3 and 
CHC13:IAA as mentioned for other DNA preparations and was precipitated by the addition of 
NaCl to 0.2 M and 2 volumes of ethanol. The precipitated DNA was spooled out of solution 
on a small glass rod , washed with 80 % ethanol and air dried . The purified DNA was 
resuspended in TE buffer and the concentration was determined as above. 
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B. Transfection of NIH 3T3 Cells 
1. Maintenance of NIH 3T3 Cells 
NIH 3T3 cells (Jainchill et al 1969) were obtained from Mariano Barbacid (NCI). Proper 
maintenance of these cells is critical for reproducible tumorigenesis and focus formation 
results. The cells were immediately grown in several 175cc- T flasks and frozen in liquid 
nitrogen at one passage after receipt in aliquots of approximately 106 cells. The cells were 
trypsinized as described previously at 80 % confluence and washed with growth medium. 
The cells were centrifuged at 1000 g for 5 minutes, resuspended at approximately 106 
cells/ml in freezing medium, and 1 ml aliquots were frozen first at -70°C in 1.5 ml vials 
(Nunc, Denmark) and after 2 days Equilibration, transferred to liquid nitrogen. Freezing 
medium consisted of 10 % dimethyl sulfoxide (DMSO, Sigma, St. Louis, MO) , 15 % fetal 
bovine serum (FBS, Gibco, Grand Island, NY), and 75% Dulbecco's modified Eagles 
medium (high glucose DMEM, Whittaker Bioproducts). For each transfection experiment an 
aliqout of cells was quickly thawed in a 37°C waterbath with constant agitation, and washed 
by dilution with 1 o ml growth medium and centrifugation at 1000 g. The cells were then 
resuspended in growth medium and plated into 2- 75cc flasks at 2/3, and 1 /3 of the frozen 
cells per flask. Growth medium was DMEM with 100 mg/ml penicillin G, 135 mg/ml 
streptomycin sulfate, 2 mM glutamine, and 10% heat inactivated calf serum (Colorado 
Serum Co., Denver, CO). The cells were observed daily and the flask that was 80 to 90 % 
confluent on the day before transfection was used as seed stock. 
2. Calcium Phosphate Mediated DNA Transfection 
NIH 3T3 cells were co-transfected with tumor or cellular DNA and pSV2neo using a 
modification (Wigler et al 1979) of the procedure of Graham and Van der Eb (1973) . The 
procedure was obtained from Mariano Barbacid 's laboratory (NCI) . Briefly, on the day 
before the transfection, NIH 3T3 cells were plated at 105 cells per 100 cm2 dish (Falcon) in 
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growth medium. On the morning of the transfection day, the plates were observed for the 
presence of a sparse even monolayer, and the medium was changed. The DNAs to be 
transfected (usually 600 ng pSV2neo and 80 to 100 µg tumor DNA for 2 plates) were first co-
precipitated with 0.2 M NaCl and 2 volumes of 95% ethanol for 30 minutes on dry ice. The 
DNAs were pelleted and washed with 80% ethanol and dried under vacuum. The DNAs 
were treated as sterile at this point, and resuspended in sterile distilled water (0.25 
ml/plate). A calcium phosphate-DNA co-precipitate was prepared by the addition of 0.25 
ml/plate of 0.5 M Cac12 to the resuspended DNAs, followed immediately by dropwise 
addition of the DNA mixture to an equal volume of 2X HNP buffer (49 ml of 50 mM Hepes, pH 
7. 1, 280 mM NaCl mixed with 1 ml of 70mM sodium phosphate, pH 7.1 just before using) 
with constant mixing. The co-precipitate was allowed to form for 30 to 60 minutes at room 
temperature. This fine precipitate was then gently resuspended and pipetted onto the NIH 
3T3 cell monolayers. Twelve hours later the media were changed, and 2 hours later 
changed again to make sure that all of the precipitate was washed off. 
3. Focus assay 
If the transfection was for a focus assay, then pSV2neo was omitted and the 
transfected cells were fed with maintenance medium (DMEM with 5% CS). The cells were 
re-fed at 3 to 4 day intervals and observed for the formation of foci of cells growing on top of 
the growth arrested monolayer. Negative plates were discarded at 6 weeks. Foci were 
picked using trypsin soaked filter paper discs. Briefly, the location of the foci were marked 
on the bottom of the plate and the monolayer was washed with 4 ml DPBS, which was then 
removed. Small discs of Whatman 3MM paper that had been cut with a hole punch and 
autoclaved, were soaked in trypsin EDTA solution and using flamed forceps the soaked 
paper was placed on the focus for approximately 30 seconds. The paper disc was then 
lightly rubbed back and forth to dislodge the cells . The paper and the trypsinized cells were 








were allowed to attach overnight and the paper was removed and medium changed the next 
day . 
4. Tumorigenesis Assay. 
If the transfection was for tumorigenesis assays , then the co-transfected cells were 
incubated for 18 to 20 hours after washing off the precipitate to allow for the expression of 
the transfected DNA. For sib-selection of primary transfections, each dish of cells was split 
1 to 1 O and fed with selection medium containing 300 µg/ml G418 (Gibco) to select for the 
presence of the co-transfected plasmid , pSV2neo . Since the co-transfected genomic donor 
DNA was in excess (300 ng plasmid to 30-50 µg genomic DN/l), all cells expressing the 
selectable marker should also have integrated donor DNA sequences. The medium was 
changed every 3 to 4 days until distinct colonies of resistant cells formed (approx. 2 weeks). 
The efficiency of transfection of pSV2neo was approximate ly 3 to 5 thousand colonies per 
300 ng plasmid per 106 cells. Ten pools of 300-500 colonies each (usual ly one plate from 
the 1 to 10 split) were transferred to a 175 cc flask plus a 75 cc flask each and fed with 
selection medium . For secondary transfections , each plate ol co-transfected cells was split 
1 to 8 and all of the colonies were pooled before transfer to larger flasks as above. For co-
transfection of purified phage clone DNAs, the pSV2neo concentration was reduced to 200 
ng/plate using 500 ng/plate of each clone and NIH 3T3 ce ll carrier DNA to total 20µg 
DNA/plate . Each of these plates were split directly into T 175 flasks for selection since most 
G418 resistant cells also expressed the transfected oncogene . 
The resistant cell pools were allowed to grow to 80 % confluence for injection into nude 
mice. At the time of injection , an aliquot of the pooled ce lls was also frozen in liquid 
nitrogen. The cells were prepared for injection by trypsinization and washing with 10 ml 
growth medium . The cells were washed again with DPBS and counted with a 
hemocytometer. The cells were then pelleted and resuspe nded in DPBS to a final 
concentration of 2x107 cells/ml. For primary transfections , 1D independent pools were 
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prepared for injection (5 mice/ pool). One mont11 old female NIH Swiss nu/nu mice were 
injected subcutaneously over the rigl1t rea r leg with 0.1 ml of cells. The mice were then 
observed for tumor production at the site of inoculation for 16 weeks. Mice injected with NIH 
3T3 cells co-transfected with positive cont rn l DN~ from T24 human bladder carcinoma cells 
(c-H-ras, ATCC# HTB 4) routinely developed tumors within 1 to 2 weeks. Mice injected with 
NIH 3T3 cells transfected with pSV2neo alone pr:>duced tumors at a very low frequency and 
then only after prolonged incubation (1 4- 16 wks) . Tumor growth was recorded and when the 
tumors reached 15-20 mm diameter tl1e mice were sacrificed and the tumor tissue was 
frozen at -70°C for further analysis as per animal use protocol number R-89-2 . Mice were 
also inspected for the presence of metastases. ~Jo metastatic tumors were seen . 
C. Detection of transfected DNA 
1. Screening for Human Repeated Sequences 
Southern blots of digested genomic DNA from primary and secondary transformants 
were hybridized with probes for repeated sequences unique to the donor transforming DNA. 
Genomic DNAs (1 O µg/lane) from primary and secondary NIH 3T3 cell tumors were digested 
to completion with 5 Units/µg of the restriction endonuclease, EcoRI (BAL, high 
concentration) at 37°C for 2 to 4 hours and electrophoresed in 0.8 % agarose (BAL) gels 
(see appendix 1 for Universal restriction enzyme buffer and electrophoresis buffer) . The 
position of the molecular weight markers (1 kb ladder, BAL) were marked by stabbing the 
gel with a needle dipped in India ink, and the digested DNAs were transferred to a charged 
nylon membrane (Nytran , Schleicher and Scheull, Keene, NH) by a modification of the 
method of Southern (44) . Briefly , the gels were soaked in 0.25 M HCI , to nick the high 
molecular weight DNA, for 15 minutes with rockirg. The gels were rinsed in distilled water 
and soaked in denaturing solution (see appendix A) 2 times for 15 minutes each with 
rocking. The gels were rinsed in distilled water arid transferred to neutralization solution for 
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two additional 15 minute incubations and finally soaked in transfer buffer, 1 ox SET. 
Capillary transfer (Maniatis et al 1982) of the DNA from the gel to the membrane was 
allowed to proceed overnight. 
The DNAs were initially fixed to the blots by baking at 80 °C under vacuum for 2 hours. 
The method was changed after determining that UV cross-linking with the Stratalinker TM 
(Stratagene, La Jolla, CA), set to the auto-crossfink mode to deliver 12000 µJules, gave a 
higher signal to noise ratio than baking. In parallel experiments using RNA slot blots and a 
v-H-ras probe, the Nytran support membrane showed increased sensitivity when UV 
crosslinked, approximately 2 to 5 fold over baking. Another nylon membrane, Duralon 
(Stratagene) was also tested, but even though UV crossfinking gave a stronger signal, it was 
weaker than Nytran. The Southern blots were pre-hybridized in hybridization solution 1 (see 
appendix A) for 1 to 4 hours at 68°C and hybridized with a 32P-labelled probe for human 
repeated sequences. 
The BLURS plasmid containing a 300 bp human Alu family repeated sequence (41) was 
purchased from Amersham. The BamHI fragment containing human repeated sequences 
was efectroefuted out of a new type of agarose called NUSIEVE (FMC Bioproducts, 
Rockland ME). This agarose separates DNA with resolution similar to polyacryfamide gels 
thus eliminating the toxic hazards associated with acrylamide. The BLURS insert probe was 
labelled by the random priming method of Feinberg and Vogelstein (1983) which employs 
random hexadeoxyribonucleotides to prime for DNA synthesis by the Kienow fragment of 
DNA polymerase and [cx32PJdCTP (3000 Ci/mM, Amersham, Arlington Heights, IL). 
Routinely 30 to 40 ng of insert DNA was labelled for 2 hours at room temperature with 100 
µCi [cx32p)dCTP using the Pharmacia oligolabeling kit according to instructions provided by 
the manufacturer. The unincorporated nucleotides were removed by size exclusion 
chromatography on a prepacked Sephadex G-50 column (NICK column, Pharmacia) 
according to the instructions of the manufacturer. The buffer used for elution was 20 mM 
sodium phosphate pH 7.2, 0.5 mM EDTA, 0.05 % SDS. This type of column purification was 
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used for all DNA and oligonucleotide probe purifications. Hybridization conditions for 
Southern blots of genomic DNA with the BLURB probe were 5X106 cpm/ml probe In 
Hybridization Solution I at 65 °C for 16 to 18 hours. The blots were washed once at room 
temperature for 5 minutes in 0.1 X SET, 0.1 % SDS, followed by 3 to 4 washes in the same 
buffer at 60°C for 20 minutes each . The blots were exposed to film (XAR5, Eastman Kodak 
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Rochester, NY) with intensifying screens (Lightning Plus, Dupont NEN, Boston MA) at -7o 0 c 
overnight , followed by re-exposure for 3 to 5 days depending on the strength of the signal. 
Exposed films were developed using an automatic developer (Picker Intl.). 
2. Screening for ras Genes 
Primary tumors that were positive for human sequences using the BLURB probe were 
tested for the presence of ras sequences by hybridization with probes for !j_-,_!i- and K-ras . 
Probes for H-ras included a 700bp Hindlll fragment from clone HI of v-H-ras (Ellis et al 1981) 
that contains most of the coding sequence of v-H-ras, and the 3.2kb Sacl fragment from 
PT24c3 (Santos et al 1982, ATCC# 41000) including the entire active human c-H-ras 
oncogene without any repetitive sequences. Probes for various parts of the human N-ras 
gene were excised from the N-ras mini-gene plasmid, pNRSac (ATCC# 41031) . Exon 1 was 
isolated on a 300bp Hindlll fragment; exon 2, on a 760bp Hindlll to EcoRI fragment; and 
exons 3 and 4 on a 4.5kb EcoRI to Sacl fragment . Another probe specific for human N-ras 
3' untranslated sequences was isolated on a 1.5kb Pvull fragment from p52c- (Murray et al 
1983, ATCC# 41030). Probes for the beginning and end of the c-K-ras gene were excised 
from a plasmid clone of human c-k-ras cDNA, pSW11-1 (McCoy et al 1984, ATCC# 41027) . 
Exons 1 2 and 3 were contained within a 480bp EcoRI to Pstl fragment , and the end of , , - -
exon 3 through 4b was contained on a 640bp EcoRI fragment. Another probe specific for 
human c-K-ras intronic sequences was isolated on a 640bp EcoRI to Hindlll fragment from 
P640 (McCoy et al 1983, ATCC# 41026) . This probe, like the probe from p52c-, does not 





human genes from mouse genes. All ras probes were puriied twice by sequential 
electrophoresis through agarose and electroelution to remJve contaminating plasmid 
sequences, and were labelled by nick translation (Rigby eta! 1977) using the BAL nick 
translation kit and 10 µI (100µCi)[<X-32PJdCTP (3000 Ci/mN, Amersham) . Tumor DNAs were 
digested with EcoRI for detection of N-ras, K-ras and Alu sequences, and with BamHI for 
detection of human H-ras sequences, and separated in O.e % agarose gels for Southern 
transfer to Nytran . Hybridization conditions were initially identical to those for the Alu probe . 
After some problems with background hybridization , the cmditions were changed to a 
modification of the Church and Gilbert protocol (1984). Th~ hybridization conditions were 
changed to Hybridization Solution II at 68 cc for 15 to 18 hcurs followed by 3 washes in 2 
mM Tris, pH 8.0, 2 mM EDTA, 0.1 % SOS for 15 minutes each at 60 to 65°C. 
D. Detection of RNA 
1. Isolation of Total RNA from Tumor Tissue 
Whole cell RNA was isolated from frozen tumor tissue by the method of Chomczynski 
and Sacchi (1987), with slight modifications. A small piece of tissue (less than 1 g) was 
thawed quickly and immediatly homogenized with a sonica lor in 5 ml solution D (see 
appendix C). The following reagents were added to the mirture with thorough mixing 
between each addition : 0.5 ml 2 M sodium acetate , pH 4, 0.5 ml water saturated phenol , 
and 1 ml cholorform: isoamyl alcohol (49: 1). The final suspension was shaken vigorously 
and allowed to stand on ice for 15 minutes. The aqueous phase was separated by 
centrifugation at 10,000 g for 20 minutes at 4cc and the RtJAwas precipitated with an equal 
volume of isopropanol. The RNAs were precipitated at -20°C for at least 1 hour, usually 
overnight. The precipitate was pelleted in a microfuge for 20 min at 4 cc and the pellet was 
redissolved in 0.5 ml Solution D. Rapid solubilization of the pellet was critical for good 
recovery of intact RNA; more Solution D was sometimes needed to accomplish this and 
each tube was treated individually. The RNA was then re-precipitated with 1 volume 
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isopropanol at -20 °C for 1 hour and the precipitate was centrifuged as above. The pellet 
was washed 2X with 70% ethanol and dried under vacuum. The RNA was resuspended in 
500 µI sterile RNase-free water, and a small aliquot was quantitated by OD at 260 using an 
extinction coefficient of 40 OD/µg RNA. The 260/280 ratio was routinely 1.9 to 2.0. 
2. Isolation of Cytoplasmic RNA from Cells 
Cytoplasmic RNA was isolated from tissue culture cells by a modification of the 
procedure of Favaloro et al (1980) . All butlers are described in appendix C. Briefly, 1 to 2- T 
175 flasks of cells were grown to 80 % confluence. The cells were trypsinized, washed once 
with medium containing serum to inactivat~ the trypsin and twice with cold DPBS. The final 
pellet was resuspended in 1 ml cold lysis buffer containing vanadyl ribonucleoside 
complexes to inhibit RNases and transferr:id to a polypropylene tube (2063 Falcon). The 
lysate was underlayed with 1 ml sucrose lysis buffer and allowed to stand on ice for 5 
minutes. The nuclei were pelleted througl1 the sucrose cushion at 6,000 g in a Sorvall RC5 
centrifuge with an HS4 rotor at 5 °C tor 15 minutes. The upper cytoplasmic layer was 
transferred to a clean tube containing 1 volume of 2X PK buffer with 400 ug/ml proteinase K. 
The digestion was carried out at 56 °C tor 30 minutes. The RNA was extracted once with 
Phe:CHCl3 and once with CHCl3 :IAA. The RNA was then precipitated with 2.5 volumes of 
95 % ethanol at -20°C for 2 hours to overnight . The RNA precipitate was pelleted at 4,000 g 
in a Sorvall RC3 at 4 °C for 30 minutes . Tile precipitate was washed with 80 % ethanol and 
dried under vacuum. RNA preparations were either re-extracted and precipitated with 0.3 M 
sodium acetate, pH 5.2, and ethanol , or used directly for poly-A+ RNA purification. 
Ouantitation of cytoplasmic RNA was t11e same as for tumor RNA (see above). 
3. Poly-A+ RNA Purification 
Poly-A+ RNA was purified by oligo -c\T cellulose column chromatography (Aviv and 
Leder 1972). Oligo-dT cellulose (12-18-mer, Pharmacia) was swollen in high salt buffer 
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(buffer formulas are in appendix C). The slurry was allowed to settle and was resuspended 
in low salt buffer , allowed to settle again and resuspended in high salt buffer to pack the 
column. Small polypropylene co lumns (poly-prep columns , BioRad, CA) were siliconized 
(Maniatis et al 1982) , DEPC treated (Kumar and Lindberg 1972) and stored in canisters until 
use . Columns were packed with 0.2 to 0.4 ml pre-swollen oligo-dT cellulose depending on 
amount of RNA to be processed. Typica lly 200 to 400 µg RNA were purified at a time to 
yield 5 to 1 o µg poly-A+ RNA. The RNA was dissolved in low salt buffer and heated to 65 °C 
for 5 minutes, then cooled quickly on ice to room temperature and NaCl was added to 0.5 M. 
The RNA was cycled through the column 5 times and the column was washed with 3 column 
volumes of high salt buffer. The poly-A + RNA was eluted with at least 2.5 column volumes 
of low salt buffer and precipitated wi tl1 0.3 M sodium acetate, pH 5.5, and 2.5 volumes 95 % 
ethanol at -20°C overnight . The poly A + RNA was stored precipitated until it was used for 
Northern blots or cDNA library constru ctiori . 
4. Northern Blot Analysis 
RNAs were separated in denaturing formaldehyde agarose gels and electroblotted to 
Nytran for hybridization. The recipe for formaldehyde agarose gels is in appendix C. 
Typically 15 µg of each total RNA sample was denatured in 20 µI loading buffer (see 
appendix C) at 65°C for 5 minutes and 4 JJI of 5X STOP solution was added to facilitate 
loading. A marker lane was included in each gel (RNA ladder, BRL). The gels were run at 
100 volts until the bromphenol blue dye had migrated through 3/4 of the gel. Since the 
concentration of ethidium bromide in the egarose was high , it was difficult to visualize the 
RNA directly in the gel. The gel was equi librated in 1X TAE (see appendix A) and transferred 
to Nytran by electroblotting for 3 hours at 4°C in an IBI electroblotter at 25 volts , 800 mA 
according to the instructions of the manufacturer. The RNA bound to the Nytran support 
was then visualized with a Fotodyne transilluminator and pictures were taken of the blot. 
The RNA was fixed to the damp blot by UV crosslinking in the Stratalinker in the auto 
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crosslink mode. The blot was then air dried and pre-hybridized for at least 2 hours in 
hybridization buffer (see appendix Ci at 55 °C in a heat sealed bag . Blots were hybridized 
with the indicated probes at 55° C for 14 to 18 hours. Northern blots were washed with 0.1 X 
SET, 0.1 % SDS at 60 to 65 °Cat least 3 times until the background was low when scanned 
with a geiger counter. The damp Northern blots were wrapped in plastic wrap and exposed 
to film with intensifying screens as with Southern blots. The probe was stripped from 
Northern blots by incubation in 0.1 XSET, 0.1 % SDS, 50 % formamide at 80°C for 4 hours. 
The blots were rinsed in buffer without formamide and exposed to film to verify that the 
signal was gone. Stripped blots were kept moist and stored frozen at -20°C in sealed bags 
for re-hybridization. 
E. Cloning and Sequencing the Transforming Genes 
1. Genomic Library Construction and Screening (N -ras) 
A genomic DNA library of EcoRI partially digested primary tumor DNA in the EMBL4 
vector (Frishauf et al 1983) was screened for human N-ras containing clones. The library 
was prepared by digesting 6 pools of tumor DNA with a series of Eco Al concentrations from 
0.75 U/µg to 0.12 U/µg for 30 minutes at 37°C in Universal restriction enzyme buffer. The 
partially digested DNAs were pooled and run slowly (30 mA) overnight in two large 0.6 % 
agarose gels without ethidium bromide. Molecular weight standards (high molecular weight 
ladder, BAL) were run in a side track and cut out for staining. The gel was aligned with the 
standards and the area equivalent to the 15 to 18 kb size range was cut out of the gel. The 
size-fractionated DNA was electro-eluted using 1 X TAE by placing the agarose gel slice into 
prepared dialysis tubing (3/4 inch , BRL) and purified on a NACS column (BAL) according to 
the instructions of the manufacturer. The eluted purified DNA was precipitated with 2 
volumes of ethanol at -20°C overnight. Five µg Lambda EMBL4 (Frishauf et al 1983), 
purchased from Stratagene, was double digested to completion with excess EcoAI and 
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BamHI to prevent re-ligation of the stuffer sequence wi1h the vector during construction of 
the library. The size fractionated DNA was ligated to th9 vector arms at two molecular ratios, 
1: 1 and 2: 1 insert to vector (ie . 320 ng insert to 1 µg vector in a 10 µI reaction) with T4 DNA 
ligase (New England Biolabs) in 1 X ligase buffer (see appendix A) at 5°C overnight . The 
ligation products were packaged in phage heads using Gigapack gold TM packaging 
extracts (Stratagene) . Briefly, 1 to 2 µI of the ligation mixture was mixed with 10 µI of the 
freeze-thaw extract and 15 µI of the sonic extract was inmediately added. The packaging 
reaction was incubated at room temperature for 2 hours and stopped by the addition of 500 
µI SM buffer and 20 µI chloroform . 
Since the phage vector stuffer fragment carries the red and gam genes of the P2 
phage , E.coli lysogenized with this phage will not support the growth of non-recombinant 
clones. The packaged library was titrated in a permissive and restrictive E.coli host, LE392 
and P2392 respectively, to determine the percen1 recombinant phage. The phage titrations 
and large scale library screening were plated on LB agar plates with 100 µI infected cells in 
2.5 ml top agarose for small plates and 300 µI infected cells in 6 ml for large plates. The 
phage were diluted in TM buffer and incubated with freshly prepared cells for 20 minutes to 
allow for attachment. The host cells were prepared by growing an overnight culture in LB 
broth plus 0.2 % maltose with shaking overnight at 37°C followed by centrifugation and 
resuspension of the pellet in 0.4 volumes of 1 O mM MgS04. The prepared cells could be 
stored refrigerated for up to 5 days with only slightly decreased plating efficiency. 
To screen the library, ten- 150mm petri dishes were seeded at approximately 20,000 
recombinant phage/ plate and grown overnight. The next morning the plates were overlayed 
with nitrocellulose discs (HATF, Millipore) that had been numbered with permanant ink to 
correspond with the plate. Using a needle dipped in Inola ink the orientation of the discs 
were marked and the discs were carefully lifted off the plates and placed , phage side up, on 
a sheet of filter paper soaked with denaturing solution (see appendix A) for 3 minutes. The 
plates were overlayed with fresh nitrocellulose discs to make duplicate filters , and after 3 to 
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5 minutes they too were marked for orientation and placed in denaturing solution. All discs 
were treated as follows : two- 3 minute incubations in denaturing solution , and blotting to 
remove excess buffer, followed by !wo- 3 minute incubations in neutralization buffer and 
finally a brief submersion in 10 X SET. The filters were air dried and baked at 80°C under 
vacuum for 2 hours . The filters were sorted and prehybridized in two- 150 mm petri dishes at 
68 °C for 2 to 4 hours with 4 ml/ disc Hybridization buffer I. Since human N-ras is contained 
on two EcoRI fragments , and the library was by partial digestion with this enzyme, full length 
clones were picked by hybridizing one filter from each plate with a 3' probe and the other 
with a 5 ' probe. The filters were hyaridized at 68 °C for 12 hours and washed 4 times at 
60°C in 0.1 X SET, 0.1 % SOS for ' 5 minutes each. The filters were air dried and exposed 
to film overnight. Positive spots frorn both hybridizations were aligned and double positive 
clones were picked for purification . Plugs of approximately 5 plaques were picked with the 
fat end of a glass pasteur pi pet into 0.4 ml SM buffer. A drop of chloroform was added and 
the phage were allowed to diffuse into the buffer for 2 to 4 hours, then 25 µI of a 1: 100 
dilution was re-plated on permissive E.coli LE392. The phage were grown overnight again 
and re-probed as before . Well isolated positive plaques were picked with the small end of a 
pasteur pi pet into 100 µI SM . 10 µI of these phage stocks were plated again to test for 
sufficient titer and for purity by a final hybridization with the 3' probe . Plate lysates of pure 
phage clones were grown for phage DNA preparation (see section on DNA) . Southern blots 
of phage clone DNAs digested with EcoRI were hybridized with 3' and 5' probes and several 
full length clones were identified . Large scale phage DNA preparations were made for 
transfection into NIH 3T3 for tumorigenesis and focus forming assays, and for isolation of 
insert DNA to subclone. 
The first subclone, pNe12, contained N-ras exons 1 and 2 on a 3.2 kb ~II to Eco RI 
fragment cloned into the plasmid vector pGEMblue (now renamed by Promega as pGEM5) 
double digested with BamHI and EcoRI. Exons 3 and 4 were subcloned as a 6.2 kb EcoRI 
fragment into the vector pGEM7z digested with EcoRI and dephosphorylated, named 
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pGNras3 'Eco5 . Further subclones from this plasmid were made for sequencing through the 
3' untranslated exons : pN3 '14 contains a 5 kb EcoRI to Sacl fragment encompasing exon 3 
through the beginning of exon 6, pN3 '25 contains a 900 bp Sac I fragment spanning a large 
portion of exon 6 (see diagram of N-ras sequencing strategy for location of sub-clones) . 
2. cDNA Library Construction and Screening (H-ras). 
A cDNA library was constructed from reverse transcribed poly-A+ RNA from a nude 
mouse secondary tumor that contained large amourts of ras p21 without a correspondingly 
increased amount of ras mRNA, 1921. The preparation of tumor RNA and poly-A+ RNA 
purification are described above . The cDNA library was prepared using the cDNA library 
synthesis kit from Pharmacia according to the directions of the manufacturer. Briefly, 5 µg 
of poly~A + RNA, in RNase free water, was heated to65°C for 5 minutes and reverse 
transcribed using oligo d(T) 12_18 with Moloney murine leukemia virus reverse transcriptase 
at 16°C for 1 hour. A tace amount of [a32PJdCTP (10 µCi) was added to the reaction as a 
means of evaluating the quality of the newly synthes ized cDNA. The second strand 
synthesis reaction was done by a modification of the procedure of Gubler and Hoffman 
(1983) using RNase Hand DNA polymerase I to replace the RNA with DNA by nick 
translation . The second strand reaction mix was incubated at 12 °C for 1 hour followed by 
22°C for 1 hour. The Kienow fragment was added a1d the incubation was continued for 30 
minutes at 37°C to insure blunt ended cDNA. The cDNA was extracted once with 
Phe:CHCl3 and a 5 µI aliquot was run in a 1 % agarose gel and autoradiographed to check 
for adequate size distribution of the newly synthesized cDNA. The cDNA was purified away 
from unincorporated nucleotides by spin column chr~matography on a Sephacryl S300 
column equilibrated with ligase buffer (66 mM Tris, pH 7.6, 1 mM spermidine, 10 mM 
MgCl2, 15 mM OTT, 44 µg/ml BSA) . The effluent was collected and dephosphorylated 
EcoRI adaptors (supplied with the kit) were ligated to the cDNA by the addition of ATP and 
T4 DNA ligase and incubated overnight at 12°c. Tl1e ligase was inactivated by heating to 
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65 °C for 1 o minutes and the adaptor ligated cDNA was phosphorylated with T 4 
polynucleotide kinase and ATP at 37°C for 30 minutes. Another spin column was 
equilibrated with 20 mM Tris pH 7.5, 1 mM EDTA, 150 mM NaCl, and the kinase was 
inactivated by heating to 65°C for 10 minutes followed by extraction with Phe:ChCl3. The 
cDNA was again purified by spin column chromatography and precipitated overnight at 
-20°C in ethanol. The precipitate was pelleted in a microfuge, washed with 80% ethanol 
and dried under vacuum . The cDNA was resuspended in water and ligated at two estimated 
molar ratios (1 : 1 and 2: 1) to 1 µg of EcoR I digested , dephosphorylated lambda GT11 arms 
(Promega) for 14 hours at 12 °C. The extent of ligation was checked by electrophoresing an 
aliquot of each reaction in a 0.7 % agarose minigel and looking for radioactivity in the high 
molecular weight region of the gel by autoradiography. The ligation reaction was packaged 
with Gigapack Gold TM (Stratagene) packaging extracts as with the genomic library. The 
resulting cDNA library was titrated in E.coli Y109or- on LB plates containing X-gal and IPTG 
in the top agar (see appendix B) . This cloning vector contains an Eco RI cloning site within 
the lacZ gene (Young and Davis 1983), so when phage contain inserts that disrupt the 
coding sequence of beta galactosidase no functional enzyme is produced and the plaques 
are clear. The packaging efficiency and percent re combinant phage were determined by 
counting the total number of plaques and the number of blue non-recombinants. 
The library was plated at 30 ,000 plaques per 150 mm plate on E.coli Y109or- without 
indicators, and lifted onto Colony/PlaqueScreen hybridization transfer membranes (DuPont 
NEN) according to the recommendations of the manufacture, and screened by hybridization 
with H-ras probes. These membranes bind DNA without baking or UV-crosslinking. The 
membranes were marked for orientation as with the previous library screening , but the 
processing of the membranes had to be modified . The lifted phage DNA was denatured by 
placing the membranes in individual 0.7 ml pools of 0.5 M NaOH on plastic wrap for 2 
minutes . The excess buffer was blotted off with 3M paper and the membranes were re-
treated with NaOH and blotted again . The membranes were neutralized with 1.0 M Tris , pH 
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7.5 two times with blotting in between , and dried at room temperature. The membranes 
were hybridized using Hybridization Solution II after a 2 hour pre-hybridization in the same 
buffer at 68 °C. The library was first screened with 1X106 cpm/ml v-H-ras Hindlll fragment 
probe. Plugs from positive areas of the plates were re-plated (as with the genomic library) 
and re-screened with the same probe and an oligonucleotide probe specific for the 3' 
untranslated region (UTR) of mouse c-H-ras , CB64 (see appendix F) . The v-H-ras probe 
was labelled by nick-translation as described under pr::>bing for ras, and the oligonucleotide 
was end-labelled using [y-32P]ATP and T4 polynucleotide kinase. 200 ng of purified 
oligonucleotide was incubated at 65°C for 5 minutes , and labelled in 70mM Tris, pH 7.5, 10 
mM Mgc12, 5 mM OTT, 100 µCi [y-3
2PJATP, 10 U T4 polynucleotide kinase (BRL) in a final 
volume of 30 µI at 37°C for 30 minutes. The reaction was stopped by adding EDTA to 10 
mM and TE buffer to 60 µI. The labelled oligonucleotide was purified by Sephadex G50 
column chromatography on a pre-packed NICK™ co lumn (Pharmacia). Membranes were 
hybridized with 2 X 106 cpm/ml in Hybridization solution Ill at 42°C for 12 hours, and washed 
2 times at room temperature in 6 X SET, followed by 2 times at 55°C in 0.5 X SET, 0.1 % 
SOS and exposed to film overnight at -70°C with an in1ensifying screen. As with the 
genomic library, the positive clones were plaque purified twice and minipreparations of 
phage DNA were prepared from plate lysates using Lambdasorb. 
The phage clone DNAs were digested with EcoRI and the clones with the largest inserts 
were subcloned into the Eco RI site of pGEM7zf +. The EcoRI cleaved phage inserts were 
cut out of agarose gels, electroeluted into dialysis bags (3/4 inch prepared dialysis tubing, 
BRL), extracted and precipitated with 0.5 volumes 7 M ammonium acetate and 2 volumes 
ethanol at -20°C overnight. The washed and resuspended insert DNAs were ligated to 
Eco RI cleaved and dephosphorylated vector DNA and the ligation products were 
transformed into E.coli DH5cx: library efficiency competent cells (BRL) using the 
manufacturer's protocol for small volumes. Briefly , 1 \JI of the ligation reaction was mixed 
with 50µ1 competent cells on ice. The cells were incubated on ice for 30 minutes and heat 
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shocked at 42°c for 45 seconds . Ten volumes of room temperature SOC medium (BAL) 
were added and the cells were incubated for 1 hour at 37°C with shaking. The transformed 
cells were plated on LB+ AMP plates containing Xgal to detect insert containing plasmid 
clones. Several white colonies were tested for t11e preserce of the insert by cleavage of 
miniprep DNA with EcoRI and agarose gel electrophoresis followed by Southern blotting 
and hybridization with the v-H-ras probe used to screen tl'e library. The orientation of the 
clones was determined by single and double digestions Vvith selected restriction enzymes. 
Larger preparations of plasmid DNA were purified on Oiagen columns (see DNA purification) 
for sequencing. 
3. Sequence Analysis (N-ras , H-ras) 
All sequencing was done using double stranded plasmid DNA and (o:-35sJdATP by 
modifications of the dideoxy sequencing method of Sanger et al (1977). The coding exons 
of the N-ras genomic subclones were sequenced accordi1g to the strategy depicted in Fig.4 
using oligonucleotides specific for the cloning vector RNA polymerase start sites and the 
sense and anti-sense strands of the insert DNA (see appendix F for table of sequencing 
oligonucleotides). The vector specific oligonucleotides S=>6 and T7, were purchased from 
Promega. Exon 1 and 2 sequencing oligonucleotides were purchased from Clontech as 
part of a PCR amplification kit. Other sequence specific oligonucleotides were synthesized 
on a Biosearch Model 8700 Automatic Synthesizer using triester chemistries (kindly 
provided by Alvaro Puga, NICHD). All oligonucleotides were 20-mers with G + C contents as 
close to 50 % as possible . Oligonucleotides were re ce ived in concentrated ammonium 
hydroxide and were incubated at 56°C for 4 hour·s to cleave the protective blocking groups 
from the bases . The ammonium hydroxide was rnmoved by lyophilization and the 
oligonucleotides were resuspended in 200 i.il water·, and precipitated with 0.5 volumes 7 M 
ammonium acetate and 2 volumes ethanol at -20°C for 2 nours. The precipitates were 
pelleted in a microfuge , washed with 80 % ethanol, dri ed under vacuum, and resuspended 
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in 100 µI water. The oligonucleotides were then purified over a NICK column (Pharmacia) 
equilibrated with TE buffer and collected in 400 µI. The concentration of each purified 
oligonucleotide was crudely estimated using an extinction coefficient of 40 OD per mg 
ssDNA at 260nm. Oligonucleotides were diluted to 10 nglµI for use in sequencing reactions. 
Three sequencing kits were used. Originally reverse transcriptase and the Kienow 
fragment of DNA polymerase were used to sequence N-ras (GEM-SEQ KIRT sequencing kit, 
Promega) . Then sequenase (Tabor and Richardson 1987) , a modified version of T7 
polymerase was shown to be a better general enzyme for sequencing and the sequencing 
kit from US Biochemical , Cleveland, OH, was used. To sequence through some regions of 
high G + C content, and to resolve some ambiguities, Taq polymerase (Thermal base 
sequencing kit, Stratagene) was used. The kits were used according to the instructions of 
the manufacturers for sequencing plasmid DNA with [o:-35SJdATP. Plasmid DNA purified by 
Oiagen column chromatography (see DNA purification section) gave the best sequencing 
results . Plasmid DNA was denatured using essentially the same method (Zhang et al 1988) 
regardless of the enzyme used for sequencing; the only thing that differed was the quantity 
of DNA used per reaction . Briefly, plasmid DNA (2 µg for The KIRT and Thermalbase 
systems, and 3 µg for the Sequenase system) was suspended in 18 µI water and incubated 
at 80°C for 5 minutes with 2 µ12 M NaOH, 2 mM EDTA. The denatured plasmid was 
neutralized with 3 µI 3M sodium acetate, pH 5.0 and precipitated with ethanol on dry ice for 
15 minutes. The precipitate was pelleted in a microfuge, washed with 70 % ethanol and 
dried under vacuum. 
When using the Gem-seq KIRT sequencing system the DNA was resuspended in 10 µI 
buffer (10 mM Tris, pH 7.5, 50 mM NaCl for Kienow, and 34 mM Tris, pH 8.3, 50 mM NaCl, 5 
mM Mgc12, 5 mM OTT for AMV reverse transcriptase) containing 30 ng primer and 
incubated at 37°c for primer annealing . Primer extention and dideoxy-nucleotide 
incorporation were accomplished in one step as follows: 40 µCi [cx-35SJdATP and 5 Units of 







divided, 3 µI each , among 4 tubes containing 3 µI each deoxy- ,dideoxy-nucleotide mixture 
(provided in the kit). The reactions were incubated for 20 minutes at 37 °C for Kienow or 
42 °C for reverse transcriptase, 1 µI of chase solution Vlias added to each tube and the 
incubation was continued for 15 minutes . The reactions were stopped by addition of 5 µI 
stop solution supplied with the kit and boi led for 3 minutes before loading into a sequencing 
gel. 
The sequencing reactions using Sequenase required 3 µg of plasmid template but 
much less primer and [o:-35S]dATP. This system gave more reliable sequence data than the 
KIRT system and was used almost exc lusively for sequencing the H-ras cDNA clones. The 
denatured plasmid was resuspended in 10 µI of 40 mM Tris, pH 7.5, 20 mM MgCl2, 50 mM 
NaCl, 10 ng primer, heated to 65 °C and allowed to cool slowly to room temperature for 
primer annealing . The primer was extended by adding 1 µ11 M DTT, 2 µI labelling mix (1.5 
µMeach dGTP, dCTP, dTTP) , 10 µCi [o:-35S]dATP, and 1 Unit Sequenase, and incubated 
at room temperature for 5 minutes . The primer extention mixture was then divided among 4 
tubes containing 2.5 µI each of the deoxy- dideoxy chairi termination mixes provided in the 
kit and incubated at 37°C for 5 minutes . The reactions were stopped by the addition of 4 µI 
stop solution provided and boiled for 2 minutes as above. 
To resolve sequence ambiguities in regions of high G + C content, the Thermalbase 
Taq polymerase kit was used. Two micrograms of plasmid DNA was denatured for each 
primer as above. The plasmid was resuspended in 10 µI of 1 X Taq sequencing buffer 
(supplied as 10 X) containing 25 ng primer. The primer was extended by adding 2 µI 
sequencing extension mix, 20 µCi [o:-35SJdATP and 1 Lnit Taq polymerase and incubating 
the mixture at 42°C for 10 minutes . The primer extensi::>n reaction was divided among 4 
tubes containing 2 µI each of the deoxy- dideoxy nu cleotide mixes supplied with the kit and 
incubated at 70 °C for 5 minutes . The reaction was stopped by the addition of 5 µI stop 
solution provided and boiling for 2 minutes. 
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The BRL sequencing apparatus model S2 was used for all sequencing gels. The plates 
were treated as mentioned in appendix D and 0.8 '1/o wedge gels were poured by placing a 2 
inch long strip of 3 MM paper cut to the width of th:! spacer along the bottom of the gel 
before taping the plates together . Eight percent denaturing gels were prepared using 
Sequagel™ premixed ingredients (see appendix D, purchased from National Diagnostics, 
Mannville NJ) on the night before sequencing . The sequencing gels were pre-run with 1 X 
TBE buffer (see appendix D) at 75 watts for approximately 45 minutes to warm up the 
system and to test the integrity of the wells produc:id by the Sharkstooth combs (fine, BAL) . 
Approximately 3 µI of each sequencing mix, G-A-T·C, was loaded in 4 adjacent wells and run 
at 75 watts until the bromphenol blue dye ran off the bottom and a second aliquot of the 
same reaction mixes was loaded in another set of 4 adjacent wells and run until the 
bromphenol blue dye ran off the bottom again . The gels were fixed with 1 O % methanol, 1 o 
% acetic acid and dried in a BioRad gel dryer at 80°C for 2 hours. The dried gels were 
exposed to film at -70°C for 24 to 48 hours . 
The autoradiograms were read by hand and entered into a VAX 750 computer using the 
Wisconsin Genetics Computer Group sequence analysis software package and its fragment 
assembly system (Devereux et al 1984) . All sequence analysis was performed using this 
software including searching for homologies with Genbank and setting up alignments 
between clones. 
F. Analysis of mouse c-H-ras expression 
1. PCR Amplification of RNA and DNA 
To determine whether the alternative splicing detected by sequencing the cDNA clones 
was a general phenomenon in the expression of mouse c-H-ras , RNAs from several tumors , 
untransfected NIH 3T3 cells, and L cells were reverse transcribed with Moloney murine 
leukemia virus (MoMuLV) reverse transcriptase (BRL) and specific areas of the c-H-ras gene 
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were amplified with Taq polymerase using the polymerase chain reaction technique 
(Kawasaki, and Lang 1989) . Briefly, 8 µg of either total RNA or cytoplasmic RNA was 
reverse transcribed from a primer specific for the 3 ' end of the mouse c-H-ras mRNA, CB74 
(see appendix F for location) using the following conditions: 2.5 mM of each 
deoxynucleotide, 200 ng primer CB74, 100 µg/ml BSA, 50mM Tris, pH 8.3, 75 mM KCI , 3 
mM Mgc12, 5 mM OTT, 80 U RNasin , 200 U MoMuLV reverse transcriptase in a 20 µI 
reaction volume at 37 °C for 30 minutes . The reaction was boosted with an additional 100 
units of reverse transcriptase and the incubation was cont inued for 30 minutes. The 
synthesis was stopped by the addition of 10mM EDTA an::! extraction with CHCl3: IAA. The 
cDNA was precipitated with 0.5 volumes ammonium acetate and 2 volumes ethanol at 
-20°C. The cDNA precipitate was pelleted , washed witl1 70 % ethanol and dried under 
vacuum . The cDNA was resuspended in 8 µI sterile water and the equivalent of 1 µg input 
RNA was used to amplify specific regions of the c-H-ras riessage by the polymerase chain 
reaction. 
The Perkin Elmer kit was used according to the instructions of the manufacturer at half 
of the normal reaction volume to save reagents . Using a reaction volume of 50µ1, each 1 µg 
of cDNA was amplified in 1 O mM Tris , pH 8.3, 50 mM KCI, 1.5 mM MgCl2, 0.01 % gelatin , 
0.2 mM each dNTP, 100 ng each primer, 1.2 U Taq polymerase overlayed with light mineral 
oil (Sigma). The Perkin Elmer Cetus DNA thermal cycler was set to execute the following 
program: 94 °C, 30 seconds, followed by 30 cycles of 94 °C, 1 minute, 55 °C, 2 minutes, 
72°C, 2 minutes , with a final extension of the 72 °C incubation to 7 minutes. The amplified 
DNA was stored at 4 °C until further analysis . Positive control samples of both genomic DNA 
(1 µg/ reaction) and cloned cDNAs (1 Ong plasmid/ reaction) were amplified at the same time 
using the same reaction conditions. The amplifi ca tion products were analysed by 5 % 
polyacrylamide gel electrophoresis using the BRL vertical gel electrophoresis system, 
model V16-2 , in 1 X TBE buffer at 200 volts until the brornphenol blue had migrated 75 % of 
the length of the gel. The gel was stained with 0.5 µg/ml ethidium bromide in 1 X TSE and 
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photographed . The gel was soaked in denaturing solut ion two times for 15 minutes each, 
rinsed with distilled water and transferred to neutralization solution for two- 15 minute 
washes and finally equilibrated with 0.5 X TBE. The amplified DNAs were then transferred to 
Nytran by electroblotting using 0.5 X TBE at 25 volts for 1 hour in a BioRad Transblot semi-
dry transfer cell. The DNA was fixed to the membrane by UV-crosslinking and the blot was 
hybridized with a p32_1abelled oligo probe specific for the fragment being amplified (see 
above for oligonucleotide hybridization conditions) . 
2. Construction of Chimeric cDNA Clones 
Plasmid subclones containing the 3 longest mouse c-H-ras cDNAs were used to make 
reciprocal constructs between the 3 ' UTRs, the coding sequence , and the beginning of the 
5 'UT Rs. The original cDNA inserts were cloned into the Eco RI site of pGEM7zf + oriented 
such that SP6 polymerase would synthesize sense RNA. The longest clone, pl6s, was full 
length from a predicted mRNA start site (Brown et al 1988) and including a 32 nucleotide 
long poly-A tract at the 3 'end . This clone contained an un-spliced intron Din the 3'UTR. 
Compared with pl6s, pl76 was 55 bp shorter in the 5 'UfR , and contained an alternately 
spliced intron D and a 40 base long poly-A tail at the 3'end . The final original cDNA 
subclone, pl10 was 35 bp shorter than pl6s in the 5 'UTR , and intron D was spliced 
'correctly' , but intron C within the coding sequence was unspliced, and the clone ended with 
only 5 adenosines. Due to the unspliced intron B, pl1016 codes for a truncated protein. 
Reciprocal constructs were made between all three forms of the alternately spliced intron D. 
First , pras67 was constructed by replacing the Nari to Spel fragment of pl6s, containing 
most of the coding sequence , with the corresponding 1ragment from pl76. During the 
construction of this plasmid, and all subclones cut wit~ Nari , a 57 bp Nari fragment 1 Obp 
from the 5' end of the 16s cDNA was lost . The deleted fragment contains an upstream start 
codon that is normally out of frame for p21 translation . Plasmid , pras7, was constructed by 
replacing the Nari insert of pl6s with the Nari insert of 0176; this fragment contains the entire 
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coding sequence and modi of the untranslated seq uences except for the first 65 bp of the 5' 
end of the cDNA and the last 40 bp before the po ly-A acdition site and 32 A's. Similarly, 
pras10 was made by replacing tl1e Nari insert of pl6s with the corresponding fragment from 
pl 1019. The 3' end of pras7 was replaced with t11 e 3 ' end of pras10 to change intron D to 
the correctly spliced configuration by double digestion vvith Spel and BamHI and ligating the 
plasmid containing fragment of pras1 O with the insert fragment of pras7. A similar 
construct , pras106, was made by ligating the BamHI to Spel insert fragment from pl6s with 
the same plasmid fragment as above from pras 10. pras1 was generated by digesting pl6s 
with Nari and religating to specifically delete the 57 bp Nari fragment from the 5'UTR . 
3. In Vitro Transcription and RNase Protection Mapping 
In vitro transcription of RNA probes or full length mRNA was done using purified viral 
polymerases specific for the SP6 and T7 promoter sequences found in the vector used to 
subclone the cDNAs, pGEM7zf + (Promega) . All subclones were in the same orientation 
with respect to the promoters , SP6 synthesized plus strand and T7 synthesized antisense 
RNA. Transcription and translation protocols were essentially the same as in the Promega 
Protocol and applications Guide. Briefly, high spec ific activity riboprobes were synthesized 
on linearized templates for use in protection experiments to finely map the clones in relation 
to each other. The subclone pl6s was digested to com pletion with BamHI (New England 
Biolabs) in Universal restriction buffer (appendix A) at 37 °C for 1 hour. The extent of 
digestion was checked in a 1 % agarose minigel. EDTA was added to 1 O mM to stop the 
reaction and proteinase K was added to 200ug/ml and '. he restriction enzyme and any 
extraneous RNAses were digested for 30 minutes at 56°C. The linearized plasmid was then 
extracted with CHCl3 :IAA and the DNA was pr-ecipitated by the addition of 1/2 volume of 7M 
ammonium acetate and 2 volumes of 95 % ethanol on dry ice for 15 minutes. The 
precipitate was pelleted in a microfuge for 20 minutes and the pellet was washed with 80 % 
ethanol and dried under vacuum . 0.5ug of lin earized p asmid was used for each RNA 
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synthesis reaction . Transcription buffers are available from Promega, and the [ o:-32pJCTP 
was purchased from New England Nuclear (NEG008H , 3000Ci/mM, 10mCi/ml) and used 
within 2 weeks. Using the following reaction conditions and nucleotide concentrations, the 
specific activity of the synthesized probes were 3X108 cprn/ug RNA: 40 mM Tris-HCI, pH 
7.5, 6 mM MgCl2, 2 mM spermidine, 10 mM NaCl, 10 mM DTT, 0.5 mM each of GTP, ATP 
and UTP, 12 µM CTP and 50µ Ci 32P-o:-CTP, 20 Units RNasin, and 15-20 Units of T7 
polymerase in a final volume of 20µ1. A parallel reaction using a mixture of control SP6 
templates was run to use as a molecular weight marker for denaturing gel electrophoresis. 
The marker was made at a much lower specific activity by increasing the CTP concentration 
to 50µM and reducing the (o:-32pJCTP to 1 O µCi. Tl1e reactions were incubated at 37°C for 
1 hour, then 1 Unit R01-DNase (Promega) per µg template was added to digest the DNA 
template for 15 minutes at 37°C and stop the reaction . Tl1e probe was then diluted with an 
equal volume of RNase free 1 OmM Tris-HCI, pH 7.5, 10mN EDTA buffer and 100 ng yeast 
tRNA (type xs , SIGMA) was added as carrier , and the unincorporated nucleotides were 
removed by centrifugation through an RNA Quick Spin column (Boehringer Mannheim). The 
eluate was collected and 2 µI were placed in a solvent free scintillation medium, Ready 
Cap TM (Beckman), to be counted on the p32 channel of a Beckman LS9000 scintillation 
counter. Approximately 2 ng of probe RNA (5X1 o5 cpm) was used for each RNase 
protection experiment. 
To determine whether the cDNA clones were identical in the coding sequences, the in 
vitro transcribed sense RNAs were hybridized with an antisense probe synthesized from 
pl6s-3 linearized with BamHI (see above) . 20 ng of sense RNA was hybridized in solution 
with 2 ng (5X105 CPM) of probe antisense RNA in a total volume of 40 µI. The hybridization 
buffer consisted of 80 % deionized formamide (see appendix C, FLUKA), 0.4 M NaCl, 40 
mM PIPES, pH 6.8, 4 mM EDTA. Since the G + C content of H-ras is 57%, the hybridization 
mixture was heated to 80°C and allowed to cool to 55°C , which is the calculated melting 
temperature (Tm) - 25 °C. The hybridization was incubated for 16 to 18 hours and the 
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mixture was diluted with 10 volumes of RNase buffer (10 mM Tris, pH 7.5, 0.3 M NaCl, 5 mM 
EDTA) and 40 U/ml RNase T1 , 40 µg/ml RNase A were added to digest all probe sequences 
that were not complementary to the test RNA. The RNase digestion was incubated at 30°c 
for 30 minutes and was stopped by the addition of proteinase K to 200 µg/ml for a 15 minute 
incubation at 56°C. Carrier tRNA was added to the digested RNAs and the samples were 
extracted once with CHCl3:IAA and precipitated with 2.5 volumes of ethanol on dry ice for 15 
minutes. The RNA precipitates were pelleted in a microfuge for 20 minutes and the pellets 
were washed 3 times with 80% ethanol, 0.3 M sodium acetate to get rid of some of the 
digested nucleotides. The pellets were dried under vacuum and resuspended in 10 µ125 
mM Tris, pH 7.5. The protected fragments were resolved on a 5 % acrylamide-urea gel. A 5 
µI aliquot was mixed with 2 X loading buffer (90 % formamide , 9 % glycerol , 2 X TSE, 0.04 % 
bromphenol blue), and the sample was either boiled for 3 minutes or heated to 80°C for 5 
minutes before loading the gel. The gel was prepared using the same reagents as a 
sequencing gel except that a vertical gel electrophoresis system from BAL was used (Model 
V16-2) , and the gel was run for 2 hours at 220 volts, until the bromphenol blue dye was at the 
edge of the gel. To visualize the fragments, the gel was dried in a BioRad gel drier at ao 0 c 
for 1 hour and exposed to X-ray film for 1 hour at room temperature . The sizes of the 
Protected fragments were estimated relative to the migration of SP6 control RNAs (1 .38kb, 
550bases and 220 bases, positive control template for SP6 polymerase, Promega). The 
above procedure was performed with special precautions for handling radioactive materials. 
4. §'.nthesis of Large Amounts of RNA for Translation 
The reaction conditions for synthesis of large amounts of RNA were similar to that of 
Probe synthesis except a higher concentration of linear template was used and all 4 
nucleotides were at 0.5 mM in a final volume of 50 to 100 µI ; yields of 5-10 µg RNA/µg 
template were routinely obtained. A typical synthesis reaction was performed on 2.5 ug of 
Plasmid template that had been linearized at the Xhol site and prepared as above. Sense 
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strand RNA was synthesized with SP6 polymerase for 1 l1our at 40°C. The template was 
digested as above but, instead of column pur·ification , EDTAwas added to 10 mM, and the 
reaction mixture was extracted with Phe:CH Cl3 , re -extrncted with CHCl3:IAA, and 
precipitated with o.3 volumes 7.5 M ammonuim acetate and 2.5 volumes 95 % ethanol at 
-20°C for longer than 2 hours . The synthesized RNA was pelleted in a microfuge, washed 
with 70 % ethanol and dried under vacuum . The RNA was resuspended in 50 µI sterile 
RNase free water, and a small aliquot was quantitated by OD at 260 nm using an extinction 
coefficient of 40 OD/ug RNA. The 260/280 ratio was routinely 1.9 to 2.0. 
~ vitro RNAs were capped before translation using guanylyl transferase (BRL) in the 
presence of a reducing agent S-adenosyl-L-methionine (SAM, hydrogen sulfate, Boehringer 
Mannheim). Capping reaction conditions for 2 µgin vitro transcribed RNA were 50 mM Tris-
HCI, pH 7.9, 1.25 mM MgCl2, 6 mM KCI , 2.5 mM OTT, 1 OJ µg/ml acetylated BSA (BRL), 30 
U RNasin, 100 µM SAM, 40 µM GTP, and 1 U/µg guanylyl transferase, in a final volume of 60 
µI at 37°C for 1 hour. The reaction was stopped by the addition of 10 mM EDTA and 
extraction with Phe:CHCl3, followed by CHCl3 :IAA and precipitation with 0.3 M sodium 
acetate and 2.5 volumes ethanol at -20°C overnight. The capped RNA was washed and 
dried and resuspended in sterile RNase-free water for tra1slation in rabbit reticulocyte 
lysates or injection into Xenopus oocytes. The intactness of the synthesized RNAs were 
determined by denaturing agarose electrophoresis (see Northern protocol). 
G. Protein detection 
1. Western Blot Analysis 
When nude mouse tumors were positive for the presence of both a ras gene and its 
mRNA, extracts of tumor proteins were tested for the presence of ras p21 proteins by 
Western blotting. The tumor proteins were separated on 12 % SOS PAGE reducing gels, 
transferred to nitrocellulose (0.45 µ , Schleicher and Scheull) and ras p21 s were visualized 
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With a monoclonal antibody (Futh et al 1982) that cross-reacts with H-, K-, and N-ras p21 s 
(Oncogene Science, Manhasset, NY) and 1125 protein-A (affinity purified, Amersham) . 
Tissue proteins were extracted by the method of Srivastava (1985) . Briefly, small 
Pieces of tumor tissue (less than 0.5 g) were thawed quickly and placed into a small dounce 
homogenizer fitted with a ground glass plunger, and homogenized in 1 ml of protein 
extraction buffer (see appendix E). The homogenate was transferred to a sterile Eppendorf 
tube and centrifuged at 4C for 20 minutes. The supernatant was stored immediately at 
-70°C until protein determinations were made. 
Total protein concentration was measured using a commercially available SCA kit 
(Pierce, Rockford ,IL) with dilutions of BSA (Albumin Standard, Pierce) as a standard. The 
BCA method is based on the standard biuret reaction and the Cu 1 + is detected by 
spectrophotometric measurement of the purple complex that is formed when it reacts with 
bicinchoninic acid. Briefly, the protein samples were diluted 1 :5 in sterile water and O. 1 ml 
was mixed with 2.0 ml of the color reagent according to the standard protocol. After 
incubation for 30 minutes at 37°C. the 00562 of the samples was read in a Beckman OU-7 
spectrophotometer corrected to a blank of 1 :5 diluted lysis buffer. Sample concentrations 
were extrapolated from of a linear graph of the standard dilution series. 
SOS polyacrylamide gel electrophoresis (SOS PAGE) of tumor proteins was done using 
the NOV EX precast mini-gel system according to the specifications of the manufacturer. 
Tumor protein extracts (40 ug/well) were diluted to 7 ul/well mixed with an equal volume of 
loading buffer (1 oo mM Tris pH 6.8, 4 % SOS, 20 % glycerol, 4.25 % t3-mercaptoethanol, 
0.1 % methylene blue), boiled for 3 minutes in a water bath, and loaded on diplicate 15 well-
Precast 12% sos PAGE gels (NOVEX, Encinitas, CA) . The gels were run in 1 X SOS PAGE 
buffer (see appendix E) at 35 mA per gel until the blue dye front was about to run off the 
bottom. The proteins were transferred to nitrocellulose using the BioRad Transblot cell 
electroblotting apparatus at 1 oo mA overnight at 5 °C. See appendix E for the transfer 
buffer. 
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The Western blots were immediately blocked and p21 Ras was detected according to a 
protocol obtained from S. Srivastava (N CI). The blots were blocked in BLOTTO (see 
Appendix E) for 1 hour with rocking at room temperature. First antibodies, either normal rat 
serum for the negative control blot , or monoclon al antibody Y13-259 (Oncogene Science) 
were diluted 1 :200 in fresh BLOTTO and added to the blocked blots in heat sealed bags to 
prevent evaporation . The antibodies were allowed to react for 2 1 /2 to 3 hours at room 
temperature with rocking . The blots were then thoroughly washed in 3 changes of BLOTTO 
for 1 O minutes each . The second antibody, rabbit anti -rat lgG (Accurate Chemicals, 
Westbury, N.Y.) was diluted 1 :200 in BLOTTO and both lilters were incubated back to back 
in the same bag for 1 hour at room temperature with rocking . During the second incubation, 
(1251) protein-A (affinity purified , Amersham) was diluted to 2X105 cpm in BLOTTO and non-
specific binding was absorbed out by pre-incubation with a blocked blank nitrocellulose filter 
for at least 30 minutes . The blots were washed 3 times for 10 minutes each in BLOTTO and 
incubated with the pre-absorbed [12511 protein-A for 20 to 30 minutes at room temperature 
in a sealed bag. After four- 1 O minute washes in BLOTTO, the blots were rinsed in several 
changes of distilled water and exposed to film (XAR 5, Kodak) overnight at -70°C. Several 
exposures were taken , from 7 hours to 5 days . The size of the detected ras proteins were 
calculated relative to pre-stained molecular weigl1t markers (BRL). 
2. In Vitro Translation. 
To determine whether the differentially spli ced c-H-ras clones were translated with 
different efficiencies, the in vitro transcribed rnR NAs we re translated in rabbit reticulocyte 
extracts and injected into Xenopus oocytes. Varyin g co ncentrations of capped SP6 
transcribed mRNAs (500 ng , 200 ng , 100 ng) we re tra nslated in 50 µI reactions using 
Promega rabbit reticulocyte extracts according the the protocol of the manufacturer. A 
typical reaction was as follows : 100 ng capped mRNA in 1 µI water was added to a 
reticulocyte extract containing 35 µI lysate , 6 µI H2o, 40 U RNasin , 1 µ11 mM amino acid 
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mixture minus methionine and 4 µI [35s]methionine (1200 Ci/mM, NEN, final 
[35SJmethionine concentration of 800 µCi/ml). The RNA was translated at 30°C and 6 µI 
samples were taken at 15 minute intervals for 60 minutes. The reaction was stopped by 
pipetting the samples directly into an equal volume of protein extraction buffer and storing 
them on ice for quick analysis or frozen at -20°C for later analysis . Two controls were 
included in each experiment: a blank lysate containing no added RNA to rule out 
background bands and a positive control of Brome Mosaic Virus (BMV) RNA, included with 
the kit , that translates 5 viral proteins: 110, 97, 35, 20,and 15 kd. Translation products were 
separated in pre-cast 12 % SOS-PAGE gels as for tumor proteins except that the gels were 
fi xed with 50 % methanol , 7 % acetic acid, soaked in Enlightening (Dupont), and the gels 
were dried in a BioRad Model 583 gel dryer at 60°C for 1 hour. The dried gels were 
exposed to X-ray film for varying lengths of time, from 2 hours to 2 days. The size of the 
translation products were determined relative to the BMV products and to 14c molecular 
weight markers (BAL) . 
3. lmmunoprecipitation. 
To confirm that the translation products were ras proteins, aliquots of the 60 minute 
time points were immunoprecipitated with the anti-ras monoclonal antibody, Y13-259 as 
follows : 5 or 1 o µ1 lysate was mixed with 1 o µI monoclonal antibody (Oncogene Science) 
and 200 µI protein extraction buffer (see appendix E) and incubated at 5 °C for 1 hour. 
During this incubation, an aliquot of pre-swollen protein-A sepharose (CL-4B, Pharmacia) 
equivalent to 1 O mg/reaction was washed two times with DPBS (DPBS without calcium and 
magnesium, Whittaker) , and resuspended in 100 µI DPBS/reaction. Since rat lgG does not 
bind well to protein-A, the sepharose beads were first coated with rabbit anti -rat lgG 
antibodies (Accurate) by incubation with 1 O µI antibody per 1 O mg protein-A sepharose on a 
rotator at 4 °C for 30 minutes. The coated sepharose beads were washed 3 times with wash 








firSt antibody reaction. The antibody coated protein-A sepharose was incubated with the 
first antibody reaction mix for 1 hour at 4 °C on a rotator. The immunoprecipitate was then 
washed 3 times in wash buffer and a final time in wash buffer without detergents. The pellet 
was then resuspended in 2 X protein sample buffer and boiled for 3 minutes to release the 
~ protein and denature it . Samples were separated by 12 % SOS-PAGE using the NOVEX 
sysrem as above. The gels were dehydrated in 50 % methanol 7 % acetic acid, soaked in 
Enlightening (Dupont) for 15 minutes and dried in a gel dryer (Bio Rad) at 60 °C for 1 hour. 
The dried gels were exposed to film for varying times between 1 hour and 1 day at -70°C. 
The size of the immunoprecipitated proteins were estimated by migration relative to 14c_ 
labelled protein molecular weight markers. Proteins translated in Xenopus oocytes were 
also immunoprecipitated as above, except that 300 µg of extracted oocyte proteins were 
incubated with the first antibody. 
4 . .I_ranslation in Xenopus Oocytes. 
In ~tro transcribed and capped mRNAs made from four different chimeric cDNA clones 
in PGEM7Zf + were purified and adjusted to a concentration of 1 mg/ml in sterile water. The 
RNAs were injected into albino Xenopus levais oocytes by Dr. Eric Ackerman (NCI) and 
incubated at 19 °C for 4 hours to recover in Barth-Hepes saline (see appendix E). 
Approximately 20 oocytes were injected with each mRNA sample. Individual oocytes were 
observed for viability and transferred to separate wells since oocytes that touch each other 
during the labelling reaction may die. The buffer was removed and replaced with fresh 
butter containing 200 µCi/ml r35S]methionine, 20 µ1/oocyte. The oocytes were incubated 
overnight at 19 °c and any non-viable oocytes were discarded the next morning (survival was 
approximately 90 %) . The oocytes were washed with a large volume of buffer without 35s 
and those injected with the same sample were pooled and placed in a 1.5 ml eppendorf 
tube. The oocytes were allowed to settle to the bottom of the tube, the buffer was removed 
and the tube was immediately placed on dry ice. When all pools were processed, the 
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oocytes were thawed and homogenized with 5 µI protein extraction buffer per oocyte using a 
small glass rod. The tubes were centrifuged at 4°C in a microfuge for 15 minutes. Three 
layers were visible, an upper lipid layer, a middle aqueous layer and a lower yolk layer. The 
solubilized protein extract (middle) was removed using a thin tapered pipet tip. The protein 
concentration was measured using the BCA kit as above, and 300 µg of each protein extract 
was immunoprecipitated to visualize the translated ras protein. A pool of uninjected oocytes 




A. Tumorigenesis Assay rationale and early experiments 
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Activated oncogenes have been isolated from the DNA of many human tumors and 
tumor cell lines by induction of focus formation in NIH 3T3 cells (for review see Bishop 
1987). The classic focus formation assay has tl1e limitation that the transfected oncogene 
must cause distinct morphological changes in the recip ient cell for detection . More 
recently, tumorigenesis assays have been developed tl1at have the potential to detect 
oncogenes which cause more subtle changes in ce llular morphology but induce 
tumorigenesis (Keath et al 1984). To separate any potential transforming genes from the 
original tumor DNA, should more than one be activated , a sib-selection step was included in 
a modification of the co-transfection tumorigenesis assay described by Fasano et al (1984) . 
The general scheme is represented in Fig.1 . Tl1e assay consists of co-transfection of donor 
tumor DNA with pSV2neo and separation of the G418 resistant colonies into unique pools of 
300 to 500 colonies each for injection into nude mice. It has been shown that cells taking up 
co-transfected DNA will on the average incorporate the equivalent of 0. 1 % of the donor 
DNA genome (Wigler et al 1978) . To have a 99% chance of detecting an oncogene if it is 
single copy in the donor genome, approximately 4,000 to 5,000 individual colonies must be 
screened, as calculated from the Poisson distribution equation N = ln(1 -P) / ln(1-f) , where p 
is the desired probability, f is the fraction of the genome rn presented by each colony (in this 
case 0.001), and N is the number of colonies that need to l:e screened (Clarke and Carbon 
1976) . To use the least possible number of mice and still h:1ve a high probability of 
separating any potential oncogenes into different primary tumors, 1 o pools of 300 to 500 
colonies each were used for injection into 1 O groups of 4 to 5 mice each. Mice were 
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Figure 1. Schematic diagram of the sib-selection turnorigenesis assay to detect and 
isolate human oncogenes. 
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observed weekly for tumor formation at the site of subcutaneous inoculation for 15 to 16 
weeks. DNA from the T24 bladder carcinoma cell line produced an average transfection 
efficiency of 0. 13 foci/ ug in focus assays and 5/5 tumors within 2 to 3 weeks in 
tumorigenesis assays. Negative controls included pSV2neo co-transfected with NIH 3T3 
cell carrier DNA, a salt control consisting of the calcium phosphate precipitate without any 
DNA and a medium control that did not receive any treatment during the transfection. The 
spontaneous transformation rate of the NIH 3T3 cells was low, with sporadic formation of 
tumors after 14 to 15 weeks. Representative tumors from any pool that generated tumors in 
more than half of the mice injected were analysed for the presence of human repetitive 
sequences, indicative of the presence of a transfected human oncogene. Primary tumor 
DNAs containing human sequences were used in a second round of co-transfection and 
tumorigenesis to separate the potential oncogene from any un-related co-transfected 
human sequences. The secondary tumors were again tested for the presence of human 
repeated sequences. 
To detect potential transfected human oncogenes in nude mouse tumor DNAs, 
Southern blots were first hybridized with a probe for the presence of integrated human DNA, 
as shown in Fig.2. The BLURB probe (Jelinek et al 1980) for the Alu family of human 
repetitive sequences was used for detecting human DNA. The Alu family sequence motifs 
are highly repeated throughout the human genome, with a random interspersion frequency 
of several kilobases. Since, on the average, a transfected cell incorporates 0.01 percent of 
the genome of the donor DNA, this repeat family should be well represented in the primary 
tumor DNAs. The BLURB probe hybridized to many fragments in Southern blots of primary 
nude mouse tumor DNAs (Fig.2, lanes G54, G55) , to a few specific fragments of human DNA 
in Positive secondary tumor DNAs (lanes G54-1 , G54-F) , and did not hybridize with 
untransfected NIH 3T3 cell DNA or DNA from spontaneous transformants that did not 
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Figure 2. Southern blot analysis of primary and secondary nude mouse tumor DNAs 
for human repetitive sequences. Tumor DNAs (10µg) were digested with EcoRI , 
separated by electrophoresis in 0.8% agarose gel, blotted, and hybridized with the BLURB 
Probe for human Alu repetitive sequences. Lanes G54, G55 are primary tumor DNAs; G54-1 , 
854-F are DNAs from a secondary tumor and pooled foci induced by G54 DNA; G55-4 is a 
spontaneous transformant derived NIH 3T3 cell tumor. Sizes (in kilobasepairs) of the Alu 
Positive fragments in the secondary transfectant DNAs are indicated to the right. 
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most often from human tumors, all nude mouse tumor DNAs positive for human sequences 
were also screened for the presence of ras sequences with H-ras, K-ras and N-ras probes. 
lnsulinoma and renal cell carcinoma are two tumor types that have been associated 
With chromosomal changes indicative of the loss of specific tumor suppressor genes 
(Larsson et al 1988, Zbar et al 1987). To determine whether any dominant acting 
oncogenes were also involved in the genesis of these tumor types, representative tumors 
Were screened by the sib-selection assay. Two renal cell carcinoma (RCC) DNAs were 
screened both by the tumorigenesis assay, and for focus formation on NIH 3T3 cells. Both 
DNAs were negative for focus formation, but one induced Alu positive nude mouse tumors 
and was further characterized. Of three insulinoma DNAs tested, all were negative for focus 
formation in primary transfection experiments, but induced primary tumors in the nude 
mouse tumorigenesis assay. One induced tumors through a third round of transfection and 
tumorigenesis and was chosen for further characterization. Although no novel dominant 
acting oncogenes were found in these tumor types, the increased sensitivity of the 
tumorigenesis assay allowed the detection of over-expressed ras proto-oncogenes activated 
during transfection. The mechanisms by which ras proto-oncogenes may be overexpressed 
and cause NIH 3T3 cells to become tumorigenic is the subject of this thesis. 
8· Renal Cell Carcinoma 
1 
· ~ection of Human N-ras in Mouse Tumors 
DNAs from two renal cell carcinomas (Kand L) were obtained from Dr. Marsden 
Linehan (NCI) and were tested for the presence of activated oncogenes by the sib-selection 
tumorigenesis assay. One pool out of 1 o induced the development of Alu positive primary 
tumors from tumor-K DNA in four out of five mice withing weeks of injection; two out of five 
mice injected with a second pool of primary transformants developed Alu negative tumors at 
12 and 14 weeks after injection, probably due to spontaneous transformants. The rest of the 
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- 7.2 kb 
~igure 3. Southern blot analysis of primary tumor DNAs for human N-ras. Genomic 
NAs from primary tumors K12, K11 , H84, H82, untransfected NIH 3T3 cells and T24 
human bladder carcinoma cells were digested with EcoRI , separated by electrophoresis 
th rough 0.8% agarose (10µg/lane), blotted, and hybridized with a human N-ras specific 
Probe, P52c·. The 7.2 kilobasepair human N-ras fragment is indicated. 
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pools transfected with K-DNA did not induce tumor formation . Renal cell carcinoma-L DNA 
was negative in the tumorigenesis assay. To determine whether an activated ras oncogene 
was associated with the observed tumorigenesis, Southern blots of Alu positive primary 
nude mouse tumor DNAs were hybridized with ras specific probes . The human N-ras 
specific probe from p52c- (Murray et al 1983) hybridized with a 7 kb EcoRI fragment in both 
Alu postitve primary nude mouse tumor DNAs tested and did not hybridize with 
untransfected NIH 3T3 cell DNA or DNA from other primary tumors (Fig.3) . By comparison 
with the single copy N-ras gene in human T24 bladder carcinoma DNA, the primary nude 
mouse tumor DNAs appeared to contain approximately 50 copies of N-ras. One of these 
primary tumor DNAs induced Alu positive, N-ras positive nude mouse tumors in a secondary 
co-transfection and tumorigenesis assay with higher incidence (all mice injected developed 
tumors) and shorter latency (5 weeks). To determine whether activation of the N-ras gene 
resulted from a point mutation, as had recently been detected by Bos et al (1985) using a 
similar assay, a genomic library was made from one of the primary tumor DNAs to clone and 
sequence the transfected oncogene. 
2. Cloning and Sequencing the N-ras Gene 
The active N-ras gene consists of 6 exons distributed over two EcoRI fragments (Hall 
and Brown 1985) (Fig.4) . A genomic library of Eco RI partially digested , size fractionated 
primary tumor DNA was produced using the lambda vector, EMBL4 (Frishauf et al 1983) . A 
library of 5X1 o5 independent phage clones was generated that contained approximately 
90% recombinants. Since the gene was highly amplified in the DNA used to make the 
library, approximately 5 to 10 positive plaques were detected per plate of 20,000 
recombinant phage . Six full length clones were isolated by double screening the library with 
probes specific for both halves of the human N-ras gene. Four of the full length clones were 
tested in the tumorigenesis assay, using a codon 61 mutant (Bos et al 1984) N-ras minigene 
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Figure 4. Human N-ras genomic structure and sequencing scheme. The coding exons 
are represented by shaded boxes, the non-coding exons are represented by open boxes, 
the intrans and surrounding sequences are indicated by black lines. The recognition sites 
for EcoRI are indicated above the diagram. The regions of the gene subcloned for 
sequencing are indicated by solid lines with the names of the subclones to the right. The 
arrows below the diagram indicate the direction and extent of sequencing. 
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l ib ra ry th at contained only the 5 ' half of the N-ras gene , >...ex1, as a negative control. The 
results of this experiment are summarized in Table 1. All four full length N-ras clones 
e ffi c iently induced tumorigenesis , but with a slightly longer latency period as compared with 
p N R Sac. These phage clones were also tested for focus formation but failed to form 
d is tin guishable foc i in 3 weeks while the positive control , pNRSac, produced approximately 
1 00 easily distinguishable foci/ µg . 
Since N-ras with codon 13 mutations had recently been shown to induce tumors in 
nude mice while causing very little alteration in NIH 3T3 cell morphology (Bos et al 1985), the 
poss ibility that this or a similar mutation had activated the gene was pursued by subcloning 
regions of the c loned N-ras gene and sequencing the coding exons. The location of the 
subc lones and the sequencing strategy are depicted in Fig.4 . Since the sequence of human 
N-ras was known , oligonucleotides specific for the first two exons were obtained 
commerc ially , and additional sequence specific primers were synthesized to directly 
sequence the coding exons (see Appendix F for primer sequences and locations) . No point 
mutations were found in the coding sequence of the N-ras gene , though a few base changes 
and a small deletion were noted in the 3 ' untranslated region . Since ras genes can cause 
transformation either by point mutations in any of three known regions of the gene, or by 
over-expression of the normal protein (reviewed in Sistonen and Alitalo 1986) the possibility 
of an alteration in regulatory sequences or other untranslated regions causing 
tumorigenesis was considered . 
3. Activation of N-ras by Gene Amplification 
The standard method to localize which part of a gene contains an activating mutation 
is to test reciprocal constructs between the different parts of the normal and mutant gene for 
the ability to confer a detectable phenotype to indicator cells . To first determine whether 
transfection of the normal c-N-ras gene was negative in the tumorigenesis assay, I obtained 






TABLE 1. Tumorigeneis Analysis of N-ras Lambda Phage Clones 
1'RANSFECTED TUMOR FORMATION RAS DETECTION 
DNA 
Incidence Onseta DNAb ProteinC 
===== (weeks} 
Phage clones of N-ras (500ng/dish) 
AN21 
5/5 4 + + AN£ 
AN23 
5/5 4 + + 
5/5 4 nd nctd AN14 
A exJ 5/5 
4 nd nd 
(neg. cont.) 0/5 
PNRsac (pos. cont.) 5/5 2 nd nd 
~ clone vs. c-N-ras (250ng/dish) 
1i. N21 
5/5 5 + + P793 
(~ 5/5 6 + + 
a 
Time between injection of mice and detection of first palpable tumor. All mice within a 




Detection of N-ras specific sequences on genomic DNA of the induced tumors by 
Southern blotanaiysis. 
Detection of p21 Ras by western blot analysis 
nd == Not determined. 
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tested it in . 
parallel with one of the full length clones isolated from the nude mouse tumor 
l'b I rary. Sur . . 
pnsrngly, DNA from the normal c-N-ras gene induced tumorigenesis with similar 
incidence 
and onset as compared with the gene cloned from the mouse tumor (Table 1). 
ihe first h 
P age clone transfection and tumorigenesis experiment was done using 500 ng 
Phage DNA/ 
plate; the second transfection was performed using half as much DNA, 
resulting i . . 
n tumor induction with a longer latency. 
'
0 determine whether N-ras p21 was expressed in the nude mouse tumors, Western 
blots oft 
umor proteins were prepared. A combination of Y13-259, a monoclonal antibody 
th
at cross-reacts with all ras p21 's, and 1251-labeled protein-A coated with rabbit anti-rat 
antibodi 
es was used to visualize the ras protein. All K-series nude mouse tumors tested by 
Vve
st
ern blot analysis showed drama: overexpression of p21 Ras protein, including the 
tumors · 1nduced by normal N-ras. As shown in Fig.5, p21 Ras was detected in the N-ras 
induced 
tumors, including a secondary nude mouse tumor induced by K11 DNA, tumors 
induced b 
Y the full length N-ras clone >,.N21 , and two tumors induced by the normal c-N-ras 
Clone >.. N 
' c ras; no p21 was detected in NIH 3T3 cell protein extracts or in a spontaneous 
tumor ari . 
sing from a pSV2neo transfectant . Western blot results of phage clone induced 
tumors ar 
e summarized in Table 1. 
Southern blot hybridization of genomic DNAs from the tumors induced by both control 
andtestN . ~ Phage cf ones showed high copy numbers of integrated N-ras, as had been 
Previou I H bl s Y detected in the primary and secondary nude mouse tumor DNAs. owever, ot 
hybrid· · · 1zat1on of the original human tumor DNA and three metastases from the same patient 
Showed that the N-ras gene was not amplified in the patient tumor tissues (Fig.6) . It was 
conc1ud d d · th 
ed from these experiments that an amplification event had occure unng e 
Primary transfection , and that integration and expression of amplified copies of transfected 
norma1 N . . 
~ 1s sufficient to produce tumors in nude mice. 
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Figure 5. Western blot analysis of N-ras induced nude mouse tumors. 30 µg of protein 
extracts from tumors induced by transfection of human proto-oncogene c-N-ras, >..cNras; a 
phage clone isolated from the K12 genomic library, \N21; a secondary tumor induced by 
K11 DNA, K11-1 (labelled K11 in panel B) ; a spontaneous tumor derived from transfection 
with pSV2neo, neo; and untransfected NIH 3T3 cells , NIH 3T3, were separated in a 12 % 
SOS polyacrylamide gel, and blotted. Panel A, first antibody was normal rat gamma globulin . 
Panel B first antibody was Y13-259 anti-ras monoclonal antibody. Antibody binding was 
visualiz~d by [1251)protein-A and rabbit anti-rat antibody follov.:ed by fluorography. The 
relative migration of pre-stained molecular weight markers is indicated ()(1000) and p21 Ras 
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Figure 6. Southern blot analysis of human , and nude mouse tumor DNAs for the 
presence of human N-ras sequences. All DNAs were digested with EcoAI and 10 µg/lane 
were separated in 0.8 % agarose, blotted and hybridized with the human N-ras specific 
probe from p52c-. DNA samples were from secondary nude mouse tumors , K113, K112; 
primary nude mouse tumors , K12, K11; untransfected NIH 3T3 cells , 3T3; human renal cell 
carcinoma (ACC) lymph nodal metastasis used to induce the K series tumors , K(met) ; two 
other metastases from the same patient , met-1 , met-2; the patient 's primary tumor 
propagated in nude mice , NM (this sample is contaminated with mouse cells and represents 
less than single copy human sequences) ; the primary tumor , AOC ; and insulinoma I, INS. 
The relat ive migration of selected fragments from the 1 kb ladder (BAL) are indicated in 
kilobasepairs at the right . The arrow indicates the human N-ras specific fragment. 
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C. lnsulinoma 
1. Screening Human lnsulinoma DNAs for Activated Oncogenes 
Three human insulinoma DNAs were screened for active oncogenes by the sib-
selection tumorigenesis assay. The results of these assays are summarized in Table 2. All 
insulinoma DNAs induced tumor formation in primary transfections . Primary pools of 
transfected NIH 3T3 cells were designated by a two part code, the letter represents the 
donor tumor DNA and the number designates which of the ten pools of cells were used for 
injection . The primary tumors were then named by this two part code followed by the 
number of the mouse that was injected, usually 1 through 5. A third number was added to 
the code used to name secondary tumors arising from transfection of the primary tumor 
DNA, designating again which mouse of the group injected bore the tumor. For example, 
G54 is a primary tumor from the fourth mouse injected with pool -G5 cells, and G54-1 is a 
secondary tumor generated by transfection of G54 tumor DNA. 
Of ten pools co-transfected with lnsulinoma-G DNA, two induced Alu positive primary 
nude mouse tumors . A third pool, G3, induced Alu negative tumors at a lower frequency and 
later onset , indicative of spontaneous transformation . Genomic DNA from the Alu positive 
primary tumor G54 induced Alu positive secondary tumors in 3/5 mice over a period of 5 to 
1 o weeks in one of three transfection and tumorigenesis experiments . In the one positive 
secondary transfection experiment , a parallel pool of G54 transfected NIH 3T3 cells was 
positive for focus formation, designated G54-F. DNA from both a secondary tumor, and the 
pooled foci exhibited the same pattern of Alu fragments in Southern blots hybridized with the 
BLURS probe (Fig.2, lanes G54-F and G54-1). Genomic DNAs from both G54-1 and G54-F, 
however, failed to induce tertiary tumors in four separate experiments. This could be due to 
either the presence of a very large oncogene that is difficult to transfect intact or that the 





TABLE 2. Tumorigenesis Analysis of Human lnsulinoma DNAs 
POoLa TUMOR FORMATION HYBRIDIZATION 
Incidence Onsetb Alu ras 
-== (weeks} 
INSULIN OMA G 
G3 2/5 1 5 
G4 
GS 
3/5 1 3 + 
5/5 1 0 + 
INSULIN OMA H 




3/4 1 1 + + 
2/4 8-14 + 
INSULIN OMA I 
I2 5/5 7-9 
I6 
+ + 
5/5 9-11 I9 
+ + 





T24 Iilli. 10/10 3 + + 
PSV2neoc 12- 15 4/3 8 
Only Pools inducing 2 or more tumors are shown. All assays were done with 10 pools. 
r· P '~e between injection of mice with transfected NIH 3T3 cells and detection of first 
a Pable tumor. In most cases, all mice within a group developed tumors within one 
Week of the time of onset. If not, a range is given representing time of onset of the first 
and last tumor. 
Summary of relative tumor incidence by spontaneous transformation of NIH 3T3 cells 
Co-transfected with pSV2neo and NIH 3T3 cell carier DNA in 10 separate transfections. 
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lnsulinoma-H DNA induced Alu positive primary tumors in 3 out of 1 O pools with low 
incidence and varying latencies (Table 2). None of these tumor DNAs induced secondary 
nude mouse tumors upon repeated transfections. In ten secondary transfection and 
tumorigenesis assays, only two mice developed tumors and they were Alu negative. 
lnsulinoma-1 DNA induced Alu positive tumors in 3 out of 1 O pools from the primary 
transfection. Three Alu positive primary tumor DNAs from pool-12 hybridized with the v-K-ras 
probe but failed to induce Alu or ras positive secondary tumors in three separate 
transfections (Table 3). Genomic DNA from primary tumor, 192, produced both secondary, 
and tertiary tumors and was chosen for further analysis . 
2. Analysis of the 1-9 Series Nude Mouse Tumors 
Representative tumors from each pool of transfected NIH 3T3 cells generating two or 
more tumors were screened for the presence of human DNA and activated ras oncogenes 
by Southern blot hybridization. Southern blot analysis was done with both Alu and ras 
probes to primary, secondary, and tertiary 1-9 series nude mouse tumor DNAs. The code 
used to designate the origin of the 1-9 series of nude mouse tumors was the same as that for 
the G and H tumors with one exception . When two separate tertiary transfections from the 
same secondary DNA generated tumors, the second group of tertiary tumors was named 
with a new letter and number designation, ie. 1921-3 and 0-14-1 were both tertiary tumors of 
1921 from different transfection events. Two representative Southern blots of the 1-9 series 
tumor DNAs are shown in Fig . 7. The BLURS probe hybridized to many fragments in 191 , 192, 
and 193 primary tumor DNAs (data not shown) . Three Alu positive restriction fragments were 
present in both secondary tumor DNAs tested (panel A, lanes 192-1 , 192-3) , but the human 
sequences were not transferred to the tertiary tumor, 1921 -3. Southern blot hybridization 
with a mouse H-ras cDNA probe (panel B) revealed a new fragment at approximately 11 kb 






TABLE 3. Tumorigenesis Analysis of lnsulinoma I Series DNAs 
TRANSFECTED TUMOR FORMATION HYBRIDIZATION WESTERN 
DNA Incidence Onseta Alu ra s Rasb 
(weeks) 
PRIMARY POOLSC 
I2 5/5 8 + + nctd 
I6 5/5 1 1 + + 
I9 5/5 5 + 
SECONDARY TUMORS 
I21 1/4 1 1 nd nd nd 
I22 5/5 6 nd 
I22 (repeat) 0/5 
I6 2 4/4 5 + nd 
I9 2 3/4 5-7 + + + 
I9 3 0/5 
I9 5 0/5 
TERTIARY TUMORS 
I921 5/5 4 + + 
I921 (repeat) 5/5 4 + + 
CONTROLS 
T24 ras 5/5 3 + + + 
pSV2neo 2/14 1 5 
a Time between injection of mice with transfected NIH 3T3 cells and detection of first 
palpable tumor. If all mice within a group did not develop tumors within the time of 
onset , then a range is given representing the time of onset from the first to last tumor. 
b Detection of p21 Ras by Western blot analysis . 
c Only pools inducing 2 or more primary tumors are shown; all primary tumorigenesis 
assays were done with 10 pools. 
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figure 7. Southern blot analysis of 19-series nude mouse tumor DNAs . Panel A. 1 O µg 
of each DNA was digested with Eco RI and the blot was probed with the BLURB insert for 
human repetitive sequences . Panel 8 . 10 µg of each DNA was digested with BamHI and the 
blot was hybridized with mouse c-H-ras cDNA (16s) . DNA samples were from : untransfected 
NIH 3T3 cells , 3T3; pool 19 primary tumors , 191, 192; secondary tumors induced by 192 DNA, 
192-1, 192-3; a secondary tumor negative for ras sequences, Q1 0-1 ; a tertiary tumor induced 
by 1921 DNA, 1921-3; and NIH 3T3 cells transformed by cloned Ha-MSV DNA, v-ras . The 
relative migrat ion of se lected fragments from the 1 kb ladder (BAL) are indicated in 
ki lobasepairs. The fragments just below the 4kb and 2kb markers in panel B represent 
endogenous mouse c-H-ras, the fragment at 11 kb in lanes 1921, 1923 and 1921-3 is the newly 
integrated c-H-ras . 
76 
present in the primary tumor DNAs, it was concluded that a co-transfected mouse DNA 
fragment, containing the H-ras gene, had integrated into the secondary tumors and was 
transferred to tertiary tumors . This gene was not closely linked to the integrated human DNA 
since the Alu positive sequences were not co-transferred to the tertiary tumors. 
Since the secondary and tertiary tumors contained ras sequences integrated in the 
DNA, ras expression was analysed by Northern and Western blotting . Total RNA from 
several tumors and untransfected cells was separated in denaturing agarose gels, 
transferred to nylon membranes and sequentially hybridized with mouse H-ras and chicken 
13-tubulin cDNA probes (Fig .8, panels A and B respectively) . No significant differences were 
detected in H-ras specific mRNA levels between the ras positive tumors (1924, 0 -14-1, 0-14-
2) , and untransfected NIH 3T3 cells and tumors from spontaneous transformants that did 
not contain integrated ras sequences (nee, neo4). Hybridization with the (3-tubulin probe in 
panel B shows that equivalent amounts of RNA were transferred in each lane. 
Western blot analysis was performed on tumor proteins from the 19- series tumors to 
determine whether p21 Ras was expressed in the tumors containing the newly integrated 
ras fragment in the DNA. In contrast to the equivalent H-ras specific mRNA levels found in 
all of the 19- series tumors, p21 Ras was only detected in the secondary and tertiary tumors 
by Western blot analysis (Table 3). Northern blot, and Southern blot hybridizations with 
probes for v-K-ras and N-ras showed no difference between the tumors and controls (data 
not shown) , thus ruling out activation of these genes as the source of increased p21 Ras in 
the tumors . Western blot analysis of the 19- series and the amplified N-ras induced tumor 
proteins were performed in parallel since monoclonal antibody Y13-259 recognizes these 
two proteins with similar affinities (Furth et al 1982). As shown in Fig . 9, p21 Ras was not 
detected in the 192 and 195 primary tumors (lanes 9, 10) , untransfected NIH 3T3 cells (lane 
6), and other tumors not containing transfected ras sequences (lanes 7, 12, 13) . Ras proteins 
were equally well detected in both the 1921 tumor (lane 8) and in the tumors containing 
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figure 8. Northern blot analysis of tumor and cellular RNAs. RNA samples, 15 µg, were 
separated in a denaturing formaldehyde agarose gel, blotted and sequentially hybrid ized 
with mouse c-H-ras 16s cDNA probe in Panel A, and a chicken f3 tubulin probe in Panel B. 
RNA samples were extracted from untransfected L cells, L cel l; NIH 3T3 cells, 3T3 cell; a 
secondary tumor, 1924 ; two tertiary tumors induced by 1921 DNA, 0-14-1, 0 -14-2; and two 
spontaneous tumors generated from NIH 3T3 cells transfected with pSV2neo, neo, and 
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Figure 9. Western blot analysis of tumor proteins for p21 Ras expression. In Panel A, 
the first antibody was Y13-259, a rat monoclonal anti -ras antibody that cross-reacts with H-
' N-, and K-ras proteins; Panel B first antibody was normal rat gamma globulin . Antibody 
reactivity was visualized with [1251] protein-A coated with rabbit anti -rat antibodies . Protein 
samples include: lanes 1 and 2, tumors induced by \cNras; lanes 3, 4, tumors induced by 
\ N21 ; lane 5, K series secondary tumor, K11-1 ; lane 6, NIH 3T3 cells ; lane 7, primary 
tumor, 162; lane 8, secondary tumor induced from 192 DNA, 1921 ; lanes 9, 10, pool 19 
primary tumors , 195, 192; lane 11 , positive control tumor induced by T24 DNA (codon 12 
mutant human c-H-ras) , lanes 12 , 13, spontaneous transformant tumors that do not contain 
a transfected ras gene, 010-1 , and 3T3neo. The blots were over-exposed to show the p21 
Ras in the positive control T24 induced tumor, lane 11 . A shorter exposure of the left side of 
each blot is shown in Fig. 5. The size of prestained protein molecular weight markers is 
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carcinoma DNA which has a codon 12 mutant H-ras gene expressed barely detectable 
amounts of p21 (lane 11). Since the 19- series secondary and tertiary tumors expressed 
larger amounts of ras proteins, and arose with a longer latency than the codon 12 mutant H-
ra · ~ induced tumors, a mechanism of H-ras activation other than mutation at the strongly 
transforming regions around codons 12 and 61 had to be considered. Two hypotheses were 
teSted to explain the observation of increased p21 Ras without a concomitant increase in 
specific mRNA levels. The first hypothesis was that a stabilizing mutation in the expressed 
Ras protein caused an increased steady state concentration of Ras p21 which induced NIH 
3T3 cells to become tumorigenic. The second hypothesis was that a non-coding mutation in 
the newly integrated gene caused the H-ras mRNA to be more efficiently translated. 
To test these hypotheses, a cDNA library from poly(A) purified 1921 secondary tumor 
RNA was made in lambda GT11 and H-ras cDNA clones were isolated and sequenced. The 
library contained 2x106 independent clones with 92% recombinants. Approximately 3X105 
clones were screened with two H-ras specific probes: a Hindi II fragment that includes most 
of the H 3' UTA 'f' ~ coding sequence (Ellis et al 1980), and a mouse c-H-ras speer re 
01' 
'Qonucleotide, cs65_1. Five H-ras positive cDNA clones were isolated and mapped with 
restrict' d · h E A I site of ron enzymes. The three longest clones were subclone rnto t e co 
PGEM7zf + TM and sequenced directly using primers specific for plasmid sequences 
flank· H rng the multiple cloning site and oligonucleotides specific for mouse~ sequences. 
A list of 1· · A d'x F The cDNA 0 rgonucleotides used for sequencing can be found rn ppen 1 · 
sequences were aligned and compared with a combination of sequences from the Genbank 
database using the sequence analysis software package of the Genetics Computer Group 
(Dever . f th cDNA sequences with 
eaux et al 1983) on a VAX 750 computer. Comparison° e 
sequence data from mouse v-H-ras BALB-MSV (Reddy et al 1985) and rat v-H-ras Ha-MSV 
(Dhar et 
1 
. d mmal H-ras amino acid 
a 1982) , and a compilation of predicted viral an ma -
sequen tations in the cDNA coding 
ces (Lacal et al 1988) indicated that there were no mu 
sequenc . ed protein stability. 
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· ~ternative Splicing in Mouse c-H-ras mRNA 
To test the second hypothesis, the 3' and 5 ' non-coding regions of the cDNAs were 
analysed f . 
or any differences that could account for a change in the translatability of the 
mRNA. The most striking differences between the sequences of the three cloned cDNAs 
Were found in the 3 'UTR . All three sequences diverged 6 bases 3 ' of the p21 termination 
COdon (F' 
ig.10). The sequences surrounding the point of divergence were found to conform 
With the 
consensus rules for splice donor sites (Mount 1982). Inspection of the two sites 
Where th 
e sequences re-aligned , revealed that these areas resembled splice acceptor sites. 
Moreover, the areas of divergence and re-alignment (underlined in Fig.10) coincided exactly 
With Pred· 
icted splicing patterns. It was suspected that a previously undescribed intron was 
Present in this region of the gene, and that alternative splicing of this intron gave rise to the 
various mRNAs from which the cDNA clones were derived . If this were true , then the various 
alignm . 
ents of the cDNA clones with the mouse and rat viral H-ras sequences could be easily 
explained F' · · 1 · h' · t DNA · 1rst, mouse v-H-ras encoded by BALB-MSV was 1dent1ca in t 1s region o c 
clone 110 . . 
, containing the largest deletion (Fig.10, compare MSV-ras with 110). This virus 
may ha 
ve transduced the spliced form of the mRNA from the mouse. Second, the longest 
CDNA 16 · 1· d ' ' s, was identical at 103 out of 11 o nucleotides within the potentially spice region , 
to the . 
sequence of rat v-H-ras encoded by Ha-MSV (compare Rat-H-ras with 16s). As 
expected · · I · H , this homology ends at the integration site between rat and vira sequences in a-
Msv, so this virus seems to have transduced the unspliced form of the mRNA. The third 
CDNA I 
cone, 176, was intermediate in length between 16s and 110 and may represent an 
alternar · 33 b 5 ' to ively spliced form of the H-ras mRNA that used a splice acceptor site ases 
Clone 110. 
io det · th 3'UTR of mouse c-H-ras ermine whether alternative splicing occurs in e 
mRNA and Whether the pattern of splicing is different between the tumor and normal cells , 
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iiGTGTGCTG TCCTGACACC AGGTGAGGCA GGGACCAGCa AGACaTCTGG GGCAGTGgc~
4
0 
GTGTGCTG TCCTGACACC AG . .. . . .. . 
1;g;g;GCTG TCC TGACACC AG . . . . . . . . : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : 
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rciGCrAGCc AGArGiicrr ciri rccicr crGATGrccr rc;crccccci i rrcrc;ccii 
901 
TCCCCC.tGC CTGCA 960 
· · · · · . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . .. . G CTCAGGACAT 
· · · · · . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .... . ... G CTCAGGACAT 
. .. . .. · · ·· . . . . .. TCAG TCATGTCCTT TGTGCCCGTC CCGGCACAGG CTCAGGACAT 




GGAGGTGCCG GATGCAGGGA GGAGGTGCCG ACGGMGGM GGMAGAGGC GGGAAGGMG 
GGAGGTGCCG GATGCAGGGA GGAGGTGCCG ACGGMGGM GGAMGAGGC GGGAAGGMG 
GGAGGTGCCG GATGCAGGGA GGAGGTGCCG ACGGMGGM GGAMGAGGC GGGAAGGMG 
1021 1080 
GAMCGGTGC TGGAGCCAGG CCAGTCCAGG GATGGTGGAC AGATGTGACC MGACCTTCG 
GAAACGGTGC TGGAGCCAGG CCAGTCCAGG GATGGTGGAC AGATGTGACC MGACCTTCG 
GAAACGGTGC TGGAGCCAGG CCAGTCCAGG GATGGTGGAC AGATGTGACC MGACCTTCG 
1081 1140 
CATGGACMT TTGMCAGAC TGTCATGMC TGTCCCTGTT GCCACTGGCA CCCMGTCCT 
CATGGACMT TTGMCAGAC TGTCATGMC TGTCCCTGTT GCCACTGGCA CCCMGTCCT 
CATGGACAAT TTGMCAGAC TGTCATGMC TGTCCCTGTT GCCACTGGCA CCCMGTCCT 
1141 1200 
CCACCCCTCT CAGTTCCTCC GGGCGCCTGC CTGTGAGGGC ACACGTTGCA TCACAGTAM 
CCACCCCTCT CAGTTCCTCC GGGCGCCTGC CTGTGAGGGC ACACGTTGCA TCACAGTAM 
CCACCCCTCT CAGTTCCTCC GGGCGCCTGC CTGTGAGGGC ACACGTTGCA TCACAGTAM 
1201 




Pigure 10 f 
Clo · Comparison of the 3 , untranslated regions of c-H-ras cDNAs. Sequences o 
seq::s isolated from the 192-1 cDNA library, 110, 176, 16s, are aligned with Genbank derived 
H-ras tees: rat v-H-ras from HaMSV (Genbank:MHSp21) is labeled Rat-H-ras, and mouse~ 
~ rom BALS:Msv (Genbank:MSVRAS) is labeled MSV-ras . Dots were added for . 
the r rnent and the differences between mouse and rat are indicated by lower case letters ,n 
Sign~! sequence. Numbering is relative to the 16s clone as in figure 16· The st0P codon 
Sites rng the end of p21 Ras translation is italicized, the putative splice donor and acceptor 
are underlined, and the consensus splice sequences are indicated. 
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Oligonucle t'd . 0 1 e primers were synthesized complementary to sequences 5 ' and 3 ' of the 
Spliced ar . . 
ea . A thrrd olrgonucleotide specific for sequences within all of the predicted 
amplified t 
ragments was used as a probe to detect the specific amplified products. Cellular 
RNA from 
several tumors and cellular and cytoplasmic RNA from cell lines were reverse 
transcrib 
ed and the area of interest in the H-ras message was amplified by PCR. The 
amplified 
Products were separated by electrophoresis through 5 % polyacrylamide gels, 
transf 
erred to nylon membranes and hybridized with an H-ras specific oligonucleotide 
Probe. The results of several independent amplifications are shown in Fig. 11 . Samples in 
the right h 
alt of the figure were amplified from whole cell RNA except where indicated. 
Since th 
e observed alternative splicing could be due to partially spliced forms of the RNA 
found i 
n the nucleus and not in mature mRNA, cytoplasmic RNA from NIH 3T3 cells and L 
Cells wa 
s also amplified (lanes: 3T3 cyt. , L-cell cyt.) . The same pattern of alternative splicing 
Was detected in all RNA samples thus ruling out this possibility and supporting the 
suspected alternative splicing of this previously undescribed intron E. The upper 415 bp 
amp,·f' 1 
red fragment, represented by clone 16s, was the same size as the product amplified 
from 
genomic DNA and therefore corresponds to an unspliced form of the mRNA. As 
iudged by th I . f . 'f' t e re ative hybridization signals, this unsplrced orm represents a srgnr rcan 
fractio 
n of the~ mANA in all samples, including cytoplasmic RNA from normal NIH 3T3 
cells Th 
· e 268 bp amplified fragment , corresponding to the spliced form of the mRNA, was 
repres 
ented by clone 110 (lane p1019) . This fragment appears to be derived from another 
Signific 
ant Part of the mRNA population in both tumor and normal cells. The 301 bp 
fragment 1 · 1 1· d amplified from clone 176, the one predicted to represent an a ternatrve y sp rce 
form of . the~ mANA, appears to represent a minor fraction of the H-ras transcrrpts. In 
some la . . . 
nes thrs fragment is not visible in the figure, however rt was represented rn the 
amplific t ' f RNA a ron products of all RNAs tested. The lower abundance of this form o them 
may be due to inefficient recognition of a splice acceptor site that deviates from concensus. 
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:ig~r_e 11 . Polymerase Chain Reaction (PCR) amplification analysis of alternative 
Phcing at intron E of mouse c-H-ras. Reverse transcribed ANA samples and DNA 
controls were amplified by 30 cycles of PCR. The amplified fragments were separated by 
el~ctrophoresis in a 5 % polyacrylamide gel , blotted and hybridized with a r32PJlabeled 
~llgonucleotide, CB63, to detect H-ras specific amplified fragments . Reverse transcribed 
NA samples included cytoplasmic ANA from: NIH 3T3 cells and L cells , 3T3 cyt ., L-cell 
cyt ,; and whole cell ANA from: NIH 3T3 cells, 3T3; a tumor derived from spontaneous 
:ranstormants transfected with pSV2neo, neo; two secondary tumors induced by 192 DNA, 
92
·1 (two separate amplifications), 192-4; a tertiary tumor induced by 1921 DNA, 0-14-1 (two 
separate amplifications). Control DNA samples included: plasmid subclones of the mouse 
~ ~DNAs isolated from the 1921 library, p1019 (elsewh.ere referred to as 110) , pl~6, pl6s; 
frwo altquots of an unpackaged portion of the 1921 cDNA ltbrary: !921 ~DNA; genomic DNA 
on, untransfected NIH 3T3 cells, genomic; and a sample ampl1f1ed with no added 
template. The sizes of the amplified fragments are indicated in kilobasepairs. 
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elative abundance of all three forms of the the H ras mRNA . The r _:-__ were approximately 
. alent in all tumor and normal cell RNAs tested equiv · 
Alternative splicing within intron D of the human H ras gene ti h _-_ wasrecen ys ownto 
have an effect on expression and transforming efficiency of a codon 12 mutant gene (Cohen 
et al 1989) . The authors demonstrated that alternative splicing within intron D (between 
exons 3 and 4) results in inefficient processing of the mRNA. The putative truncated form of 
H-ras protein encoded by these transcripts is of unknown function and its existence was not 
:.---
proven . However, loss of the splicing mechanism by mutations within the intron resulted in 
Sed expression of p21. To test whether alternative splicing also occurs within th'is increa 
intron in mouse c-H-ras and whether loss of this alternative splicing mechanism could have 
been the activating event in the nude mouse tumors, RNAs were amplified by PCR at intron 
Alternative splicing does occur at intron Din a minor fraction of mouse H-ras mRNAs as o. --
shown in Fig .12. The 150 bp fragment representing the bulk of the mRNA is amplified from 
the spliced form ; pl6s , and all of the cDNA clones isolated from the tumor library were in this 
conformation . The faint un-numbered band between 150 and 490 may be an artifact since it 
was amplified from both plasmid DNA and RNA. The fragment amplified from genomic DNA 
was 740 bp and was used to show the size of any unspliced transcripts or contaminating 
DNA. The 490 bp fragment amplified in all of the RNA samples may represent alternatively 
I
. d mouse H-ras mRNA since it is 250 bp smaller than the fragment amplified from 
spice -
·c DNA The 490 bp fragment represents a low abundance form of the mRNA as had 
genom1 · 
been reported for the human alternatively spliced transcript, but unlike the human and rat, 
this potential alternatively spliced intron is approximately 340 bases long. In both human 
and rat the reported size is smaller, 80 and 89 bases respectively (Cohen 1989). This 490 
bp fragment is present in both untransfected NIH 3T3 cell and tumor RNAs, ruling out the 
loss of alternative splicing in this region as an explanation for increased H-ras expression in 
the tumors . 
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~Q~r~ 12. P_olymerase Chain Reaction (PCR) amplification analysis of alternative 
Phc,ng at mtron D of mouse c-H-ras. Reverse transcribed RNA samples and DNA 
~~ntrols were amplified by 30 cycles of PCR. The amplified fragments were separated by 
01~ctrophor~sis in a 5 % polyacrylamide gel, blotted and hybridized with r32P]labeled 
R~onucleot1de, HS-2, to detect H-ras specific amplified fragments. Reverse transcribed 
c ~ samples included cytoplasmic RNA from : NIH 3T3 cells and L cells , 3T3 cyt ., L-cell 
t Yt. , and whole cell RNA from : NIH 3T3 cells, 3T3; a tumor derived from spontaneous 
1;~~sformants transfected with pSV2neo, neo; two secondary tumors induced by 192 DNA, 
C 1 (two separate amplifications) , 192-4; a tertiary tumor induced by 1921 DNA, 0 -14-1. 
19 ontr.ol DNA samples included: a plasmid subclone of mouse H-ras cDNA isolated from the 21 library, pl6s; an aliquot of an unpackaged portion of the 1921 cDNA library, 1921 cDNA; 
Qenomic DNA from untransfected NIH 3T3 cells, genomic; and a sample amplified with no 
added template . The sizes of the amplified fragments are indicated in kilobasepairs . 
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To test Whether the presence of the alternatively spliced 3 'UTRs have an effect on the 
efficiency oft . 
ranslat1on of the mRNA, the cDNA clones were linearized and transcribed in 
Vitro us· S 
ing P6 polymerase. The in vitro transcribed mRNAs were capped with guanylyl 
transferase and translated in rabbit reticulocyte extracts using [35sJmethionine. In pilot 
experiments 200 ng of mANA, when translated for 1 hour at 30°C in 50 µI reactions, 
Produced . 
an easily detected signal. This was determined to be the concentration most 
likely to detect differences in translation efficiency, since twice as much RNA produced a 
Prop0 t' 
r ionally larger signal. The identity of the translation products was verified by 
immunopr · . . . . . 






e translation products were immunoprecipitated specifically by the anti-ras 
monoclon 1 · . 
a antibody, (lanes 2 through 7) , and were not recognrzed by normal rat serum 
(lanes a th
rough 11) . No translation product was produced without the addition of 
exogenous mRNA (lane 1), and un-related translation products from the Brome Mosaic Virus 
Were not. 1
mmunoprecipitated (lane 8) in this system. The mRNAs were translated with , and 
Without . . 
Prror heat treatment, since some mRNAs require heat treatment to disrupt 
second 
ary structures that may inhibit translation initiation. Comparison of lanes 2,4,6 
(heated) With lanes 1,3,5 (not heated) showed that heat pre-treatment did not have an effect 
on the t 'ff · · 
ranslation rate of the H-ras mRNAs. A slight but reproducible d1 erence rn size was 
noted b . h 
etween the 16s and 176 translation products. Compared with molecular we1g t 
ll'larkers and co-electrophoresed Brome Mosaic Virus in vitro translation products, the 
apparent molecular weight of the 176 translation product was approximately 21 ,ooo and the 
16
s Pr d d · ·t 
o Uct was approximately 23,000. Clone 110 mRNA produced a truncate rn v1 ro 
trans, · · I' · g ·n 
at1on Product (lanes 6, 7) . As determined by sequence analysis, alternative sp icrn I 
intron c . h' 1 hich resul ts in a created a frame shift within the coding sequence rn t is c one w 
truncated translation product from premature termination in exon 3. This truncated form of 
Ras is n · d · the epitope 
ot efficiently immunoprecipitated by the monoclonal ant1bo Y srnce 
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Figure 13. lmmunoprecipitation of In vitro translation products with anti-Ras 
monoclonal antibody, Y13-259 . In vitro transcribed and capped mRNAs (500 ng) from the 
mouse cDNA subclones 110, 176 and 16s, were translated in rabbit reticulocyte extracts with 
135SJmethionine for 1 hour at 30°C in a 100 µI reaction volume. An aliquot of each sample 
was immunoprecipitated by monoclonal antibody, Y13-259, (lanes 1-8) or normal rat gamma 
globulins (lanes 9-11) and protein-A sepharose coated with rabbit anti-rat antibodies. The 
immunoprecipitated proteins were separated by 12 % SOS PAGE under reducing conditions 
and visualized by fluorography. Duplicate RNA samples were ei ther heated to 65°C prior to 
translation (lanes 2,4,6) or received no pre-treatment (lanes 3,5, 7). The relat ive migration of 
prestained molecular weight markers is indicated at the right (X1000). The major translation 
products are indicated by arrows . The truncated protein produced by 110 is poorly 
recognized by the monoclonal antibody. Lanes 1 and 8 were translations run with no added 
RNA and with Bromo Mosaic Virus RNA respectively. Though the viral RNA produced 
several protein products, they were not recognized by the monoclonal antibody. 
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recognized b th ' . 
Y 1s antibody (aa 63-73) is close to the site of sequence divergence. When 
the transfati 
on products were run on SOS polyacrylamide gels without prior 
immunopre · · . 
cipitat1on, the truncated protein was translated with the same efficiency as the 
Other two 1 c ones (not shown). Since the predicted translation product of pl 1 O would not bind 
GTp a
nd 
could not be localized to the membrane, two prerequisites for ras protein function , 
this clo 
ne was not pursued further. 
The apparent difference in size between the translation products of pl6s and pl76 
coufd not b 
e accounted for by any obvious changes in the coding sequences of the two 
CDNAs T . 
· 
0 determine whether the molecular weight difference was due to undetected 
coding se 
quence changes, the clones were mapped by RNAase protection. Clone pl6s was 
digested · . · 32 
with BamHI and a full length antisense probe was synthesized using (ex PJCTP 
and T7 RNA 
polymerase. This probe was hybridized in solution to the in vitro transcribed 
mRNAs and the hybrids were digested with A Nase to cleave the probe at sites of mis-
match 
es (Melton et al 1984) . The products were separated on denaturing polyacrylamide 
Qels and th . . 
e protected fragments were visuallzed by autorad1ography. No truncated 
fragme 
nts were detected (data not shown) , as would occur if there were sequence 
mismatch 
es between the clones. Since the protected fragments were not smaller than 
expected · f h 
• Coding sequence differences between the clones could not account or t e 
differenc . 
es in size of the translation products. 
To determine whether the difference in size between the translation products was due 
to altern t· . ' d' . 
a ive Splicing in the 3' UTA or to sequence differences in the 5 non-co mg region, 
recipro d 3 'UTA f 
car constructs were made between the 5 ' UTRs, coding sequences an so 
the CDN b 
A clones. In vitro transcribed mRNAs from these chimeric clones were assayed Y 
transr . . - -- . . 
ation in rabbit reticulocyte extracts to determine which region of the mRNA was 
resPon · t f apped 
Sible for the different sizes of the translation product. The same amoun ° c 
mRNA w t The structure of 
as translated and immunoprecipitated in all reticulocyte extrac s. 
the ch· · d ·n Fig 14 
imeric cDNA clones and the respective translation products are summarize I • . 
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'Qure 14. S . . . ~ranstatio chemat1c diagram of the structure of the c-H-ras chimeras and their 
1ntrons, an~ products. The various sized triangles represent the alternatively spliced 
en2:yrne sit the transcription start sites and termination sites are indicated. The restriction 
names of t~s us~d for construction of the chimeras are indicated above the first clone. The 
are the or' _e chimeric plasmids are indicated to the left of each diagram. 16s, 176 and 11 O 
?'ones. c'~1nal cDNAs clones, the others are derived from the indicated fragments of these 
1n rabbit ~Ped SP6 transcribed mRNAs from the chimeric c-H-ras genes were translated 
under th;et,culoc~te extracts or in Xenopus oocytes. The translation products are indicated 
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Figure 15. In vivo and In vitro translation of chimeric c-H-ras mRNAs. Translation 
Products of~ Vitro transcribed and capped chimeric mRNAs were immunoprecipitated with 
monoclonal antibody Y13-259 and the proteins were separated by 12 % SOS PAGE under 
reducing conditions. The chimeric plasmids used for mRNA production are indicated above 
each lane. RNAs translated in rabbit reticulocyte extracts are within the bracket labeled 
reticulocyte and the RNAs translated in Xenopus oocytes are within the bracket labeled 
oocyte. The different sizes of the translation products are indicated by arrows. The smaller 
band may be a degradation product. 
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The Presence of the alternatively spliced 3 'UTRs had no effect on the apparent size of the 
translatio . 
n product, since ras7, ras107, and ras67 all had different 3' UTRs and all produced 
th
e same P21 product. The longer translation product was made only by those clones that 
contained the upstream 5' UTA sequences since the translation products of 16s and ras 106 
were P23 and the product of lras1, which has a 54bp deletion within the 5'UTR, was p21. To 
verify that the observed difference in size of translation products was not an artifact of the in 
Vitro tra 1 . - ns at1on system, capped mRNAs from selected constructs were also translated in 
~ oocytes. The same amount of each mRNA was injected into each oocyte, and the 
oocyte Proteins were labeled by overnight incubation in [35S]methionine. Protein extracts 
Were made from pools of 20 oocytes injected with each mRNA and equivalent amounts of 
extracts, as determined by the BCA protein assay, were immunoprecipitated and separated 
by SDs Polyacrylamide gel electrophoresis. Translation products of the same size as those 
of the reticulocyte extracts were seen when the mRNAs were translated in Xenopus oocytes 
(Fig· 15) . Extracts from uninjected oocytes that were similarly treated did not contain 
immunoprecipitatable [35sJ-labeled proteins (lane labeled no RNA). All chimeric mRNAs 
Were translated with similar efficiencies within either system. The low signal in the 
reticu1 · t t I ocyte system with ras6? in Fig .15 was due to a calculation error, no o a rea 
differen . 
ce 1n translation efficiency. 
~ 
The 5 'UTA d between the cDNA clones, the normal mouse sequences were compare 
~ genomic sequence (Brown et al 1988)' and the rat v-H-ras sequence from Ha-MSV 
(figure 16). The sequence between the two Nari sites at positions 9 and 65 contains an ATG 
trans1ar . . . . · · 50) Deletion of this Nari 
ion 1n1t1ation codon (italicized in the figure at position · 
fragment invariably caused a shortening of the translation product. The original cDNA clone 
176, Whi h . 1 t does not contain the c Produced the shorter protein in ret,culocyte ysa es, 
0Pstrea nee (Fig 17) shows that the 








· · · ........ GCCCGCAGC CCGAGCCGCA CCCGCCGCGG ACGGAGCcCA 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .... CGCGG ACGGAGCTCA 
CCGCTCCCGG CGCCCGCAGC CCGAGCCGCA CCCGCCGCGG ACGGAGCTCA 
CCGCTCCCGG CGCCCGCAGC CCGAGCCGCA CCCGCCGCGG ACGGAGCTCA 
Narr 
50 100 
TGCGCGGGCC CAGtCGGCGC CCGTCCGCGC CCCCGCCCTG CCCCGGCCCC 





TGCGCGGGCC CAGCCGGCG* CCGTCCGCGC CCCCGCCCTG CCCCGGCCCC 
GCGGGCC CAGCCGGCG* CCGTCCGCGC CCCCGCCCTG CCCCGGCCCC 
Gen 1?8 TGCGCGGGCC CAGCCGGCG* CCGTCCGCGC CCCCGCCCTG CCCCGGCCCC 















GGCCCCG ...... GGGGCAG TCGCGCCAGC AAGCGGTGGG GCAaGAGCTC 
GGCCCCG . CC CCGGGGGCAG TCGCGCCAGC AAGCGGTGGG GCAGGAGCTC 
GGCCCCGGCC CCGGGGGCAG TCGCGCCAGC AAGCGGTGGG GCAGGAGCTC 
GGCCCCGGCC CCGGGGGCAG TCGCGCCAGC AAGCGGTGGG GCAGGAGCTC 
GGCCCCGGCC CCGGGGGCAG TCGCGCCAGC AAGCGGTGGG GCAGGAGCTC 
GGCCCCGGCC CCGGGGGCAG TCGCGCCAGC AAGCGGTGGG GCAGGAGCTC 
><intron A 
150 200 
CTgGtTTGGC AGCCcCTGTA GAAGCgATGA CAGAATACAA GCTTGTGGTG 
CTAGATTGGC AGCCGCTGTA GAAGCTATGA CAGAATACAA GCTTGTGGTG 
CTGGATTGGC AGCCGCTGTA GAAGCTATGA CAGAATACAA GCTTGTGGTG 
CTGGATTGGC AGCCGCTGTA GAAGCTATGA CAGAATACAA GCTTGTGGTG 
CTGGATTGGC AGCCGCTGTA GAAGCTATGA CAGAATACAA GCTTGTGGTG 
CTGGATTGGC AGCCGCT.Gib GAAGCTATGA CAGAATACAA GCTTGTGGTG 
p21> 
F'igure 16 C · h 'UTA cDN · omparison of c-H-ras 5' untranslated regions (UTRs). T e 5 s of the 
rat v~ clones 11 o, 176, and 16s were aligned with Gen bank derived sequences sequences: 
BA~ from Ha-MSV (Genbank:MHSp21) is labeled rat-H-ras, and mouse v-H-ras from 
seque·MSV (Genbank:MSVRAS) is labeled MSV-ras; and with the mouse ge_nomic c-H-ras 
diff nee from Brown et al 1988 labeled Genomic. Dots were added for alrgnment and the 
erenc ' · h Nu es between mouse and rat are indicated by lower case letters int e rat sequence. 
niber' · d · ·t 1· h co rng rs relative to the 16s clone as in figure 1 o. The ATG start co ons are rn , a res, t e 
of ;see~sus sequences for initiation are underlined, as ~re the Nari restriction s_ites. Deletion 
"fhe in~! fragment in subclone ras1 results in translation of the smaller prot~rn prod~c_t. 
for. rtratron site of ras P21 is indicated by p21 > under the sequence. The srte of. splrcrng 
se rntron 1 is indicated and the intronic sequences were removed from the genomic 
Quence for alignment. The single base deletion at position 69 is indicated with *. 
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1 CGCTCCCGGC . . . . . . 
GCCCGCAGCCCGAGCCGCACCCGCCGCGGACGGAGCTCAIGCGCGGGCCCAGCCGGCGCCCGTCCGCGCC 
upstream ORF>M R G P S R R P s A p 




~ P G P G P G P G G s R A S K R W G B S S W r G s 
GCCGCTGT . , . . . . . . 
AGAAGCTAJ:GACAGAATACAAGCTTGTGGTGGTGGGCGCTGGAGGCGTGGGAAAGAGTGCCCTGACCATCCA 
iL_s:__ P2 l >M T E Y K L V V V G A G G V G K S A L T I Q 
Rs Y QR T O A CGG GRWRRGK E CPQHe_ 
GCTGATCCA. . . . . , . 
L I Q GAACCACTTTGTGGACGAGTATGATCCCACTATAGAGGACTCCTACCGGAAACAGGTGGTCATTGATGGGG 
4-.i)__p_ NHFVDEYDPTIEDSYRKQ VVI DGE 
BP l c GR V ~d 
AGACATGT . . . . . . . . 
T C CTACTGGACATCTTAGACACAGCAGGTCAAGAAGAGTATAGTGCCATGCGGGACCAGTACATGCGCACAGGG 
L L D I L D T A G Q E E Y S A M R D Q Y M R T G 
401 GAGGGCTT . . . . . . . . 
481 
E G CCTCTGTGTATTTGCCATCAACAACACCAAGTCCTTCGAGGACATCCATCAGTACAGGGAGCAGATCAAGCG 
F L C V F A I N N T K S F E D I H Q Y R E Q I K R 
G~TG~GATTCAGATGATGTGCCAATGGTGCTGGTGGGCAACAAGTGTGACCTGGCTGCTCGCACTGTTGAGTCTCGGC 
D S D D V p M V L V G N K C D L A A R T V E S R Q 
561 AGGcccA . . . . . . . . 
A GGACCTTGCTCGCAGCTATGGCATCCCCTACATTGAAACATCAGCCAAGACCCGGCAGGGCGTGGAGGATGCC 
721 
Q D L A R s y G I p y I E T S A K T R Q G V E D A 
TTcrA . . . . . . . . 
F y TACACTAGTCCGTGAGATTCGGCAGCATAAATTGCGGAAACTGAACCCACCCGATGAGAGTGGTCCTGGCTGCAT 
T L V R E I R Q H K L R K L N P P D E S G P G C M 
GAGCTGC . . 
s C AAATGTGTGCTGTCCTGA 
K C V L S end 
,=:-• 19ure 1? . . . 
from the ·e Translation of normal c-H-ras. This sequence 1s a composite of sequences 
Sequen 9 nom/c sequence up to the second exon from Brown et al 1988, and the v-H-ras 
.u?~erlin:edfrom BALB-MSV, Genbank:MSVras. The translation Initiation codons ~re 
1n1t1at/on and the upstream out-of-frame open reading frame starts at -126 relative to p21 
Oi,,=:- is u~~nd~ at + 97, and is indicated by ORF> . The potential translation product of the 
truncated erlined. The p21 Ras protein is indicated by p21 > and the sequence Is 





l CGCTCCCG . • . . . . * . 
GCGCCCGCAGCCCGAGCCGCACCCGCCGCGGACGGAGCTCAIGCGCGGGCCCAGCCGGCGCCGTCCGCGCCC 
fusion protein >M R G P S R R R p R p 
81 CCGCCCTGC. . . . . • . 
R p CCCGGCCCCGGCCCCGGCCCCGGGGGCAGTCGCGCCAGCMGCGGTGGGGCAGGAGCTCCTGGATTGGCAG 
=--APAPAPAPGAVAPASGGAGAPGLAA 
161 c · p21> CGCTGT · · · · · · A V AGAAGCTA'.ilzACAGAATACAAGCTTGTGGTGGTGGGCGCTGGAGGCGTGGGAMGAGTGCCCTGACCATCCAG 
=' EAMTEYKLVVVGAGGVGKSALTIQ 
241 CTGATCCA . . . . . . . 
L I Q GAACCACTTTGTGGACGAGTATGATCCCACTATAGAGGACTCCTACCGGAMCAGGTGGTCATTGATGGGGA 
N H F V D E Y D P T I E D S Y R K Q V V I D G E 
321 GACATGTC . . . . . . . 
T C TACTGGACATCTTAGACACAGCAGGTCAAGAAGAGTATAGTGCCATGCGGGACCAGTACATGCGCACAGGGG 
L L D I L D T A G Q E E Y S A M R D Q Y M R T G E 
4 01 AGGGCTTC . . . . . . . 
G CTCTGTGTATTTGCCATCAACAACACCAAGTCCTTCGAGGACATCCATCAGTACAGGGAGCAGATCAAGCGG 
481 
F L C V F A I N N T K S F E D I H Q Y R E Q I K R 
GTGAAA . · · · • · · 
V K GATTCAGATGATGTGCCAATGGTGCTGGTGGGCAACAAGTGTGACCTGGCTGCTCGCACTGTTGAGTCTCGGCA 
D S D D V p M V L V G N K C D L A A R T V E S R Q 
GGccc · · · · · · · · A QAGGACCTTGCTCGCAGCTATGGCATCCCCTACATTGAMCATCAGCCAAGACCCGGCAGGGCGTGGAGGATGCCT 
D L A R S y G I p y I E T S A K T R Q G V E D A F 
TC;ATACACTAGTCCGTGAGATTCGGCAGCATAMTTGCGGAMCTGAACCCACCCGATGAGAGTGGTCCTGGCTGCATG 
T L V R E I R Q H K L R K L N P P D E S G P G C M 
721 AGCTG . . . . . . . . 
s CAAATGTGTGCTGTCCTGACACCAGGTGAGGCAGGGACCAGCGAGACGTCTGGGGCAGTGACCTCAGCTAGCCAG 
C K C V L s end >unspliced intron E------- ----- ------------- ----- - -
801 ATG . . . . . . . . 
__ AACTTCATATCCACTCTGATGTCCTTGCTCCCCCMTTCTGCCMTCCCCCCCGCCTGCAGTCAGTCATGTCCTTTG 
----- ---------------------------------------------------- -------------
Ba1 TGcc . . . . . . . . 
____ CGTCCCGGCACAGGCTCAGGACATGGAGGTGCCGGATGCAGGGAGGAGGTGCCGACGGMGGMGGAMGAGGCGG -------------< 
961 GAA . . . . . 
GGAAGGAAACGGTGCTGGAGCCAGGCCAGTCCAGGGATGGTGGACAGATGTGACCAAGACCTTCGCATGGACAATTT 
1041 GAAc . . . . . . . . 
AGACTGTCATGAACTGTCCCTGTTGCCACTGGCACCCAAGTCCTCCACCCCTCTCAGTTCCTCCGGGCGCCTGCCT 
GTGAGG . . . . 
GGCACACGTTGCATCACAGTAAATTATTTGATGGTCTTAAMAJ7 
F=· rgure 18 . 
Present · Translation of clone 16s. The complete sequence of cDNA clone 16s rs 
transfati~d, _t~~ u~spliced intron E in the 3' untranslated region i~ indicate~ _by > --~ , t_he 
by a *) n rnrtratron codons are underlined. A single base deletion at positron 69 (rndrcated 
of p21 ~:anges the reading frame of the upstream ORF to ma_k~ it coincide with _translation 
the p21 sand a fusion protein is predicted. The fusion protern rs double underlrned up to 
translation initiation site (indicated by p21 >). 
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upstream ATG . . . 
is out-of-frame with respect to the p21 coding sequence. The upstream ATG 
can Potential! · · . 
Y initiate translation of an open reading frame (ORF) that is 123 bases long and 
overlaps the . 
P2 1 translation start site by 97 nucleotides. This ORF codes for a very 
hydrophilic p t . 
u at1ve protein product 74 amino acids long. 
Translat' 
ion of clone 16s starting from the upstream ATG predicts a fusion protein 
between th 
e upstream ORF and H-ras p21 sequences (Fig .18). The deletion of a cytosine-at 
Position 69 
created a frame shift mutation and the reading frame of the upstream ORF 
became I' . 
a igned with the ras coding sequence. The predicted length of this fusion protein is 
231 amino . 
acids, which is longer than expected if it is to account for the observed shift from 
P21 to P23. . 
rn the denaturing SDS polyacrylamide gels. Single point mutations have been 
Shown to c . . 
ause changes in the apparent molecular weight of Ras proteins when assayed 
under sim ·1 . . . . 1 
ar cond1t1ons (Srivastava et al 1985) , so this discrepancy 1s not unprecedented. 
Ko2ak (19 89) has recently shown that downstream secondary structure enhances the 
recognir 
ion of an upstream ATG. The sequence between the upstream ATG of c-H-ras and 
the first . 
intron is approximately 96% G + c (Fig .16) and has the potential to form several 
stern-10 
op structures. As shown in Figs. 13 and 15, the presence of the upstream ATG 
results in . ATG · 
exclusive initiation at this site, with no initiation detected at the downstream in 
either of 
the translation systems used. When the upstream ATG was removed from the 
rt1RNA 
as in constructs 176, ras7, ras107, ras67, and ras1 ' the normal ATG was used to 
efficient, . . . . . . d . 
y inrtiate translation of p21. Since the upstream ATG is efficiently recognize in 
bo
th 
transl · · th ' may also happen in 
ation systems to initiate translation of a ras fusion protein , is -
V' -
~ and co · . f rotein seen in the 1921 , 
nst11ute a novel mechanism for the overexpression ° ras P 
and d . 
errvative tumors . 
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esrs rs known to be a multi-step process (reviewed in Land et al 1983b) . 
Similarly tran f . 
' s ormatron of normal cells in culture into tumor cells requires the cooperation 
of more th 
an one activated oncogene (Newbold et al 1983, Ruley et al 1983, reviewed in 
8Pandid 
os and Lang 1989). Oncogenes have been assigned to one of two 
comp1 ement t' 
a ron classes , the myc- or the ras class, based upon their ability to cooperate in 
the tumor; . 
genre transformation of primary cell cultures (Land et al 1983a, Parada, et al 
1984) . One 
of the properties that has made the NIH 3T3 cell line the most used indicator for 
transtormin . 
g genes rs the fact that these cells are pre-neoplastic, and only require the action 
Of a · 
srngle activated oncogene to become tumorigenic (Cooper et al 1982). NIH 3T3 cell 
transfecuo 
n assays for activated oncogenes have been designed to detect the presence of 
a Singled . 
omrnant oncogene in the donor DNA. Since NIH 3T3 cells transfected with 
activated r 
~ -type oncogenes induce more rapidly growing tumors than those transfected 
With onco 
genes from the myc class, the most dominant acting gene in a tumor DNA 
PreParar 
ron masks the transforming activity of any other oncogene also present in the tumor. 
Portuitous1 . 
Y, rn a few cases two activated oncogenes were detected in the same tumor 
(Murray e . . . 1 al 1983, Fasano et al 1984) . The tumorigenesis assay was modrfred to rncrease 
the Chane . . 
e of detecting both strongly and weakly transformrng oncogenes from the same 
Original tu . . 
mor. A preliminary sib-selection step was added to the broassay for transforming 
9enes d . 
escrrbed by Fasano et al (1984). This sib-selection procedure was also used by co-
Workers to . . 
detect an activated ras oncogene in human chorrocarcrnoma (Cohen et al 1988) . 
'hesib- . - . . 
Selection step separates into pools individual colonies that have rntegrated different 
Parts of th 
e donor cell genome. The pools are then injected into different groups of mice for 
tumor; 
Qenesis analysis. Using this approach, pools containing potential weakly 
97 
transforming transfected genes can be separated from pools transfected with oncogenes 
which induce rapid tumor growth . 
Renal cell carcinoma (RCC) , and pancreatic beta cell insulinoma were the two tumor 
types tested for the presence of dominant acting oncogenes using the sib-selection 
tumorigenesis assay. Both of these malignancies have been associated with chromosomal 
abnormalities indicative of the loss of a tumor suppressor gene. The multiple endocrine 
neolpasia syndrome type I, a hereditary pre-disposition to develop endocrine tumors, 
including insulinoma, has been mapped to the loss of alleles on chromosome 1 (Mathews et 
al 1987) . Both the sporadic and hereditary form of RCC are associated with chromosomal 
abnormalities on the short arm of chromosome 3 (Zbar et al 1987) . Since tumorigenesis 
results from the loss of gene expression, these types of genetic abnormalities cannot be 
assayed by transfection of NIH 3T3 cells . The aim of these experiments was to determine 
whether any dominant acting oncogenes were also involved in the tumorigenic process in 
RCC and insulinoma. While these experiments were in progress, Fujita et al (1988) 
reported the detection of H-ras codon 12 mutation in a very low proportion of renal cell 
carcinomas (one out of fifteen). To date, no activated oncogenes have been associated with 
human insulinomas. 
No novel dominant acting oncogenes were detected in the 5 tumor DNAs tested . The 
increased sensitivity of the tumorigenesis assay, as compared with the focus formation 
assay, allowed the detection of overexpressed ras proto-oncogenes activated during 
transfection . Overexpression of ras proteins resulting in tumorigenesis occured by two 
profoundly different mechanisms. 
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B. Overexpression by N-ras Gene Amplification 
Transfection and tumorigenesis analysis of a renal cell carcinoma DNA resulted in the 
production of primary nude mouse tumor DNAs containing approximately 50 copies of the 
human N-ras gene (Fig . 3) . Secondary tumors induced by transfection of genomic DNA 
from a primary tumor also showed N-ras gene amplification, although to a lesser extent 
(approx. 20 copies) . Analysis of full length phage clones isolated from a library of primary 
nude mouse tumor DNA showed that the clones efficiently induced tumors but not focus 
formation . A codon 61 mutant N-ras minigene used ass positive control in these 
experiments induced faster growing tumors and produced easily distinguishable foci. 
Mutations at codon 13 of N-ras has been reported to induce tumors but not produce foci 
when transfected into NIH 3T3 cells (Bos et al 1985, Hirai et al 1987) . The possibility that 
this , or a similar mutation had activated the gene was ruled out by subcloning regions of the 
cloned N-ras gene and sequencing the coding exons. No point mutations were found in the 
coding sequence of the N-ras gene, though a few base changes and a small deletion were 
noted in the 3 ' untranslated region. DNA from a cloned normal human c-N-ras gene induced 
tumorigenesis with similar incidence and onset as compared with the gene cloned from the 
mouse tumor suggesting that the mutations detected in the 3' UTR probably had little to do 
with the observed tumorigenesis . 
To determine whether the nude mouse tumors induced by transfection of human N-ras 
produced detectable ras protein, Western blot analysis of tumor proteins was done using a 
monoclonal antibody specific for p21 Ras. As shown in Fig . 5, p21 was overexpressed in N-
ras induced tumors, including tumors induced by the lambda phage clone of normal human 
c-N-ras . In contrast , tumors induced by a codon 61 mutant N-ras minigene expressed 20 to 
50 fold less p21 Ras, and no detectable levels of Ras protein were found in spontaneous 
NIH 3T3 cell tumors. Southern blot hybridization of genomic DNAs from the tumors induced 
by both control and test N-ras phage clones showed high copy numbers of integrated N-ras , 
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as had been detected in the primary and secondary nude mouse tumor DNAs. Southern 
blot hybridization of the original human tumor DNA and three metastases from the same 
patient showed that the N-ras gene was not amplified in the patient tissues (Fig.6) . The 
most probable explanation of the data is that an amplification event had occured during the 
primary transfection and tumorigenesis assay, and that integration and expression of 
amplified copies of transfected normal N-ras is sufficient to produce tumors in nude mice. 
Several other groups have isolated N-ras from human tumors using nude mouse 
tumorigenesis assays. Fasano et al (1984) originally showed that amplified human N-ras 
could cause nude mouse tumors , although in those experiments the amplification was also 
present in the original tumor DNA. The amplified N-ras gene was cloned but not sequenced 
to rule out the possibility of concomittant amplification and mutation . In parallel 
transfections, however, the cloned normal c-N-ras was tumorigenic with the same incidence 
and onset as the amplified gene. Using a modification of the tumorigenesis assay described 
by Fasano et al (1984) , another laboratory reported detection of human N-ras with a point 
mutation at codon 13 in acute myeloid leukemia DNA (Bos et al 1985) . The mutant N-ras 
gene was amplified up to 30 fold in some of the primary nude mouse tumors, and in their 
experiments normal N-ras did not induce tumorigenesis . Hiarai et al (1987), using a 
modification of tumorigenesis technique used by Bos, reported the isolation of codon 13 
mutant N-ras from myelodisplastic syndrome , an early stage of acute myeloid leukemia. 
Again , the authors reported that normal N-ras did not induce tumorigenesis. 
In agreement with Fasano 's results, the Sib-selection tumorigenesis assay could detect 
amplified normal ras genes . The major difference between the two assays that showed no 
tumor formation from the normal N-ras gene and the two assays that showed normal N-ras 
induced tumorigenesis is the length of time the cells were kept in culture prior to injection 
into mice. The methods showing positive results used fully selected cells that were pooled 
and grown to mass culture for injection . The methods showing lack of tumor formation 
injected , pooled cells that had been in under selection for only 7 to 10 days after 
100 
transfection . The shorter pre-selection period may have resulted in injection of fewer cells 
expressing the co-transfected gene and a less sensitive assay. Also, comparison of the 
different assays showed a rough correlation between the amount of cells injected per mouse 
and the latency period for tumor formation. For example, injection of 1 x1 o7 cells resulted in 
development of positive control tumors within one week or less (Fasano et al 1984) ; when 
2x1 o5 cells were used , similar positive control tumors took 4 to 1 O weeks to develop (Bos et 
al 1985) . In the current study, injecting an intermediate amount of cells (2X106) resulted in 
positive control tumor formation in 2 to 3 weeks. Hiari et al (1987) used a similar inoculum 
(1 .5X106) but did not report positive control results. 
In an earlier study designed to correlate gene dosage and transformed phenotype, it 
was noted that when cells expressing low amounts of a mutant K-ras gene were injected into 
mice, the tumors that were produced contained amplified copies of the K-ras gene and 
produced more ras protein (Winter and Perucho 1986) . The current work has also 
demonstrated that tumors arising from normal N-ras invariably show amplified copies of the 
transfected gene possibly more as a result of how much expression of the normal gene is 
required for tumorigenesis than an indication of gene amplification in the original tumor. 
C . Alternative Splicing of c-H-ras 
Southern blot analysis of the 19- series of nude mouse tumor DNAs revealed that a new 
copy of the mouse H-ras gene had co-integrated with human sequences during the 
secondary transfection event and, in two independent transfection experiments, was 
transferred to tertiary tumors . This gene was not highly amplified as had occured with N-ras 
from RCC. Rather , overexpression of normal ras protein appears to have occured by a novel 
mechanism in these nude mouse tumors . A new fragment hybridizing with a mouse H-ras 
cDNA probe was detected in secondary tumors at the same intensity as the normal H-ras 





tertiary tumors in two separate experiments . This mouse H-ras gene was not closely linked 
to the integ rated human DNA since the Alu positive sequences were not co-transferred to 
the terti ary tumors. To confirm that the newly integrated H-ras gene was expressed, the 
tumors we re analysed by Northern and Western blotting . Surprisingly, no significant 
differences were detected in H-ras specific mRNA levels between the ras positive tumors, 
untransfected NIH 3T3 cells , and tumors from spontaneous transformants that did not 
contain integrated ras sequences. In contrast to the baseline levels of H-ras specific mRNA 
found in all of the 19- series tumors , p21 Ras was overexpressed in the secondary and 
terti ary tumors. 
The 19- series secondary and tertiary tumors expressed approximately 20 to 50 times 
more ras proteins than tumors induced by codon 12 mutant H-ras . Ras protein 
overexpression combined with a latency period for tumor development of greater than two 
weeks was indicative of a mechanism of activation other than mutations at codons 12 or 61 . 
As mentioned above , gene amplification was not involved in the overexpression of H-ras 
protein in the I series tumors. Also , the increased ras protein expression occurred without a 
concomitant increase in specific mRNA levels . Two hypotheses were tested to explain this 
discrepancy. The first hypothesis was that a stabilizing mutation in the coding sequence 
caused an increased steady state concentration of Ras protein which induced NIH 3T3 cells 
to become tumorigenic. The second hypothesis was that a non-coding mutation in the newly 
integrated gene caused the H-ras mRNA to be more efficiently translated. Comparison of 
the sequences from H-ras cDNAs isolated from an 1921 secondary tumor cDNA library with 
published sequences from mouse and rat indicated that there were no mutations in the 
cDNA coding sequences, thus ruling out mutational events that increased protein stability. 
To test the second hypothesis , the 3 ' and 5' non-coding regions of the cDNAs were 
analysed for any differences that could account for a change in translatability of the mRNA. 
The most striking differences between the the three cloned cDNAs were found in the 3'UTR. 
All three sequences diverged 6 bases 3' of the p21 termination codon (Fig. 10). The 
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sequences surrounding the point of divergence were found to conform with the consensus 
rules for splice donor sites (Mount 1982) . Inspection of the two sites where the sequences 
re-aligned , revealed that these areas resembled splice acceptor sites . Moreover, the areas 
of divergence and re-alignment (underlined in Fig . 10) coincided exactly with predicted 
splicing patterns, suggesting that the cDNAs were derived from alternatively spliced 
mRNAs. Alternative splicing in the 3' UTA was confirmed by PCR amplification of RNAs 
from nude mouse tumors and untransfected NIH 3T3 cells . As shown in Fig . 11, a similar 
alternative splicing pattern was seen in all RNA samples tested. This is the first time that 
alternative splicing has been directly demonstrated at this intron , providing a possible 
explanation for the differences between the 3' untranslated regions of published sequences 
of H-ras cDNAs. The sequences of mouse and rat v-H -ras diverge sharply within 6 bases of 
the stop codons. This was previously attributed to genetic drift within non-coding regions of 
the gene; it now seems obvious that the apparent divergence resulted from alternative 
splicing . Within the 3'UTR, rat H-ras mRNA transduced by Ha-MSV is approximately 90 % 
identical to the unspliced form of the mouse H-ras mRNA, represented by clone 16s. As 
expected, the sequence similarities end at the junction between rat and viral sequences in 
Ha-MSV. Therefore, it was the unspliced form of the rat H-ras mRNA that was transduced 
by Ha-MSV. The spliced form of the mouse H-ras mRNA was transduced by BALB-MSV, 
since the viral sequence is identical to clone 110 in this region (Fig . 10) . The alternatively 
spliced form of the H-ras mRNA has not been transduced by a virus and is reported for the 
first time in this investigation . The possibility of alternative splicing in the 3 'UTA of human H-
ras was alluded to recently (Cohen et al 1989) . The authors noted that their H-ras cDNA 
clones were missing 106 nucleotides within the 3' UTA in the same region detected in this 
study. This may be evidence for conservation of the 3' UTA alternative splicing mechanism 
through evolution . 
The relative abundance of all three alternatively spliced forms of the H-ras mRNA was 
the same in all RNA samples tested . The unspliced and spliced forms were approximately 
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equivalent and together represented the vast majority of the H-ras mRNA in all samples. 
The alternatively spliced form of the H-ras mRNA appeared to represent a minor fraction of 
the H-ras transcripts. The lower abundance of this mRNA form may be due to inefficient 
recognition of a splice acceptor site that deviates from concensus. This acceptor site has a 
T instead of a G at the base following the critical AG in the splice consensus sequence (Aebi 
et al 1986) . Although this is a less conserved base, only 8% of functional splice acceptor 
sites have a Tat this position (Mount 1982) . As discussed below, defective processing may 
be a mechanism of reducing the concentration of mature H-ras mRNAs available for 
translation. 
Alternative splicing that suppresses gene expression has recently been shown to occur 
in the human H-ras mRNA. The alternative exon , IDX, within intron D of the Human c-H-ras 
gene acts as a down regulator of H-ras expression by a possible mechanism of defective 
splicing (Cohen et al 1989). Deviation from consensus at the 5' splice junction can interfere 
with the second step of splicing and result in defective intermediates that are lost during 
processing (reviewed in Aebi and Weissmann 1987) . The 5 ' splice junction of the IDX is not 
consensus and splice reactions involving this donor are not accumulated in the cell. Point 
mutations in either splice junction of the IDX abolishes alternative splicing and up-regulate 
H-ras expression approximately 1 O fold (Cohen et al 1989). To test whether alternative 
splicing occurs at the mouse c-H-ras intron D in normal cells and whether H-ras 
overexpression in the mouse tumors was due to lack of alternative splicing , RNA from 
normal NIH 3T3 cells and several tumors was reverse transcribed and the splice junction at 
intron D was amplified by PCR . As shown in Fig . 12, alternative splicing does occur at intron 
Din a minor fraction of mouse H-ras mRNAs. The low abundance of the alternatively spliced 
transcript would be predicted by the mechanism of defective splicing proposed by Cohen et 
al (1989) . The mouse alternatively spliced intron D is approximately 340 bases long as 
estimated by the relative sizes of the spliced and alternatively spliced amplified fragments. 





1989). The differences in size suggest that the mechanism of defective splicing is more 
important than the sequence of the encoded alternative translation product . Since the 
relative abundance of the 490 bp amplified fragment was similar in RNA samples from both 
untransfected NIH 3T3 cells and ras induced tumors, loss of alternative splicing in this 
region cannot be the explanation for increased H-ras expression in the tumors. 
To test whether the presence of the alternatively spliced 3 'UTRs have a direct effect on 
the efficiency of translation of the mRNA, chimeric constructs containing the different 
3 'UTRs were transcribed in vitro, and the mRNAs were capped and translated in rabbit 
reticulocytes . The identity of the translation products was verified by immunoprecipitation 
with the p21 specific monoclonal antibody Y13-259 . No correlation between 3 'UTRs and 
translation efficiency could be made. As expected, clone 110 produced a truncated protein. 
Sequence analysis revealed that this cDNA clone was potentially alternatively spliced at 
intron C (again with a T next to the conserved AG of the 3 ' acceptor site as detected In the 
alternatively spliced form of the 3 'UTA), and translation through the alternatively spliced 
region produced a frame-shift in the coding sequence and premature termination in exon 3. 
This truncated form of Ras was not efficiently immunoprecipitated by the monoclonal 
antibody since the epitope recognized by this antibody (aa 63-73) is close to the site of 
sequence divergence . The mRNA coding for the truncated product was translated with the 
same efficiency as the other mRNAs tested . Since the predicted translation product of pl 10 
should neither bind GTP nor be localized to the membrane, two prerequisites for ras protein 
function , this clone was not studied further. 
A slight but reproducible difference in size was noted between the 16s and 176 
translation products that could not be explained by sequence analysis . After confirming that 
the clones were identical in the coding sequence by RNAase protection mapping , several 
reciprocal constructs were made between the different regions of the cDNAs to establish a 
correlation between the size of the translation product and the region of the cDNA included 
in the construct. Constructs containing the different alternatively spliced 3' UTRs produced 
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the same translation product when the 5 ' UTA was kept constant . As shown in Fig. 14, the 
larger translation product , p23, was only made by clones containing 5 ' UTA sequences 
within a 54 bp Nari fragment. To rule out the possibility that the observed difference in size 
could be an artifact of the reticulocyte translation system, selected chimeric mRNAs were 
also translated by injection of Xenopus oocytes . As shown in Fig.15, the translation 
products were identical in vivo and in vitro , and all chimeric mRNAs were translated with 
similar efficiencies within either system. 
C. Translation Initiating at an Upstream ATG 
An upstream ATG was identified within the Nari fragment required for translation of the 
p23 product . Since the cDNA clone 176 was not full length , the upstream ATG was missing 
and the shorter translation product was produced in reticulocyte lysates. The predicted 
translation product of clone 16s initiated at the upstream ATG is a fusion protein between the 
upstream open reading frame (ORF) and H-ras p21 sequences (Fig .18). In contrast, the 
upstream ORF from the published sequence of normal mouse c-H-ras is out of frame with 
respect to p21 . The normal c-H -ras upstream ATG potentially initiates translation of an ORF 
that is 123 bases long and overlaps the p21 translation start site by 97 nucleotides. This 
ORF codes for a very hydrophilic putative protein product 74 amino acids long . The deletion 
of a cytosine at position 69 in clone 16s, created a frame shift mutation and the reading 
frame of the upstream ORF became aligned with the ras coding sequence. The predicted 
length of this fusion protein is 231 amino acids , which is longer than expected if it is to 
account for the observed mobility shift from p21 to p23 in the denaturing SOS 
polyacrylamide gels. Single point mutations have been shown to cause changes in the 
apparent molecular weight of Ras proteins when assayed under similar conditions 
(Srivastava et al 1985). Therefore , discrepancies in the apparent molecular weight of H-ras 
Proteins are not unprecedented . 
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In eucaryotic organisms, the ATG closest to the cap site is preferentially used for 
initiation of translation (reviewed in Kozak 1989) . In a survey of 699 vertebrate mRNAs, 90 % 
followed the "first ATG" rule (Kozak 1987a) . Proto-oncogenes are the one group noted for 
the presence of upstream ATGs. It has been postulated that these upstream ATGs may be 
involved in modulation of proto-oncogene expression (Kozak 1987a, Marth et al 1988) . The 
survey also revealed that the context of the ATG is important for recognition as a translation 
initiation site and a consensus sequence was proposed (Kozak 1987a). Mutational analysis 
of the consensus sequence has demonstrated that purines at -3 ,-6, and -9 and the G at + 4 
are important for efficient recognition (Kozak 1987b). Recently, Kozak (1989) has shown 
that downstream secondary structure enhances the recognition of an upstream ATG that is 
otherwise not in good context for recognition . According to the consensus sequence , the 
upstream ATG in the chimeric H-ras cDNAs is in a relatively poor context for recognition, 
with the critical -3 purine absent; however, the sequence between the upstream ATG of c-H-
ras and the first intron is approximately 96% G + C (Fig . 16) and has the potential to form 
several stem-loop structures. The very high G + C content of this area may cause 
preferential initiation from the upstream ATG. As shown in Figs. 13 and 15, the presence of 
the upstream ATG results in exclusive initiation at this site , with no initiation detected at the 
downstream ATG in either of the translation systems used. When the upstream ATG was 
removed from the mRNA, the normal ATG was used to efficiently initiate translation of p21 . 
From the results of this study it may be predicted that if the upstream ATG is recognized, 
initiation of translation of a relatively long ORF which overlaps the p21 start site could 
decrease translation of p21 and be a mechanism by which the cell modulates H-ras protein 
expression . Reduced expression from downstream overlapped reading frames has been 
shown in both model systems (Peabody and Berg 1986, Peabody et al 1986) , and in viruses 
(reviewed in Kozak 1989). 
Most ras genes contain upstream ATG (s) (Kozak 1987a). Human N-ras contains 2 




within 18 bases of the p21 start site (Hall and Brown 1985) . This second upstream ORF is 
conserved between human and guinea pig (Doniger 1987) . The H-ras gene from several 
species contain at least one upstream ATG (human , Ishii et al 1985; rat, Damante et al 
1987; mouse , Brown et al 1988) . The K-ras 5 ' non-coding region in the mouse, as mapped 
by Hoffman et al (1987) does not contain an upstream ATG. Ribosomal recognition of the 
upstream ATG(s) in ras mRNA may be a general mechanism for modulation of ras 
expression in vivo . This hypothesis also provides an explanation for the observed 
discrepancies between the unchanged mRNA level and the overexpression of Ras protein in 
the nude mouse tumors . A point mutation In the 5 ' UTR causes the production of a fusion 
protein and circumvents the modulation of translation by the upstream ATG . The net result 
is an increase in production of a ras fusion protein without a concomittant increase in 
mRNA. 
There are several examples of the production of functional amino terminal ras fusion 
proteins in the literature. H-ras has been expressed in E. coli as fusion proteins with an 
amino terminal extensions (Lautenberger et al 1983, Poe et al 1985) . Bacterially expressed 
fusion proteins were fully functional in microinjection studies (Feramisco et al 1984, Stacey 
and Kung 1984). The viral Ra-SV encoded p29 is a f@g-ras fusion protein (Gonda et al 
1982); since v-Ra-ras was created by in-frame fusion of rat H-ras mRNA with a retroviral f@g 
gene, this fusion protein and the predicted fusion protein from the nude mouse tumors are 
identical in 18 of 21 amino acids within the amino terminal extention. The p29 v-Ra-ras 
fusion protein is functional as an oncogene. Therefore the presence of an amino terminal 
extension should not interfere with the function of the ras protein translated from clone 16s. 
This remains to be proven, however, by transfection of NIH 3T3 cells with the 16s cDNA 
cloned into a suitable eucaryotic expression vector . 
A recent report described the novel activation of murine H-ras by to a complex proviral 
insertion mechanism that resulted in increased expression of normal H-ras protein (Ihle et al 




in tumorigenesis from overexpression of normal H-ras p21. This was attributed solely to 
increased transcription from the viral L TR . According to the hypothesis put forth in this 
thesis , the H-ras mRNA expressed from the L TR should be more efficiently translated due to 
the removal of exon -1 and the upstream ATG . Ihle et al did not address this possibility 
because, when looking for open reading frames in the -1 exon sequenced from their 
genomic clone , they translated through the first intron . Therefore, several termination 
codons were found within the intron and it was deduced that no upstream ORF existed in 
mouse c-H -ras . Translation of exons -1 and 1 from the genomic sequence reported by 
Brown et al (1988) , as depicted in Fig . 17, shows a single long open reading frame upstream 
of , and overlapping the p21 start site. 
A related mechanism of upstream ATGs modulating proto-oncogene expression has 
been proposed for translational control of the lck gene (Marth et al 1988) . They showed that 
integration of MoMuLV within the intron between exon -1 and 1 of the lck gene caused 
increased mRNA transcription from the retroviral promoter , and increased translation 
efficiency by removing upstream ATG codons from the mRNA of the LSTRA lymphoma cell 
line. The increased translation efficiency shown by several constructs in which the upstream 
ATGs were either deleted or mutated provided support for their explanation. The presence 
of upstream ATGs in proto-oncogenes does not necessarily mean that they function as 
modulators of translation efficiency. The upstream ORFs in the long leader sequence of c-
sis/PDGF were shown to have no effect on the translation of sis/PDGF protein (Rao et al 
1988) . Instead, the presence of a long G + C rich sequence within the 5 ' UTR was shown to 
be associated with inhibition of translation of this proto-oncogene. 
Overexpression of Ras protein in the nude mouse tumors was accomplished by two 
mechanisms: 1- N-ras gene amplification , and 2- a single base deletion in the 5 ' UTR that is 
proposed to cause an upstream out-of-frame AUG which may normally serve to modulate 
gene expression , to become the initiation codon for an H-ras fusion protein that may 




transfection and tumorigenesis assays. Amplification of transfected genes is a common 
occurance. Injection of transfected cells into animals for tumorigenesis testing exerts 
selective pressure for the cell with the most transformed phenotype to make the tumor. 
Injection of cells containing low copy numbers of K-ras into syngeneic rats, resulted in the 
. formation of tumors containing amplified K-ras (Winter and Perucho 1986) . Overexpression 
of normal Ras proteins can cause NIH 3T3 cells to become tumorignic by raising the number 
of GTP bound activated Ras molecules above the threshold necessary for uncontrolled 
signal transduction to occur (reviewed in Sistonen and Alitalo 1986, Spandidos and Lang 
1989) . Western blot analysis of the 19- series and the amplified N-ras induced tumor 
proteins were performed in parallel since monoclonal antibody Y13-259 recognizes these 
two proteins with similar affinities (Furth et al 1982). Similar amounts of ras protein were 
detected in both sets of tumors , giving an indication of the amount of normal ras protein 
required for tumorigenicity (Fig . 9). Approximately 20 to 50 fold less mutant ras protein 
expression is required for tumorigenesis. If overexpression of the ras proto-oncogene can 
cause tumorigenesis, and ras p21 has a 20 hour half-life, the cell must have several 
mechanisms to insure that this does not happen. Two mechanisms that may function to 
down regulate p21 expression are defective processing of alternatively spliced mRNAs as 
demonstrated by Cohen et al (1989) and addressed in this work, and modulation of 
translation through an upstream out-of-frame ATG . A novel mechanism of H-ras 
overexpression is proposed by which the second of these processes is circumvented. 
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Appendix A: Buffers for DNA analysis 
STET (plasmid DNA) 
8 % sucrose 
5 % Triton X100 
50 mM Tris , pH 8.0 
50 mM EDTA 
filter sterilized and stored at 5 °C 
RNAase stock (100 X) 
600 µg/ml RNase A 
600 U/ml RNase T1 
boil 5 min ., cool slowly , store 5°C 
TNE (genomic DNA) 
20 mM Tris , pH 7.5 
20 mM NaCl 
10 mM EDTA 
TE buffer for DNA storage 
10 mM Tris , pH 8.0 
0.5 mM EDTA 
5X STOP 
0.1 M EDTA 
0 .1 % Bromphenol blue 
10 % Ficoll 
Denaturing solution 
0.5 M NaOH 
0 .6 M NaCl 
Denhardt 's solution (100 X) 
2 % Ficoll 
2 % Polyvinylpyrrolidone 
2 % BSA (optional) 
SET (20 X) 
3 .0 M NaCl 
0.6 M Tris pH 7.8 
40 mM EDTA 
Hybridization Solution Ill (oligos) 
5 X SET 
5 X Denhardt 's , without BSA 
0 .5 % sos 
50 µg/ml sheared, denatured salmon 
sperm DNA (Loftstrand Labs) 
TAE (50X) 
(agarose gel electrophoresis buffer) 
242 g Tris base 
57 .1 ml glacial acetic acid 
100 ml 0.5M EDTA (pH 8.0) 
1 X running buffer is 
40mM Tris-acetate, 1 mM EDTA 
Ligase buffer (10 X) 
0.5 M Tris , pH 7.8 
100 mM MgCl2 
100 mM Dithiothreatol 
5 mM ATP 
store at -20 °C in aliquots 
Universal restriction enzyme buffer (1 OX) 
330 mM Tris acetate, pH 7.9 
660 mM Potassium acetate 
100 mM Magnesium acetate 
5 mM OTT 
1 mg/ml BSA 
store at -20°C in aliquots 
Neutralization Solution 
0.5 M Tris , pH 7.5 
0.6 M NaCl 
Hybridization Solution I 
6XSET 
3 X Denhardt 's solution 
0.1 % sos 
30 mM sodium phosphate , pH 7.2 
100 µg/ml sheared , denatured salmon sperm 
DNA (Lofstrand Labs , Gaithersburg , MD) 
Hybridization Solution II 
0.5 M Sodium phosphate, pH 7.2 
0.5 g/ml Crystalline BSA 
7 % SDS 
1 mM EDTA 
50 µg/ml sheared , denatured salmon sperm 
DNA (Loftstrand Labs) 
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Appendix B: Media and buffers for Library analysis 
SM (phage storage buffer) 
2.32 g NaCl 
20 ml 1 M Tris, pH 7.5 
3.2 ml 1 M MgS04 
0.04 g Gelatin 
deionized H20 to 400 ml 
filter and autoclave 
NZCYM broth (1 liter) 
10 g NZ Amine 
5 g NaCl 
5 g Yeast extract 
1 g Casamino acids 
dist. H20 to 1 liter, pH 7.5 with NaOH , 
autoclave, add 1 O ml 1 M MgS04 last 
Ampicillin stock (AMP) 
25 mg/ml ampicillin (sodium salt) 
in H20, 0.45µ filter, store frozen 
Luria-Bertani (LB) broth 
10 g Bacto-tryptone 
5 g Bacto-yeast extract 
10gNaCI 
dist . H20 to 1 liter, pH 7.5 with NaOH , 
autoclave 
Detection of f3 galactosidase 
LB top agarose 
0.5 mM IPTG (0.1 M stock in H20) 
TM (phage dilution buffer) 
2.32 g NaCl 
20 ml 1 M Tris, pH 7.5 
3.2 ml 1 M MgS04 
deionized H20 to 400 ml , 
filter and autoclave 
LB bottom agar 
500 ml LB broth 
7.5 g Agar 
autoclave , cool to 60°C add 100 µg/ml AMP 
if necessary and pour into plates 
LB top agarose 
100 ml LB broth 
0.6 g agarose 
autoclave, cool to 50°C add 1 ml 1 M MgS04, 
use 3 ml for 100mm plates, 
use 6 ml for 150mm plates 
100 µg/ml Xgal (20 mg/ml stock in N, N 'dimethyl formamide) 
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Appendix C. Buffers for RNA Analysis 
Solution 0 
4 M Guanidinium thiocyanate 
25 mM Hepes , pH 7.0 
0.5 % Sarcosyl 
0.1 M '3-Mercaptoethanol 
(added before use) 
Sucrose lysis buffer 
140 mM NaCl 
1.5 mM MgCl2 
10 mM Tris , pH 8.5 
1.0 % NP40 
24 % (w/v) Sucrose 
High salt buffer 
10 mM Hepes, pH 7.5 
0.5 M NaCl 
0.05 % sos 
1.0 mM EOTA 
Formaldehyde agarose gels 
1 % (w/v) Agarose 
1 X MOPS buffer 
2.2 M Formaldehyde 
1 ug/ml Ethidium Bromide 
RNA gel loading buffer 
4.4 µI RNA sample 
10 µI Formamide 
3.6 µI Formaldehyde 
2.0 µ11 OX MOPS buffer 
Formamide, deionized 
50 ml Formamide 
5 g mixed bed ion exchange resin 
(AG501-X8 BioRad) 
Stir 30 minutes , filter through 
Lysis buffer 
140 mM NaCl 
1.5 mM MgCl2 
10 mM Tris , pH 8.5 
0.5 % NP40 
1 O mM Vanadyl Ribonucleoside Complexes 
(added before use) 
2X PK buffer 
200 mM Tris , pH 7.5 
25 mM EOTA 
300 mM NaCl 
2 0/o SDS 
Low salt buffer 
10 mM Hepes , pH 7.5 
0.05 % sos 
1.0 mM EDTA 
1 OX MOPS electrophoresis buffer 
400 mM MOPS, pH 7.0 
100 mM Sodium acetate 
10 mM EDTA 
Northern blot hybridization buffer 
0.5 M Sodium phosphate , pH 7.2 
0.1 % BSA 
3.5 % sos 
33 % Formamide 
20 µg/ml Yeast tRNA 
1 mM EDTA 
Whatman No. 1 paper, store -20°C in aliquots 
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Appendix D. Sequencing Preparations. 
Preparation of glass plates for sequencing gels: 
Siliconization of short plate 
0 .2 ml Dimethyldichlorosilane 
9.8 ml Chloroform 
spread even film on one side of clean plate 
bake for 3 hours at 80°C, wash 
re-treat after 5 or 6 sequencing runs 
Etching of long plate 
5 M NaOH 
coat one side of clean plate with NaOH , wash 
Sequagel™ buffers for pouring gels 
8% Acrylamide, 80 ml 
25 .6 ml Sequagel™ concentrate 
46.4 ml Sequagel™ diluent 
8.0 ml 10 X Sequagel™ buffer 
0.5 ml 10 % (w/v) Ammonium persulfate 
50 µITEMED 
10 X TBE (for 1 liter) 
1 M Tris, pH 8.3 (121 .2 g Tris base) 
1 M Boric acid (61.7 g) 
20 mM EDTA (7.4 g Disodium EDTA) 
Sequencing gel fixer10 % Methanol 
1 O % Acetic acid 
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Appendix E. Buffers for Protein Analysis 
Protein Extraction Buffer 
1.0 % Triton X100 
0.1 %SOS 
0.5 % DOC 
0.1 M NaCl 
1 O mM Sodium phosphate , pH 7.4 
1 mM PMSF 
100 KIU Aprotinin 
PAGE Buffer 1 OX 
30.25 g Tris base 
144.0 g Glycine 
dist. H20 to 1 liter 
Electroblotting Buffer (3 liters) 
30 ml 1 OX PAGE buffer 
600 ml methanol 
distilled H2D to 3 liters 
BLOTTO for blocking Western Blots 
2% Carnation Nonfat dry milk 
1 % Triton X100 
50 mM Tris pH 7 .5 
10 mM EDTA 
Barth-Hepes Saline(for oocytes) 
88 mM NaCl 
1.0 mM NaHC03 
0.82 mM MgS04 
0.33 mM Ca(N03)2 
0.41 mM CaCl2 
10 mM Hepes 
1 O mg/liter penicillin and streptomycin 
Sample loading buffer (2X) 
20 % glycerol 
4 % SDS 
100 mM Tris , pH 6.8 
0.02 % Bromphenol blue 
4.25 % f3 Mercaptoethanol 
(for reducing gels) 
SOS PAGE Running Buffer 
50 ml 1 OX PAGE buffer 
2.5 ml 20% SOS solution 
dist. H20 to 500 ml 
lmmunoprecipitation Wash buffer 
50 mM Tris pH 7 .5 
100 mM NaCl 
1.0 % Triton X100 
0 .5 % DOC 
0.1 % sos 
1 mM EDTA 
PAGE gel fixing and dehydration solution 
500 ml Absolute Methanol 
70 ml Glacial acetic acid 
430 ml deionized water 
final pH 7.0 to 7.2 with NaOH , filter sterilized 
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Appendix F. List of Oligonucleotide Primers: 
1. Human c-N-ras sequencing oligonucleotides : 
name 
N-ras 12, 13(5 ') 
N-ras 12, 13(3 ') 
N-ras 61 (5') 






















location in gene 
Exon 1-5 ' (Clontech) 
Exon 1-3' (Clontech) 
Exon 2-5' (Clontech) 
Exon 2-3 ' (Clontech) 
EXON 3-5 ' 
EXON 3-3 ' 
EXON 4-5 ' 
EXON 4-3 ' 
EXON 5-5' 
EXON 5-middle , forward 
EXON 6-forward 
EXON 6-middle, forward 









5 ' intron D 
3 'intron D * 
H5 '1 
H5 '2 * 
5'UTR (AP55) 














location in cDNA 
CODON 12/13, forward 
3'UTR, reverse 
EXON 1, reverse 
3 'UTR, reverse 
EXON 3, reverse 
INTRON E, forward 
INTRON E, reverse 
EXON 3-middle, forward 
EXON 4, reverse 
EXON 2-middle , forward 
EXON 4-middle, forward 
EXON 1-beginning, reverse 
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